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Part I
Dissertation
1
‘The tackle of my heart is crack’d and burn’d, And all
the shrouds wherewith my life should sail Are turned
to one thread, one little hair: My heart hath one poor
string to stay it by. . . ’
William Shakespeare’s King John (5.7.52-5)
Chapter 1
Introduction
The heart has held a key role in understanding the human body since antiquity
(Singer, 1958). In the fourth century B. C., the Greek philosopher and physician
Aristotle (384-322 BC) believed it to be the supreme organ of the human body
(Van Praagh & Van Praagh, 1983). Throughout the ages, the heart has been seen
as the seat of intelligence, motion, and sensation(Findlen & Bence, 1999). In the
second century, Galen of Pergamon (129-216 AD), another Greek physician, care-
fully observed many of its unusual physical properties in his treatise ‘On the Use-
fulness of the Parts of the Body’ (May, 1968). He wrote that ‘[. . . ]the heart is a
hard flesh, not easily injured. In hardness, tension, general strength, and resist-
ance to injury, the fibres of the heart far surpass all others, for no other instrument
performs such continuous, hard work as the heart’ (Findlen & Bence, 1999). In
Galen’s conception, the heart’s fibres and strings expanded or contracted likewise
under the experience of strong emotion (May, 1968). In the sixteenth and seven-
teenth centuries, advances in anatomy enabled a sharper conception of the true
functioning of the heart (Reynolds, 2007). An English physician, William Har-
vey (1578-1657 AD), is thought to be the first to describe the heart’s chief role in
the body’s blood circulatory system in his book, ‘On the Circulation of the Blood’
(Khan, Daya & Gowda, 2005). As a result, the idea of the heart as key organ func-
tion executor ceased (Reynolds, 2007). Nevertheless, Harvey still referred to the
heart as the ‘king’ or the ‘sun’ of the body (Findlen & Bence, 1999). Across the
ages, the heart has remained an inherent symbol of the soul and human emotions
(Reichbart, 1981). In his works, Shakespeare refers to Galen’s fibres as symbols
for emotion. Here, they become ‘heartstrings’, or ‘threads’ that can ‘crack’ under
stress or be ‘pulled’ under emotional upheaval (Findlen & Bence, 1999). Through
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Shakespeare’s visual vocabulary, the above-cited passage from his play ‘King John’
gives us a sense of the heart’s importance: strong emotion may cause the heart to
enlarge to such an extent that the fine strings become the quintessential threads
that hold it together and prevent it from breaking (Iyengar, 2014, p. 349). Beyond
the emotional and semantic implications of broken heart strings for literature and
culture, chordae tendineae rupture CTR is a life-threatening event, often resulting
in acute mitral regurgitation acute mitral regurgitation (AMR) with significant hae-
modynamic dysfunctions that require immediate medical intervention. While the
psycho-emotional comorbidities of heart disease have received much attention, so
far little is known about patients’ psychological burden after AMR due to CTR.
This work aims to elucidate the background of psychological stress in cardiac pa-
tients. By using a mixed-method approach, we will assess and discuss cardiac
patients’ psychological burden after AMR due to CTR. Furthermore, case sample
data will be compared to age and sex-matched control sample of patients which
have suffered myocardial infarction (MI).
Following this introduction (Chapter One), the reader will be given a brief in-
troduction to cardiovascular disease in general, and acute mitral valve insufficiency
and chordae tendineae rupture in particular (Chapter Two). Also, the reader will
receive an overview of the current state of research with regard to psychological
stress and cardiovascular disease (Chapter Three). After presenting the aims and
hypothesis of this work’s study (Chapter Four), a detailed report of the materials
and methods used for its implementation is given (Chapter Five). Then, we will
report on our quantitative and qualitative results (Chapter Six), before discussing
them against the backdrop of the extent findings of the field (Chapter Seven). Fi-
nally, this work’s study is critically scrutinised with regards to its limitations and
possible further research and a conclusion is given (Chapter Eight). In Chapter
Nine, this work is summarised first in English, then in German language. Addi-
tional information, such as study instruments and consent forms can be found in
the Appendix.
3
Chapter 2
Background
This chapter aims to briefly introduce the reader to the prevalence, diagnosis,
and treatment, as well as mortality and prognosis of selected cardiac diseases that
form the backdrop of this work. Particular focus is put on the nature and context
of chordae tendineae rupture.
2.1 Cardiovascular disease
cardiovascular disease (CVD) is the leading cause of death in the world, ac-
counting for 31% of all deaths in 2013 (Clark, 2013). Figure 2.1 shows a world map
of the global distribution of CVD mortality rates in males (age standardised, per
100, 000) as published by the World Health Organisation (WHO) in collaboration
with the World Heart Federation and World Stroke Organisation in 2011 as part
of the Global Atlas On Cardiovascular Disease Prevention and Control. The report
states that recent decreases in cardiovascular disease mortality have plateaued in
the United States (Bhave & Eagle, 2017; Wilmot, O’Flaherty, Capewell, Ford & Vac-
carino, 2015; Micha et al., 2017) and worldwide death rates due to CVD are on the
increase, rising 42% between 1990 and 2013 (Roth et al., 2015). In 2015, there were
an estimated 422, 7 million cases of CVD (Roth et al., 2017).
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Figure 2.1: Global mortality rates in males due to cardiovascular disease per 100.000 in 2011a
aSource:(Mendis, Puska & Norrving, 2011) Originally published jointly by the World Health Organisation in collaboration with the World Heart Federation
and World Stroke Organisation in 2011 as part of the Global Atlas On Cardiovascular Disease Prevention and Control; permission for use granted by World Health
Organisation, Mai, 29th, 2019 (Permission ID: 289666).
The percentage of premature deaths from CVDs ranges from 4% in high-income
countries to 42% in low-income countries, leading to growing inequalities in the
occurrence and outcome of CVDs between countries and populations (Roth et al.,
2017).
2.1.1 Coronary heart disease
In their 2016 review on the epidemiology of coronary heart disease and acute
coronary syndrome (Sanchis-Gomar, Perez-Quilis, Leischik & Lucia, 2016), Sanchis-
Gomar et al. summarise the incidence, prevalence, trend in mortality, and general
prognosis of coronary heart disease coronary heart diseases (CHDs) and related
conditions. They specify that the umbrella term cardiovascular disease CVDs
describes diseases of the heart and blood vessels and comprises, among other
conditions, coronary heart disease CHDs and coronary artery disease coronary
artery diseases (CADs) as well as acute coronary syndrome acute coronary syn-
dromes (ACSs) (Mendis et al., 2011). Sanchis-Gomar et al. highlight, that although
the terms CAD and ACS as well as CHD are frequently used interchangeably, they
are not the same. They define ACS as a subcategory of CAD, whilst CHD is a result
of CAD (Sanchis-Gomar et al., 2016). Moreover, CAD is characterised by athero-
sclerosis in coronary arteries and can be asymptomatic, while ACS is commonly
symptomatic. Here, symptoms often include unstable angina, which is frequently
associated with myocardial infarction MIs (see Section ‘Myocardial infraction’), re-
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gardless of the presence of CAD (Lippi, Sanchis-Gomar & Cervellin, 2016). In
turn, CHD mortality results from CAD. As Sanchis-Gomer et al. point out, the
development of novel immunoassays in the measurement of cardiac troponins has
prompted a revision of this classification (Sanchis-Gomar et al., 2016). Today, the
spectrum of clinical conditions previously defined as ‘unstable angina’ has been
progressively reclassified as either non-myocardial infarction or myocardial infarc-
tion (Cervellin, Mattiuzzi, Bovo & Lippi, 2016). To improve legibility, this work will
refer to CAD as CHD.
Prevalence, mortality, and prognosis
In an Heart Disease and Stroke Statistics update in 2016, the American Heart
Association (AHA) reported that 15.5 million persons older than 20 years of age
in the USA have CHD (Mozaffarian et al., 2016). For both sexes, data show that
prevalence increases with age and, shockingly, one American will suffer an myocar-
dial infarction approximately every 42 seconds. Since the 1990, absolute numbers
of CVD deaths have significantly increased (Sanchis-Gomar et al., 2016). However,
largely due to a shift in age demographics and causes of death worldwide, the
age-standardised death rate has fallen by 22% over the same period of time (GBD,
2013).
When writing about the epidemiology of cardiovascular disease, the Framing-
ham Heart Study cannot go unmentioned (W. B. Kannel, Dannenberg & Abbott,
1985). It is a long-term, ongoing cardiovascular cohort study of residents of the city
of Framingham, Massachusetts that initially began in 1948 with 5, 209 adult parti-
cipants, currently assessing the third generation of participants (Mahmood, Levy,
Vasan & Wang, 2014; Dawber, Meadors & Moore Jr, 1951). Data from 44 years of
follow-up of this cohort and 20 years of follow-up of their offspring has enabled
the approximation of the incidence of initial coronary events, such as myocardial
infarction, angina pectoris, unstable angina, and sudden and non-sudden coronary
deaths (Gordon, Kannel, Hjortland & McNAMARA, 1978; Lerner & Kannel, 1986;
W. Kannel, 1987). The Framingham data shows that for people aged 40 years, the
lifetime risk of developing CHD was 49% in men and 32% in women, while the
lifetime risk was 35% in men and 24% in women for those aged 70 years. The in-
cidence for total coronary events strongly increased with age (Sanchis-Gomar et al.,
2016). For women, incidence was generally 10 years later than for men. However,
the incidence sex ratio decreased progressively with advancing age or the more
serious manifestations of CHD, such as myocardial infarction and sudden death
(Lloyd-Jones et al., 2010). Moreover, compared to people aged 35–64 years, the
incidence at ages 65–94 years more than doubled in men and tripled in women.
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Furthermore, coronary events made up 33% to 65% of atherosclerotic cardiovas-
cular events in men and 28% to 58% in women. In addition, angina pectoris was
commonly more frequent in men than women. For women aged over 75 years,
angina pectoris was more frequent than myocardial infarction and was more likely
to be uncomplicated (80%). For men, angina often occurred after myocardial in-
farction (66%). Across all ages, myocardial infarction was most dominant in men in
whom only 20% of events were preceded by long-standing angina; the percentage
was even lower for silent or unrecognised myocardial infarction (Lerner & Kannel,
1986; W. B. Kannel, Cupples & D’Agostino, 1987). However, whether the initial
presentation of CHD is an acute myocardial infarction or stable angina is not only
conditioned by sex: a case-control study assessing first CHD presentation adults
with either myocardial infarction (n = 916) or stable exertional angina (n = 468)
found that recent prior therapy with statins and beta blockers affects the clinical
presentation (Go et al., 2006).
2.1.2 Myocardial infarction
An acute myocardial infarction is defined as a myocardial necrosis caused by
an acute obstruction of a coronary artery. Symptoms generally include chest dis-
comfort with or without dyspnea, nausea, and sweating or cold sweating. The
diagnosis commonly results from the electrocardiogram (ECG) and the presence or
absence of serological markers. myocardial infarction treatment comprises platelet
aggregation inhibitors, anticoagulants, nitrates, beta-blockers, statins, and reper-
fusion therapy. In ST-segment elevation myocardial infarction ST-segment elev-
ation myocardial infarction (STEMI), emergency reperfusion is performed using
fibrinolytics, percutaneous coronary intervention (PCI), or occasionally coronary
bypass surgery. In myocardial infarction without ST-segment elevation non-ST-
segment elevation myocardial infarction (NSTEMI), reperfusion is performed by
percutaneous intervention or coronary bypass surgery (Thygesen et al., 2012).
Prevalence, mortality, and prognosis
In the USA, about 1.5 million people suffer a myocardial infarction every year
(Thygesen et al., 2012). This has a fatal outcome for 400, 000− 500, 000 people. In
Germany, the incidence is about 300 infarctions per 100, 000. The epidemiology
of myocardial infarction has been assessed by several studies with regard to the
influence of sex, race, and age. The Atherosclerosis Risk in Communities (ARIC)
study focused on the risk of CHD events among 360, 000 residents aged 35− 74
years in four communities in the USA (Watkins et al., 2005; Rosamond et al., 2008).
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Between 1987 and 1996, they assessed a total of 14.942 hospitalised patients with
definite or probable myocardial infarction. The age-adjusted incidence of hospit-
alised myocardial infarction was highest in black men and lowest among white
women (Thygesen et al., 2012). However, case-fatality rates after myocardial in-
farction decreased significantly during the 1987–1996 period in both genders, i.e.,
by −6.1% and −6.2%. These improvements in CHD outcome were attributed to
secondary rather than primary prevention strategies (Watkins et al., 2005; Rosam-
ond et al., 2008; Goldberg, Yarzebski, Lessard & Gore, 1999). NSTEMI in relation
to STEMI have increased over the past years(Furman et al., 2001; Rogers et al.,
2008; Roger et al., 2010). A report from the National Registry of myocardial in-
farction reviewed over 2.5 million myocardial infarction cases between 1990 and
2006 (Rogers et al., 2008) and found that the proportion of myocardial infarction
due to NSTEMI increased from 19% in 1994 to 59% in 2006. This change in pro-
portion was associated with an absolute decrease in the incidence of STEMI and
either a rise or no change in the rate of NSTEMI (Roger et al., 2010). The incid-
ence of myocardial infarction decreased significantly after 2000 and the incidence
of STEMI decreased markedly after 1999 within a large community-based popula-
tion (Yeh & Go, 2010). The authors attributed reductions in short-term case fatality
rates for myocardial infarction to a decrease in the incidence of STEMI, a lower rate
of death after NSTEMI (Yeh & Go, 2010), and the enhanced diagnostic effectiveness
of modern cardiac troponin immunoassays in the detection of minor myocardial
injury.
Risk factors
Although many cases of myocardial infarction seemingly occur suddenly, pa-
tients frequently have an ominous coronary risk profile (Sanchis-Gomar et al., 2016)
and signs of pre-symptomatic CHD. Approximately 2− 4% of the general popu-
lation has silent coronary ischemia, which despite being an asymptomatic condi-
tion, can be easily detected with an exercise test or ambulatory ECG monitoring.
The prevalence is significantly higher in men with two or more major coronary
risk factors (10%) and in patients with known CHD (25 − 50% in stable angina
patients, for instance) as diagnosed via exercise testing or ambulatory monitor-
ing (W. B. Kannel, 1985). The most specific indicator of the existence of silent
myocardial ischemia in ECG recordings is a Q-wave myocardial infarction (Sheifer,
Manolio & Gersh, 2001). Framingham Heart Study data suggests that for patients
who had suffered a renewed myocardial infarction during routine biennial ECG,
the infarct was silent in 26% of men and 34% of women (W. B. Kannel, Cupples &
Gagnon, 1990). In men, the frequency of unrecognised myocardial infarction was
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higher in diabetic than in non-diabetic individuals (39% vs. 18%) (W. B. Kannel,
1985). For the past decades, it has been shown that the risk for CHD death and
all-cause mortality has substantially decreased after Q-wave myocardial infarction,
largely attributed to improvements in post-myocardial infarction therapies and in
post-myocardial infarction survival of individuals with depressed left ventricu-
lar (LV) systolic function (Guidry et al., 1999). Nevertheless, silent myocardial
infarction as well as clinically apparent myocardial infarction are strongly associ-
ated with age (Goldberg, Glatfelter, Burbank-Schmidt, Lessard & Gore, 2006; Sig-
urdsson, Thorgeirsson, Sigvaldason & Sigfusson, 1995). Although the coronary
risk factor profiles of individuals with previously unrecognised myocardial infarc-
tion are similar to those of patients with clinically recognised myocardial infarction
(Sheifer et al., 2001), two CVD risk factors, namely hypertension and diabetes mel-
litus, are associated with a higher likelihood of having unrecognised myocardial
infarction. The Framingham Study confirmed diabetes as a risk factor for silent
infarction in men but not in women (W. B. Kannel, 1985). In men with diabetes,
the fraction of unrecognised myocardial infarction was more than twice as high as
in those without (39% vs. 18%)(W. B. Kannel, 1985; Shlipak et al., 2001). How-
ever, in patients over 75 years with test-positive angina, the coronary mortality
ratio has been shown to be higher in women (LaCroix et al., 1990). The incid-
ence/prevalence of myocardial infarction increases progressively in women after
the age of 45 (Maddox et al., 2008). Women are generally 6− 10 years older than
men during their first symptomatic myocardial infarction and also more likely to
have a history of diabetes, hypertension, hyperlipidemia, heart failure, and un-
stable angina patterns (White et al., 1993; Maynard, Litwin, Martin & Weaver,
1992). The outcomes in women with ACS and no ST elevation [unstable angina
or NSTEMI has received particular attention: despite showing more comorbidities,
women have a similar (Hochman et al., 1997) or even better outcome than men
(Chang et al., 2003; Hochman et al., 1999; Roger et al., 2000). According to a mul-
tivariate analysis (Roger et al., 2000), women showed a trend toward a lower risk
of death (Riskratio(RR), 0.81) and a significantly reduced risk for a cardiac event
(RR, 0.83).
2.1.3 Heart failure
myocardial infarction is the most common cause of heart failure (HF) world-
wide and for almost 50 years HF has been recognised as a determinant of adverse
prognosis after myocardial infarction (Cahill & Kharbanda, 2017). HF is defined
as ‘a clinical syndrome that occurs as the end result of any structural or func-
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tional cardiac disorder that impairs the ability of the ventricles to fill with or eject
blood’(Sidebotham & Doughty, 2007; Yancy et al., 2013). This has been translated
into several validated diagnostic criteria (e.g., the Framingham criteria (McKee,
Castelli, McNamara & Kannel, 1971) and the European Society of Cardiology cri-
teria (Members et al., 2012)). However, the primary definition of HF as a clinical
syndrome has led to differing clinical, imaging, and bio-marker definitions coex-
isting in clinical practice and research. Unlike myocardial infarction there is no
‘universal definition’ and consequently, the diagnosis of HF is often heterogeneous
between studies and over time (Thygesen et al., 2012). HF following myocardial
infarction has been assessed using clinical criteria, such as the Killip and New York
Heart Association classifications (NYHA) (Killip III & Kimball, 1967; Yancy et al.,
2013).
The NYHA stages
The NYHA classification system is a scale used to categorise heart failure into
defined stages. As a result, the indicated treatment for a specific stage of heart fail-
ure can be applied. The following symptoms are used in order to classify a heart
failure as enumerated below: shortness of breath (dyspnea), frequent nightly urina-
tion (nocturia), discoloration of the skin due to lack of oxygen saturation (cyanosis),
general weakness and fatigue, angina pectoris or cold extremities, oedemas.
NYHA stage I Movement or performance is not impeded. Complete absence of
symptoms or ailments under stress despite diagnosis of a cardiac disease.
NYHA stage II Slightly reduced resilience under pressure. No symptoms present
while at rest or light stress. Increased stress leads to appearance of symptoms.
NYHA stage III Severe reduction of resilience under pressure. Symptoms already
become present even with light increase of stress.
NYHA stage IV Symptoms are constantly present, even when at rest.
Diagnosis
The development of echocardiography led to objective measurement of ejection
fraction and ventricular volumes as an intrinsic part of a HF diagnosis and thus
redefined clinical HF scoring (Cahill & Kharbanda, 2017). The timing of HF follow-
ing myocardial infarction is important clinically, mechanistically, and for research.
Three key time periods need to be distinguished: HF at the index myocardial infarc-
tion presentation, during the course of the first admission, and after discharge. Not-
ably, research studies often fail to define HF timing, making comparison between
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studies challenging. Cahill et al. state that particularly older studies failed to
treat HF as a time-dependent, progressive factor which is influenced by the up-
front treatment, meaning that late-onset HF after myocardial infarction is less well
characterised than HF at presentation (Cahill & Kharbanda, 2017). Several over-
lapping mechanisms contribute to HF after MI: HF during the index myocardial
infarction occurs due to a combination of myocardial stunning, myocyte necrosis,
decompensation of pre-existing HF or acute mitral regurgitation due to papillary
muscle dysfunction or CTR. HF during hospitalisation may also be due to any of
the above, compounded by fluid or contrast overload, renal dysfunction, or com-
plications such as ventricular septal defect or cardiac tamponade. Late HF reflects
the consequences of cardiomyocyte death and scar formation occurring alongside
ventricular remodelling.
Mortality and prognosis
O’Connor et al. state that neurologically intact survival to hospital discharge
is the key outcome compared to the simple return of spontaneous circulation
(O’Connor et al., 2010). Although survival rates vary significantly, they list the
following factors as favourable for a positive outcome: witnessed arrest, quick
and effective bystander-initiated cardiopulmonary resuscitation (CPR), in-hospital
location (particularly a monitored unit), initial rhythm of VF or VT, early defibrilla-
tion (of VT or VF after initial chest compression), post-resuscitative care, including
circulatory support and access to cardiac catheterisation. Furthermore, in adults,
targeted temperature management (body temperature of 32 to 36° C) and avoid-
ance of hyperthermia reduces mortality (Bernard et al., 2002; Nielsen et al., 2013).
In favourable circumstances, about 40% of patients survive to hospital discharge.
Overall, in-hospital arrest (VT/VF and asystole/PEA) survival is about 25%. How-
ever, if factors are largely unfavourable (e.g., patient in asystole after unwitnessed,
out-of-hospital arrest), survival is, sadly, unlikely. Overall, reported survival after
out-of-hospital arrest is about 10%. Moreover, only about 10% of all cardiac arrest
survivors have good CNS function at hospital discharge.
Treatment
Unsurprisingly, rapid intervention is essential and the treatment of primary
causes is a key factor. CPR is an organised, sequential response to cardiac arrest.
Severe circulatory shock is identified when no treatable conditions are present but
cardiac motion or pulses are detected by ECG and IV fluid (eg, 1 L 0.9% saline,
whole blood, or a combination for blood loss) is given. If response to IV fluid
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is inadequate, one or more vasopressor drugs (e.g., norepinephrine, epinephrine,
dopamine, vasopressin) are given. However, it remains controversial whether these
benefit the outcome. In addition to primary cause treatment, post-resuscitative care
typically includes the optimisation of oxygen delivery, rapid coronary angiography
in patients with suspected cardiac aetiology, and targeted temperature manage-
ment (32 to 36C ° in adults) (Moler et al., 2017, 2015).
2.1.4 Blood flow through the heart
Before detailing the function of the mitral valve, it is important to bring to mind
the general flow of blood through the heart, especially with regard to the symptoms
CTR patients experience during AMR.
In brief, the heart pumps blood to all parts of the body. Blood has the function of
providing oxygen and nutrients to the our organism and removing carbon dioxide
and wastes. As blood flows through the body, oxygen store is used up, and the
blood becomes low in oxygen(Klocke, 1976).
• Oxygen-poor blood returns to the heart through the superior vena cava and
inferior vena cava.
• Low oxygen blood enters the right atrium, or the right upper chamber of the
heart. From there, the blood flows through the tricuspid valve into the right
ventricle, or the right lower chamber of the heart.
• The right ventricle pumps oxygen-poor blood through the pulmonary valve
into the main pulmonary artery. From there, the blood flows through the
right and left pulmonary arteries into the lungs.
• In the lungs, our blood is enriched with oxygen and carbon dioxide dissip-
ated.
• The now oxygen-rich blood flows back into the left atrium, or the left upper
chamber of the heart, through four pulmonary veins.
• Oxygen-rich blood then flows through the mitral valve into the left ventricle,
or the left lower chamber.
• The left ventricle then pumps the oxygen-rich blood through the aortic valve
into the aorta, the main artery that takes oxygen-rich blood out to the rest of
the body.
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2.1.5 The mitral valve
As this structure is central to this work, a very brief overview of the workings
of the mitral valve will be given, before detailing the implications of acute mitral
valve insufficiency following CTR.
The mitral valve functions as a valve between the left atrium and left ventricle,
allowing blood to flow only from the atrium to the ventricle and not vice versa. It
was named after its shape, which resembles that of the bishop’s cap, also known
as the mitre. The valve leaflets form two sails which are attached to Chordae
tendineae (CT) or chordal tendons. These in turn are attached to a small muscle
(papillary muscle) protruding into the ventricle (see Figure 2.2). This attachment
prevents the valve leaflets from penetrating into the atrium when the chamber fills
with blood and ejects into the aorta. In the healthy state, the edges of the two
leaflets lie against each other, so that for this phase of heart action the atrium is
completely separated from the ventricle. If the heart valve does not close properly,
i.e. a leak develops, this is referred to as mitral valve insufficiency. If, on the other
hand, it is not able to open completely when blood is pumped from the atrium into
the chamber, this is called mitral stenosis (Baumgartner et al., 2017).
Figure 2.2: A schematic view of the mitral valve and an enlarged view of the mitral chordae
tendineae. The white arrows indicate regurgitant blood flow.(staff & staff, 2014) a
aSource: Blausen.com staff (2014),‘Medical gallery of Blausen Medical 2014’. WikiJournal of Medicine 1 (2). DOI:10.15347/wjm/2014.010. ISSN 2002-4436. This
file is licensed under the Creative Commons Attribution-Share Alike 4.0 International license.
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Prevalence and development
Mitral valve stenosis is the most common acquired heart valve defect world-
wide (Baumgartner et al., 2017). In Germany, (and other industrialised countries),
however, the frequency of their occurrence has significantly decreased in recent
years compared to acquired aortic valve stenoses and mitral valve insufficiencies.
In rare cases, a mitral valve stenosis can be congenital. Usually, it is caused by
rheumatic fever several years before the heart valve disease was diagnosed. This
is a consequence of a purulent streptococcal infection, which often manifests itself
in the patient as tonsillitis, pharyngitis, or inflammation of the upper respiratory
tract. A few weeks after infection, characteristic symptoms, such as inflammation
of the inner lining of the heart or heart muscle (endocarditis, myocarditis), acute
inflammation of the large joints, rheumatic nodules, etc., occur. In the context of
this rheumatic fever, the mitral valve can thicken and calcify, resulting in narrow
spots (stenoses). For some time now, streptococcus-induced inflammations ‘strep-
tococcal angina’ have been promptly treated with antibiotics in Western industrial
countries, so that rheumatic fevers with heart involvement are rare. As a result,
mitral valve insufficiencies are more common today as mentioned above. These
can also develop in the context of a rheumatic fever, which, as just described, is
rather rare nowadays. However, the most common cause today is CTR papillary
muscle dysfunction, which is a frequent complication following heart failure or
CHD. Furthermore, leaks can also be caused by bacterial infections of the mitral
valve (bacterial endocarditis). In addition to congenital diseases of the connective
tissue that cause laxity, the mitral valve of the heart can also be damaged by drug
abuse and heavy alcohol consumption.
Symptoms
If the mitral valve leaks, the blood flows back into the atrium and pulmonary
veins during the filling and ejection phase of the ventricle, increasing the blood
pressure in the pulmonary circulation due to the increased blood volume. The
right heart has to fight against increased resistance and build more muscle, thus,
reaching a critical point. When the body is weak (e.g. cold, ill, elderly etc.), the
heart can no longer build up the necessary strength and fluid is squeezed out of the
lungs and body, causing shortness of breath, general weakness, and oedema, such
as water in the legs (Maleki, Alizadehasl & Haghjoo, 2017). In addition, tachycardia
and cardiac arrest may become noticeable in the patient. In cases of a rupture of
the papillary muscle or of several CT with flail of the mitral valve leaflet, the left
heart cannot adapt to the sudden changes in pressure, which result in acute heart
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failure. This event shall be treated in more detail in the following sections ‘Acute
mitral insufficiency’ and ‘Chordae tendineae rupture’.
The symptoms of a decompensated heart failure in mitral valve stenosis are
similar (S. N. Shah & Sharma, 2019). The increased pressure that the left atrium
would have to exert in order to press the blood into the chamber is not equal to
this. It expands as more and more blood is added from the pulmonary circulation
but less can be released into the ventricle. This distension is often the cause of a
cardiac arrhythmia, called atrial fibrillation, which patients usually perceive as a
general weakness during exertion and palpitations.
Diagnosis and therapy
Patient diagnosed with the above-mentioned symptoms are examined using
echocardiography (ultrasound of the heart) and chest X-ray to determine and clas-
sify a disease of the heart valves and any other changes to the heart caused by
it (Michaux, Skarvan, Filipovic & Seeberger, 2006). If a heart valve operation is
necessary, a cardiac catheter examination is performed to determine the degree of
severity and possible damage to the heart more precisely, or to determine a pos-
sible parallel coronary stenosis. Via the catheter, contrast medium is injected into
the interesting vascular parts and heart sections and made visible under a mo-
bile X-ray device. On the basis of the ECG and transthoracic echocardiography
transthoracic echocardiography (TTE) findings, as well as in consideration of relev-
ant risk factors, such as age and present comorbidities, a decision regarding valve
repair or valve replacement is made (S. N. Shah & Sharma, 2019).
2.1.6 Acute mitral valve insufficiency
AMR is a potentially life-threatening cardiac emergency (Dudczak et al., 2016).
It is characterised by sudden onset, rapid progression of pulmonary oedema, hy-
potension, and clinical signs of a left-sided heart failure which may finally result
in a severe cardiac shock and, in some cases, pulmonary hypertension which may
lead to acute right-sided heart failure (Barber, Ratliff, Cosgrove, Griffin & Vesely,
2001; Grande-Allen et al., 2001). AMR is often caused by the abrupt rupture of
the valve’s constraining structures and must be distinguished from chronic mitral
regurgitation (MR) as the haemodynamic changes are far more dramatic in AMR.
The sudden rupture of a single leaflet’s chordae tendineae may cause the leaflet to
‘flop backward’ during systole (flail leaflet) resulting in severe valve incompetence.
Hence, AMR can be rapidly fatal if mitral valve repair is not promptly performed
(Depace, Nestico & Morganroth, 1985).
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Diagnosis
Significant causes of AMR are chordae tendineae rupture, IE with the disruption
of the MV leaflets or chordal rupture, ischemic dysfunction, or rarely the rupture of
a papillary muscle, as well as malfunction of a prosthetic valve (Maleki et al., 2017).
TTE is the gold standard for diagnosing and quantifying the severity of ischemic
mitral valve insufficiency. In the acute setting, TTE is also the only method that is
actually used and provides essential information about changes in valve size and
ventricular geometry, thus allowing the causes and underlying mechanisms to be
identified (Nickenig et al., 2013; Vahanian et al., 2012; Skarvan & Bernet, 2006). In-
sufficiency quantification is performed by determining jet length, jet width, and jet
area in the colour Doppler, by evaluating the CW Doppler spectrum, by analysing
pulmonary vein flow with pulsed Doppler, and by analysing proximal flow acceler-
ation (effective regurgitant orifice area (EROA))(Michaux et al., 2006). Quantitative
echocardiographic parameters used are the width of the Vena contracta, the regur-
gitation flow rate, the effective regurgitation area, the regurgitation volume (RVol),
the regurgitation fraction (RF), the duration of regurgitation and the flow pattern
in the pulmonary veins (Skarvan & Bernet, 2006).
Because the ‘v’ wave is significantly elevated in these patients, the reverse pres-
sure gradient between the LV and left atrium (LA) drops at the end of systole, and
the murmur can be decrescendo rather than holosystolic, ending well before the
A2. It typically is lower pitched and softer than the murmur of chronic MR. A
left-sided S4 commonly is found. Common PAH might increase the intensity of P2,
and the murmurs of PI and TR also may be heard together with a right-sided S4.
In patients with severe acute MR, a late systolic pressure rise (a v wave) may rarely
cause the premature closure of pulmonary valve, an early P2, and the paradoxical
splitting of S2 (Maleki et al., 2017).
acute mitral regurgitation, even if severe, frequently does not rise the whole
cardiac size, as is seen on chest radiography, and might produce only mild LA
enlargement despite a marked rise in LA pressure.
Echocardiography may display little increase in the internal diameter of the LA
or LV, but augmented systolic motion of the LV is noticeable. The main findings
on Doppler echocardiography are the severe jet of MR and the increase in the
pulmonary artery pressure (Lancellotti et al., 2010).
Chronic regurgitation increases left atrial size and compliance, and, accordingly,
left atrial pressures will be normal despite the regurgitant volume (Stout & Ver-
rier, 2009). Conversely, acute mitral regurgitation increases volume into a normally
compliant left atrium, resulting in a marked increase in left atrial pressure. A signi-
ficant V wave may be evident in either condition, although it is more pronounced
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in acute regurgitation. Because of the increased left atrial pressure from acute
mitral regurgitation, pulmonary oedema is a common consequence. Preexisting
conditions may affect tolerance of acutely increased left atrial and left ventricu-
lar volume. Patients with a history of chronic mitral regurgitation and preserved
ventricular function may tolerate the marked increase in volume better, whereas
patients with impaired ventricular function may quickly decompensate with acute
worsening of mitral regurgitation. Those patients with pulmonary oedema associ-
ated with ST-segment elevation myocardial infarction often have coexistent mitral
regurgitation, with under-appreciated severity and a poor prognosis (Fässler, 2014).
As with acute aortic regurgitation, there is some degree of initial compensation af-
forded by an increased preload, but the inability of the ventricle and atrium to
accommodate the increased volume results in marked increase in left ventricular
end-diastolic and left atrial pressures (Lancellotti et al., 2010).
Prevalence, treatment, and mortality
The prevalence of mitral valve insufficiency is estimated to be 1 − 2% in the
total population and increases with age to over 10% for people aged 75 years and
older (Nickenig et al., 2013; Vahanian et al., 2012). The classification is based on
causes (ischemic - non-ischemic), mechanisms, and the progression over time. As
patients in this state of emergency typically present acute pulmonary oedema or
cardiogenic shock, the definitive treatment is immediate surgery after initial stabil-
isation through medical therapy, which includes nitrates, diuretics, and inotropic
agents (Vahanian et al., 2012).
Afterload lessening is chiefly important in treating patients with acute severe
MR. Intravenous nitroprusside may be lifesaving in patients with acute severe MR
caused by the rupture of the head of a papillary muscle, complicating an AMR. It
can stabilise clinical status, thereby permitting coronary arteriography and surgery
to be performed with the patient in an ideal situation. In patients with acute severe
MR who are hypotensive, an inotropic agent such as dobutamine must be admin-
istered with nitroprusside. Intraaortic balloon counterpulsation may be necessary
to stabilise the patient while preparations for surgery are made (Maleki et al., 2017).
Emergency surgical management may be essential for patients with acute LV
failure caused by acute severe MR. Emergency surgery is correlated with higher
mortality rates than those for elective surgery for chronic MR. Nonetheless, unless
patients with acute severe MR and HF are treated aggressively, a fatal outcome is
nearly certain (Maleki et al., 2017). The pathogenesis of acute mitral regurgitation
determines its management. In a series of acute mitral regurgitation (Stout & Ver-
rier, 2009), there were several different causes: acute myocardial infarction (45%),
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degenerative valvular disease (26%), and infective endocarditis (28%). Each of these
causes is managed by different strategies, and each has different outcomes (Lorusso
et al., 2008). Unlike aortic regurgitation, for which repair is rarely possible, mitral
regurgitation may be treated with either repair or replacement. However, the risk
of open heart surgery to repair or replace CT is often very high for unstable, mostly
elderly patients (Adamo et al., 2017). Surgical mortality rates also are greater in pa-
tients with severe acute MR and refractory HF (NYHA functional class IV), than
in those with prosthetic valve dysfunction, and those with active IE (of a native or
prosthetic valve) (Maleki et al., 2017). Despite the higher surgical risks, the efficacy
of early surgery has been established in patients with IE complicated by medically
uncontrollable congestive HF and recurrent emboli.
Therefore, in this common scenario, AMR caused by chordal rupture is often
treated with transcatheter mitral valve repair (Mokadam, Stout & Verrier, 2011),
which is associated with lower operative mortality, preservation of left ventricular
function, and better long-term survival when compared to open surgery (Hauptmannová
et al., 2014)(Nishimura et al., 2014, 2017). Transcatheter mitral valve repair is a pro-
cedure that involves the approximation of the anterior and posterior mitral leaflets
with the help of a suitable repair system (e.g. the MitraClip procedure), leading to
the formation of a double-orifice valve (Feldman et al., 2011). The event of AMR is
highly acute and associated with a poor prognosis (Barzilai, Davis, Stone, Jaffe &
Groupab, 1990).
Data suggest that severe mitral regurgitation in patients with cardiogenic shock
is not uncommon, approaching 7% of patients in the ‘Should We Emergently Re-
vascularize Occluded Coronaries in Cardiogenic Shock (SHOCK)’ registry. The
presence of acute mitral regurgitation in these patients is a very poor prognostic
sign, with an observed mortality of 55%, improving to only 39% in patients selected
for emergency surgery (Stout & Verrier, 2009). The SHOCK trial demonstrated that
early revascularization improves outcomes at 6 months in patients with cardiogenic
shock and acute myocardial infarction, and further analysis demonstrated the pro-
gnostic importance of mitral regurgitation in these patients (Thompson et al., 2000).
Short- and long-term survival was inversely related to the degree of mitral regur-
gitation, arguing for more aggressive treatment of those patients with significant
mitral regurgitation in the setting of acute infarction, with improved mortality in
those patients undergoing early revascularisation (Picard et al., 2003). Thus, if sur-
gical revascularisation is needed, the presence of severe mitral regurgitation should
encourage rather than discourage surgical intervention.
In 5% of deaths from acute myocardial infarction, acute ischemic mitral valve in-
sufficiency is the underlying cause (Reeder, 1995). Mortality during this early phase
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of CTR treatment using transcatheteral approaches can reach up to 50% within the
first 24 h, and up to 90% within 48 h following the occurrence. The peri-operative
mortality, when using open surgery is also high 20− 50% (Enriquez-Sarano et al.,
2005; Hickey, Wilcken, Wright & Warren, 1985; Seeburger et al., 2011). The cause
of acute regurgitation also determines the outcome. This was demonstrated by
a recent report of a series of patients undergoing surgery for acute severe mitral
regurgitation that displayed an overall 30-day mortality of 22.5% with the best out-
comes in those patients with degenerative disease (Lorusso et al., 2008).
Prognosis
The prognosis of acute mitral valve insufficiency is poor. Factors influencing
the prognosis are age, comorbidities, clinical symptoms, previous treatments, de-
gree of insufficiency, left ventricular pump function and diameter, left atrial size
> 40-50 mm, pulmonary hypertension, atrial fibrillation, neurohumoral activation,
and decreased oxygen uptake under stress (Enriquez-Sarano et al., 1999; Gillam &
Schwartz, 2010; Nickenig et al., 2013; Valuckiene˙, Urbonaite˙ & Jurkevicˇius, 2015).
The prognosis of mitral valve insufficiency after surviving myocardial infarction de-
teriorates significantly (36% mortality in development of mitral valve insufficiency
in hospital admission vs. 16% mortality in development of mitral valve insuffi-
ciency during hospital admission) (Barzilai et al., 1990; Valuckiene˙ et al., 2015).
2.1.7 Chordae tendineae
MV closure depends upon the correct functioning of each component of the
valve apparatus, which comprises the annulus, the leaflets, and the CT (Khalighi et
al., 2017). The CT are made of dense collagenous connective tissue which protrudes
from the tip of the papillary muscle (PM) and adjoins to the MV leaflets. The MV
chordae tendineae are shown in their tree-like structure in Figure 2.3. The PMs
and CT form an integrated unit (the ‘sub-valvular apparatus’) providing the struc-
tural support for MV leaflets during ventricular contraction (Neely, Leacche, Byrne,
Norman & Byrne, 2014). Commonly, pathological conditions connected with MV
regurgitation are characterised by deviations of the sub-valvular apparatus from its
healthy, homeostatic state (Ciarka & Van de Veire, 2011). Chordal rupture, which
is a very common lesion in elderly patients (Gabbay & Yosefy, 2010), often leads to
leaflet prolapse and blood leakage (Grenadier et al., 1985).
19
Figure 2.3: The MV chordae tendineae are made of dense collagenous connective tissue and form
tree-like structures which protrude from the tip of the PM and adjoin to the MV leafletsa
aSource: E.Faccio & P.Saccheri. 2007. This file is licensed under the Creative Commons Attribution-Share Alike 3.0 Unported license.
The chordae tendineae have their origin by the tip of the papillary muscles and
insert on the rough zone of the mitral leaflets (Degandt, Weber, Saber & Duran,
2007). After their origin and before their insertion, they split in numerous branches
and interconnections that ensure a balanced distribution of the mechanical forces
among chordae (Faletra et al., 2016). The simplest and perhaps most effective clas-
sification of chordae tendineae divides the chordae in three types: The first order
chordae or marginal chordae insert on the free margins of leaflets. The rupture
of these chordae always causes mitral regurgitation. The so-called commissural
chordae are marginal chordae that insert on the free margin of commissures. The
second order chordae or strut chordae insert on the confine between the rough and
clear zones of the anterior leaflet. These chordae, usually two in number, are par-
ticularly robust and thick; the tension that they experience during the systole is in
fact much higher than that of the first order chordae. Their function is other than
that of impeding the eversion of leaflets. They actually reduce the motion of the
lateral part of the anterior leaflet, leaving the central part much more mobile. Thus
in systole the anterior leaflet takes a concave shape toward the outflow tract, and
in diastole toward the inflow tract. This configuration facilitates the blood flow-
ing into the aorta and into the LV, respectively. Moreover, these chordae appear
to ensure a fibrous continuity between the leaflet and ventricular wall, supporting
the contraction of longitudinal fibers of the LV. The third order chordae or basal
chordae originate directly from the ventricular wall and insert only on the pos-
terior leaflet. These chordae should limit the motion of the posterior leaflet. One
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may speculate that the absence of basal chordae on the anterior leaflet should allow
a greater mobility to the latter.
2.1.8 Chordae tendineae rupture
The rupture of the mitral chordae tendineae predominantly occurs in male
adults older than 50 years of age (Gabbay & Yosefy, 2010). The severity of its
clinical manifestation depends on the total number of ruptured chordae. Mild
cases of CTR usually involve the disconnection of single chorda causing minimal
haemodynamic constraints and requiring no treatment and usually remain asymp-
tomatic. In contrast, patients who have suffered from significant rupture involving
the acute simultaneous separation of multiple chords exhibit AMR as outlined
above, which results in a medical emergency and requires immediate surgical in-
tervention (Dolmatova et al., 2017).
As the condition is rare, only a handful of retrospective studies have described
patient populations with CTR to date (Gabbay & Yosefy, 2010), with even fewer
studies focusing on treatment modalities for these patients (Kazui & Kawazoe,
2004; Rankin et al., 2004). To describe national trends in the incidence and out-
comes of patients with CTR, Dolmatova et al, (2016) conducted a study assess-
ing patients diagnosed with CTR between 2000 and 2012 via the National (Na-
tionwide) Inpatient Sample (NIS) registry (Dolmatova et al., 2017). They identi-
fied a total of 37, 287 (14, 833 mitral valve repair, 7780 mitral valve replacement)
CTR cases. Their results suggest that overall, in-hospital mortality in CTR de-
creased by 3% from 2000 to 2012. From 2000 to 2012, the rate of mitral valve
repair increased from 27.2% to 46.4% with a concurrent decrease in the rate of
mitral valve replacement (from 27.8 to 17.7%). After multivariate adjustment, pa-
tient age (OR = 1.04, 95% CI = 1.03 − 1.06, P < 0.001), congestive heart fail-
ure (CHF) (OR = 2.08, 95% CI = 1.19− 3.64, P = 0.01), myocardial infarction
(OR = 3.58, 95% CI = 2.10− 6.11, P < 0.001), Deyo/Charlson comorbidity in-
dex (OR = 1.23, 95% CI = 1.07 − 1.41, P < 0.003) and use of the intra aor-
tic balloon pump (IABP) (OR = 4.81, 95% CI = 2.71 − 8.55, P < 0.001) were
found to be independently associated with greater odds of mortality in these pa-
tients (Dolmatova et al., 2017). Additionally, mitral valve replacement was signific-
antly associated with higher costs of hospitalisation (coe f f icient 15693, 95% CI =
12638 − 18749, P < 0.001). Increasing age and comorbidity index, history of
CHF and myocardial infarction, and use of IABP were identified as factors that
could increase the risk of mortality in patients with CTR. Overall, 1839 (4.9%)
patients with CTR died during admission, including 284 (1.9%) of patients that
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underwent mitral valve repair and 525 (6.8%) patients with mitral valve replace-
ment. The mortality rate was highest among patients who did not receive any
surgical intervention (7.2%, P < 0.001). Mortality was higher in patients who
underwent mitral valve replacement when compared to patients that underwent
repair (6.8% vs. 1.9%, P < 0.001). While no significant changes were observed in
the incidence of CTR, or in the age or gender distribution of patients, a sustained
increase in the severity of comorbidity index was observed. This may be a true
increase that reflects the overall increase in prevalence of diabetes, cardiovascular
disease, acquired immunodeficiency syndrome, and other chronic conditions (Vos
et al., 2015; Leon & Maddox, 2015). On the other hand, it may be a consequence
of improved diagnostic techniques, resulting in more accurate reporting of comor-
bidities in these patients. The increase in the burden of comorbidities could also
be partly responsible for the significant increase in the costs of in-hospital care for
both groups of patients undergoing MVR or MVP in our study (Sabaté, Sabaté &
others, 2003). In addition, the trend of in-hospital mortality in patients with CTR
decreased over time. This effect was observed in both groups of patients undergo-
ing MVP and MVR. This could in part be explained by improvement in surgical
techniques over time. Also, overall reduction in mortality might be due to increas-
ing employment of MVP over MVR over the years (Gammie et al., 2009).
In the following, Chapter three aims to provide an overview of current research
concerning cardiovascular disease and psychological comorbidity. First, general
aspects will be discussed. The findings with regard to post-traumatic stress PTSD
disorder will be reported, before current results with regard to depression and
anxiety disorders are presented.
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Chapter 3
Psychological stress and
cardiovascular disease
The impact of psychosocial factors on cardiovascular diseases is increasingly
recognised by patients, health care providers, and health care insurances. To date,
as stated by the German Cardiac Society in its updated 2018 position paper(Albus
et al., 2019), there is firm evidence supporting the relevance of psychosocial factors
for coronary heart disease, chronic heart failure, arterial hypertension corroborat-
ing the need for their consideration in cardiological care. The following sections
aim to provide a brief overview on the current state of knowledge on psychoso-
cial factors and mental comorbidities often accompanying cardiovascular diseases.
This chapter will cover aspects such as age, gender, socioeconomic status, and so-
cial support against the backdrop of a biopsychosocial model as well as introducing
the concept of medication adherence.
3.1 General aspects and the biopsychosocial model
Commonly, onset and course of cardiovascular diseases can be described with
the help of a biopsychosocial model: cardiovascular diseases develop before the
backdrop of individual genetic dispositions and in interaction with interpersonal
experiences over an individual’s life span combined with environmental stressors
resulting from complex socioeconomic and cultural milieu synergies (Albus, Lad-
wig & Herrmann-Lingen, 2014). It has been established that genetic risk factors
play a lesser role than environmental and behavioural factors: individuals burdened
by high genetic risk can reduce their risk to that of a person with low genetic risk
through healthy life choices. The onset of cardiovascular diseases is closely tied
to an unhealthy lifestyle (smoking, poor diet, inactivity, exposure to stress) and it
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has been shown that premature deaths could be significantly reduced by actively
addressing these risk factors (Albus et al., 2014).
3.1.1 Age
Although the risk for myocardial infarction increases with age, the actual risk is
determined by modifiable risk factors (Dhingra & Vasan, 2012). Unsurprisingly, an
older patient’s risk factor profile will differ from that of a young heart attack pa-
tient. Although younger heart attack patients are often male and report familial ge-
netic predisposition, their main risk factor for infraction is tobacco abuse (N. Shah,
Kelly, Cox, Wong & Soon, 2016). Moreover, results of the INTERHEART study
have shown that psychosocial risk factors, such as depression, critical life events,
stress symptoms, and financial problems, account for 43.5% of the population’s
attributable risk in younger patients compared to 25.2% in older patients (Yusuf
et al., 2004). Risk factors such as frailty, social isolation, and cognitive impair-
ment seem to increase with age; for example, older chronic heart failure patients
are more often in need of palliative care. The prevalence of atrial fibrillation in-
creases continuously past the age of 50 (Kirchhof, 2016). In contrast, genetically
conditioned and often life-threatening cardiac arrhythmias become manifest in the
patient’s thirties (Ponikowski et al., 2016).
3.1.2 Gender
In males, CHD prevalence is consistently higher and increases exponentially
starting at the age of 45 (Gö\s swald, Schienkiewitz, Nowossadeck & Busch, 2013).
CHD incidence generally increases when women reach the age of 55 years. How-
ever, they draw equal with males if they report low social status. Alabas et al.
found that women were generally older and more likely to have comorbidities (but
less likely to smoke) and show atypical symptoms at incidence, consequently of-
ten receiving sub-optimal guideline-based therapy (Alabas et al., 2017). This often
leads to women seeking help only following longer latency. Consequently, women
are less likely to receive state of the art therapy and in a timely manner. For CHF,
it was shown that womens’ reported symptoms of tiredness and exhaustion were
often mistaken for signs of depression, while they were later diagnosed with CHF
(Regitz-Zagrosek, Oertelt-Prigione, Seeland & Hetzer, 2010). This then often resul-
ted in delayed treatment. As with acute coronary syndrome, arrhythmias such as
paroxysmal supraventricular tachycardia, are more often misdiagnosed as panic at-
tacks or attributed to other psychogenic symptoms in women than in men (Carnlöf,
Iwarzon, Jensen-Urstad, Gadler & Insulander, 2017). Their results corroborate pre-
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vious findings that women show worse relative survival and higher excess mortal-
ity than men (Alabas et al., 2017). Besides age, women show a higher prevalence
of depression and post-traumatic stress disorder PTSD, which in turn is associated
with higher cardiovascular risk (Vaccarino et al., 2013). Furthermore, McSweeney
et al. (2016) were able to show that early stress experiences, low social status,
and increased gender-specific role conventions in familial and professional envir-
onments were further risk factors for women (McSweeney et al., 2016). Moreover,
higher stress vulnerability and stress exposure was associated with atypical cardi-
ovascular pathologies in women, such as microvascular dysfunction or vasospasm
(Vaccarino & Bremner, 2017).
3.1.3 Socioeconomic status
Defined via education, income, profession, and place of residence, socioeco-
nomic status is a significant predictor of cardiovascular morbidity and mortality
(Kamphuis, Turrell, Giskes, Mackenbach & van Lenthe, 2012). As mentioned be-
fore, cardiovascular diseases impact individuals with lower social status in high-
income populations especially (Stringhini et al., 2017). Accordingly, it has been
shown that if individuals retain a low social status, characterised by work-related
factors (either no or precarious work contracts, unqualified work), environmental
factors (low-grade housing, high crime rates, traffic noise, pollution), and high
mental stress, throughout their life, this is associated with doubled cardiovascular
mortality (Stringhini et al., 2017).
3.1.4 Social support
Lack of social support is associated with a higher risk of developing cardiovas-
cular diseases and a higher risk of mortality (Stringhini et al., 2012). Moreover, for
single men, lack of social support and loneliness are significant factors for overall
and cardiovascular mortality (Stringhini et al., 2012). Xia et al. (2018) were able
to show that the effect of loneliness on mortality is comparable to that of heavy
smoking (15 cigarettes per day) (Xia & Li, 2018).
Early psychological stress exposure
Being exposed to psychological stress at a young age, such as violence, neg-
lect, sexual and emotional abuse, as well as social discrimination, increases the risk
for developing mental, cardiovascular, and metabolic illnesses, again leading to in-
creased mortality (Juonala et al., 2016; Suglia et al., 2018). Furthermore, longitud-
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inal studies have been able to show an inverse relationship between psychosocial
well-being in childhood and adolescence on the one hand, and the incidence of
atherosclerosis in adulthood on the other hand (Juonala et al., 2016).
3.1.5 Biopsychosocial mechanisms
As detailed previously, an elevated risk of cardiovascular morbidity and mor-
tality is associated with psychosocial factors, such as low socioeconomic status,
chronic stress, or mental comorbidity (Albus et al., 2014). Hence, drastically, the
life expectancy of patients with severe mental disorders is generally decreased by
up to 10 years compared to healthy populations. Figure 3.1 provides a summary of
psychosocial risk factors for selected cardiovascular diseases (Gale, Batty, Osborn,
Tynelius & Rasmussen, 2014; Wahlbeck, Westman, Nordentoft, Gissler & Laursen,
2011).
Figure 3.1: Established psychosocial risk factors in selected cardiac diseases(Albus et al., 2019)
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Furthermore, several of these factors are also negatively influenced by the ex-
perience of suffering from a cardiovascular disease itself. Compared to patients
with either physical or mental health problems, patients suffering from both sim-
ultaneously have dramatically reduced outcomes in all important health dimen-
sions: they show higher mortality rates (Jünger et al., 2005; Katon et al., 2005;
Lazzarino, Hamer, Stamatakis & Steptoe, 2013) as well as higher levels of symp-
tom burden and impairment in any medical disorder index (Read, Sharpe, Modini
& Dear, 2017). In addition, health care costs are significantly higher in patients
with both chronic conditions and comorbid mental disorders (Lehnert, Konnopka,
Riedel-Heller & König, 2011), with the higher costs largely attributable to medical,
not psychosocial, care (Egede, Zheng & Simpson, 2002). The association between
psychosocial factors and cardiovascular illnesses is mediated by behavioural and
psycho-biological mechanisms. However, the respective factors and mechanisms
are connected via complex interactions, so that the full extent of specific relation-
ships has not yet been completely understood.
3.1.6 Medication adherence
Patients’ adherence to their medication represents a crucial part of patient care
and is indispensable in the pursuit of clinical goals (Lam & Fresco, 2015). In its
2003 report on medication adherence, the WHO states that ‘[ . . . ] increasing the ef-
fectiveness of adherence interventions may have a far greater impact on the health
of the population than any improvement in specific medical treatment’ (Sabaté et
al., 2003). In contrast, non-adherence leads to poor clinical outcomes, increased
morbidity and mortality as well as unnecessary health care costs. Current data
suggests that approximately 50%− 60% of patients are non-adherent to their pre-
scribed medicine regimes (Svarstad, Chewning, Sleath & Claesson, 1999; McDon-
nell & Jacobs, 2002), especially chronic disease sufferers. Accordingly, over 30% of
medicine-related hospital admissions are seen to be the result of medication non-
adherence (Brown & Bussell, 2011; Johnson, Williams & Marshall, 1999). The WHO
defines adherence as ‘[ . . . ] the extent to which the persons’ behaviour (includ-
ing medication-taking) corresponds with agreed recommendations from a health
care provider’ (Sabaté et al., 2003). This includes treatment initiation, prescribed
regime implementation, and the discontinuation of the pharmacotherapy (Vrijens
et al., 2012). Some studies differentiate primary or secondary adherence (Lehane
& McCarthy, 2009). While primary non-adherence is understood as the frequency
with which patients fail to redeem prescriptions after new medication has been
prescribed, secondary non-adherence refers to patients not taking prescribed med-
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ication despite having redeemed the prescription (Sackett et al., 1978; Vermeire,
Hearnshaw, Van Royen & Denekens, 2001; Steiner & Earnest, 2000). Often, com-
pliance is also used to refer to medication adherence and describes the extent to
which the patients’ behaviour (including medication-taking) coincides with med-
ical or health care advice (Sabaté et al., 2003). However, it has been argued that
the term may carry negative connotations as it implies passive to submissive pa-
tient behaviour. Hence, adherence will be used in this work to underline the act-
ive and feeling role patients hold in this issue. However, as Steiner and Earnest
have pointed out, both terms may prove to be insufficient in describing patients’
medication-taking behaviours as they may implicitly over exaggerate the physi-
cian’s control over the medication process (Albus et al., 2019). According to WHO,
there are multiple factors leading to poor medication adherence, normally classified
into five categories: socioeconomic factors, therapy-related factors, patient-related
factors, condition-related factors, and health system/health care team- (HCT-) re-
lated factors (Sabaté et al., 2003). With an understanding of whether the non-
adherence is primary (initiation of pharmacotherapy) or secondary (implementa-
tion of the prescribed regime), and what factors have led to it, a proper intervention
can then be tailored individually to improve the medication-taking behaviour of
each patient (Lam & Fresco, 2015). Measuring adherence is, therefore, important
to both researchers and clinicians. Inaccurate estimation of medication adherence
can lead to several problems which are potentially costly and dangerous in both
settings.
The following sections aim to provide an overview on the research base regard-
ing selected cardiovascular diseases and specific mental health problems.
3.2 Post-traumatic stress disorder and cardiovascular
disease
Criteria for the diagnosis of PTSD have evolved (North, Hong & Downs, 2018)
since 1980, with changes in the definition of trauma and the addition of symptoms
and symptom groups. In 2013, the American Psychiatric Association revised the
PTSD diagnostic criteria in the fifth edition of its Diagnostic and Statistical Manual
of Mental Disorders (Diagnostic and Statistical Manual of Mental Disorders fifth
edition (DSM-V)) (Association, 2013). Table 3.2 summarises the current DSM-V
criteria for PTSD (Association, 2013):
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DSM-V criteria
Criterion A: stressor (one required)
The person was exposed to: death, threatened death, actual or
threatened serious injury, or actual or threatened sexual violence, in
the following way(s):
• Direct exposure
• Witnessing the trauma
• Learning that a relative or close friend was exposed to a trauma
• Indirect exposure to aversive details of the trauma, usually in the
course of professional duties (e.g., first responders, medics)
Criterion B: intrusion symptoms (one required)
The traumatic event is persistently re-experienced in the following
way(s):
• Unwanted upsetting memories
• Nightmares
• Flashbacks
• Emotional distress after exposure to traumatic reminders
• Physical reactivity after exposure to traumatic reminders
Criterion C: avoidance (one required)
Avoidance of trauma-related stimuli after the trauma, in the following
way(s):
• Trauma-related thoughts or feelings
• Trauma-related external reminders
Criterion D: negative alterations in cognitions and mood (two required)
Negative thoughts or feelings that began or worsened after the trauma,
in the following way(s):
• Inability to recall key features of the trauma
• Overly negative thoughts and assumptions about oneself or the
world
• Exaggerated blame of self or others for causing the trauma
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• Negative affect
• Decreased interest in activities
• Feeling isolated
• Difficulty experiencing positive affect
Criterion E: alterations in arousal and reactivity
Trauma-related arousal and reactivity that began or worsened after the
trauma, in the following way(s):
• Irritability or aggression
• Risky or destructive behavior
• Hypervigilance
• Heightened startle reaction
• Difficulty concentrating
• Difficulty sleeping
Criterion F: duration (required)
• Symptoms last for more than 1 month.
Criterion G: functional significance (required)
• Symptoms create distress or functional impairment (e.g., social,
occupational).
Criterion H: exclusion (required)
• Symptoms are not due to medication, substance use, or other ill-
ness.
Two specifications:
1. Dissociative Specification In addition to meeting criteria for dia-
gnosis, an individual experiences high levels of either of the fol-
lowing in reaction to trauma-related stimuli:
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• Depersonalisation. Experience of being an outside observer of
or detached from oneself (e.g., feeling as if ‘this is not happen-
ing to me’ or one were in a dream).
• Derealisation. Experience of unreality, distance, or distortion
(e.g., ‘things are not real’).
2. Delayed Specification. Full diagnostic criteria are not met until at
least six months after the trauma(s), although onset of symptoms
may occur immediately.
The DSM-V (Association, 2013) defines PTSD as a trauma- and stressor-related
disorder precipitated by a traumatic event or life-threatening disease. PTSD is char-
acterised by symptoms of re-experiencing aspects of the traumatic event, avoidance
of places, people, and activities that are reminders of the trauma, negative cog-
nitions and mood as well as arousal causing significant distress and functional
impairment with at least one month of continuous symptoms following expos-
ure. Post-traumatic stress symptoms experienced within the first month of the
traumatic event are classified as acute stress disorder (ASD), which presents with
a similar clinical picture characterised by intrusion, negative mood, dissociation,
avoidance, and arousal (Association, 2013). The inclusion in the fourth edition of
the Diagnostic and Statistical Manual of Mental Disorders (DSM) (DSM-IV; (First,
1994)) of a life-threatening disease as a potentially traumatic event that might trig-
ger the onset of PTSD prompted a new area of research that pointed to the emer-
gence of PTSD in the aftermath of a cardiac event.
Prevalence of post-traumatic stress disorder and cardiac mortality
The lifetime prevalence of PTSD in the U.S. is 7− 8% (Kessler, Berglund et al.,
2005; Kessler, Sonnega, Bromet, Hughes & Nelson, 1995). Although the global pre-
valence of PTSD is difficult to estimate, a recent World Health Organisation study
estimated a lifetime prevalence of 3% based on community samples drawn from
14 countries (largely free of conflict zones) comprising more than 20, 000 respond-
ents (Kessler et al., 2011). Prevalence estimates are as high as 30% in populations
exposed to natural and man-made disasters (Galea, Nandi & Vlahov, 2005) and
combat (Weiss et al., 1992).
Our current understanding of the link between PTSD and CVD is that PTSD
is likely an independent risk factor for acute cardiac events including acute coron-
ary syndromes (i.e., myocardial infarction or unstable angina) and possibly stroke
(Edmondson & von Känel, 2017; Galea et al., 2005). The association of PTSD with
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CVD risk is likely carried through interacting behavioural and physiological mech-
anisms that relate to PTSD symptoms and, in turn, also influence CVD risk. It
has also become clear that acute, potentially life-threatening CVD events can them-
selves cause PTSD, and that PTSD secondary to CVD events may be associated
with increased risk for subsequent CVD events and mortality (Weiss et al., 1992).
Several studies have suggested the association of PTSD with incident CVD
events and/or CVD death, with Hazard ratios (HRs) between 1.46 to 3.28 (Edmondson
& von Känel, 2017). However, a major shortfall of these studies is that data col-
lection was often only commenced years to decades after the original traumatic
event. A recently published analysis from the Millennium Cohort Study evaluat-
ing active duty US military service members examined the effects of trauma over
a shorter period. They compared self-report or medical record diagnosis of new
CHD events in service members deployed on combat vs. non-combat missions,
with the majority of deployments occurring shortly after the baseline study as-
sessment (Edmondson & von Känel, 2017). Deployment was associated with a
significantly increased risk of incident CHD assessed via self-report or medical re-
cord diagnoses. Furthermore, PTSD screened positive participants also showed an
increased probability of self-reporting incidents but not medical record CHD dia-
gnoses. Although there is ample evidence suggesting associations between stress,
trauma, and/or PTSD and CVD risk, conclusions are limited by the shortcom-
ings in their methodology, often only relying on self-reports or diagnostic codes
from administrative databases to establish CVD events. Recently, the association
of PTSD and CVD has been examined using more objective methods: in a study
assessing 281 Vietnam-era veteran twin pairs, Vaccarino et al. Vaccarino (Vaccarino
et al., 2013) was able to show that patients with PTSD had more than double the
risk of increased incident CHD events during an average of 13 years of follow-up.
Interestingly, this association proved independent of traditional CVD risk factors,
such as depression and substance abuse or dependence. Moreover, the authors
could show that participants with PTSD had decreased myocardial blood flow on
cardiac positron emission tomography scans. Another study assessing 637 veter-
ans without known CVD demonstrated that those with PTSD had higher levels of
coronary artery calcium, a marker of atherosclerosis, on computed tomography
scans (Von Känel & Orth-Gomér, 2008). It has been established that between
30% − 70% of patients with existing coronary artery disease may develop acute
myocardial ischemia, measured via perfusion imaging or echocardiography, in re-
sponse to psychological stressors (Bigger Jr et al., 1992).
However, with regard to life-threatening illnesses, cardiac events, and espe-
cially myocardial infarction and AMR in the wake of CTR, seem to hold unique
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traumatising characteristics (Vilchinsky, Ginzburg, Fait & Foa, 2017). Features to
note are the abruptness of the event, the concrete danger of death, the patients’ in-
tense sense of loss of control and experienced helplessness during the event (Kutz,
Shabtai, Solomon, Neumann & David, 1994). Furthermore, Alonzo elaborates that
the intrusive experience of the treatments, such as coronary surgery, angioplasty,
angiography, pacemaker implantation, stress testing, and even the side effects of
medications, can also be potentially traumatic events possibly resulting in the de-
velopment of PTSD (Alonzo, 2000). Moreover, although cardiac disease survival
rates are on the rise, it is still largely perceived as life-threatening. As a result,
patients as well as their partners experience intense emotional reactions, such as
fear or anxiety (of dying or recurrence), anger, sadness, and grief as well as PTSD
(Fisher & Collins, 2012).
Cardiac-disease-induced post-traumatic stress disorder
Unsurprisingly, the issue of Cardiac-disease-induced post-traumatic stress dis-
order (CDI-PTSD) has attracted a great deal of attention, and a growing body of
studies have examined its prevalence, stability, and risk factors as well as its psy-
chological and physiological consequences (Vilchinsky et al., 2017). Over the last
20 years, evidence suggests that some cardiac patients experience Post-traumatic
stress symptoms (PTSS) to the degree of warranting PTSD diagnosis (Edmondson,
Kronish, Shaffer, Falzon & Burg, 2013). To date, studies researching CDI-PTSD sug-
gest that between 12%− 15% of all patients who undergo an acute coronary event
consequently develop PTSD (Vilchinsky et al., 2017; Doerfler & Paraskos, 2005; Ed-
mondson, Richardson et al., 2012). These rates are in line with reported prevalence
rates of lifetime PTSD (8− 1%, (Norris & Slone, 2007), 2014; 5− 10% (Ozer, Best,
Lipsey & Weiss, 2008) as well as with PTSD rates among populations exposed to a
traumatic events (10− 20%, (Norris & Slone, 2007)). Similar to PTSD of other ori-
gin, CDI-PTSD has been associated with high levels of negative outcomes among
patients (Spindler & Pedersen, 2005). About half of the studies (Vilchinsky et al.,
2017) reviewed were conducted on patients following an myocardial infarction,
whereas the minority of studies focused on patients who had experienced cardiac
arrest or had undergone specific medical procedures (e.g., cardiac surgery, heart
transplantation). Comparing the rates of CDI-PTSD across illnesses, diagnoses and
procedures revealed that cardiac arrest yielded the highest CDI-PTSD prevalence,
followed by the other cardiac-disease-related diagnoses and invasive procedures,
among which the prevalence of CDI-PTSD was similar. Given the fact that indi-
viduals who have undergone a cardiac arrest have, in a way, experienced death,
this finding is not surprising. Yet we should view this prevalence hierarchy with
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caution since very few studies have focused specifically on cardiac arrest patients
(Vilchinsky et al., 2017). Overall, findings show that rates of CDI-PTSD are relat-
ively stable over time, though a trend toward recovery exists. A small group of
cardiac patients exhibited chronic CDI-PTSD; and not enough data has been ac-
cumulated regarding delayed PTSD − the development of CDI-PTSD symptoms
after an initial period in which patients were asymptomatic, or at least without a
clinical-level CDI-PTSD (Hari et al., 2010). Similar trends of fluctuations in PTSD
over time have been observed in survivors of other types of trauma such as acci-
dents (Carty, O’donnell & Creamer, 2006) and war (Andersen, Karstoft, Bertelsen
& Madsen, 2014).
3.2.1 Prevalence
The current section focuses on the studies conducted on ACS patients (mostly
myocardial infarction); therefore, the terms ‘MI’, ‘CDI (cardiac-disease-induced)’,
and ‘ACS’ will be used interchangeably. CDI-PTSD in this population was as-
sessed at various time points along the course of the illness, from hospitalisation
(e.g.(Castilla & Vázquez, 2011) to as many as 30 years later (e.g.(Chung, Dennis,
Berger, Jones & Rudd, 2011). Very few studies have focused on the manifestation
of CDI-PTSD symptoms during hospitalisation or within the first two weeks of
the myocardial infarction (defined as acute stress disorder, or ASD). These studies
presented a large variability in the prevalence of MI-induced ASD, ranging from
0%− 26% (e.g.(Castilla & Vázquez, 2011; Gao, Zhao, Li & Cao, 2015; Ginzburg et
al., 2003; Meister et al., 2016; Oflaz et al., 2014; Sheldrick, Tarrier, Berry & Kincey,
2006). An examination of these studies revealed that the prevalence of ASD was a
function of the measurement used. When ASD was diagnosed by clinical interview
(Roberge, Dupuis & Marchand, 2008; van Driel & den Velde, 1995), ASD rates were
lower than those emerging from studies which used self-report questionnaires (e.g.
(Gao et al., 2015; Ginzburg et al., 2003; Neumann, 1991)). The same pattern was
observed in studies that examined CDI-PTSD rates one month after the myocardial
infarction (e.g. (Roberge et al., 2008; Rocha et al., 2008; Edmondson et al., 2011;
Pedersen, Middel & Larsen, 2002; Sumner et al., 2015). Finally, studies in which
both interviews and self-report questionnaires were applied showed that data col-
lected by self-report yielded higher rates of CDI-PTSD than did data collected via
interview (Guler et al., 2009; Rocha et al., 2008; Wiedemar et al., 2008). Reported
rates of PTSD within three to 18 months after the myocardial infarction ranged from
3%− 21% (e.g.(Castilla & Vázquez, 2011)). These variations in the reported rates
may be attributed to a) the difference in sample sizes which in some studies was 50
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and lower (e.g.(Bennett & Brooke, 1999; Castilla & Vázquez, 2011; Doerfler, Pbert &
DeCosimo, 1994; Girard et al., 2007)) and/or b) changes in the defining criteria for
PTSD (e.g., a change in cutoff scores: see, for example, (Shemesh et al., 2001, 2004).
Only a few studies have assessed CDI-PTSD for a period that was longer than 18
months. For example, Van Driel and Den Velde (1995) interviewed 18 myocardial
infarction patients two years post-MI using the structured clinical interview for the
diagnosis of PTSD (SCID-R-PTSD), and none of the participants was diagnosed
as having PTSD (Vilchinsky et al., 2017). Wikman, Bhattacharyya, Perkins-Poraz,
and Steptoe (2008), who evaluated 179 myocardial infarction patients three years
post-MI using self-report questionnaires(Wikman, Bhattacharyya, Perkins-Porras &
Steptoe, 2008), classified 13% as havingPTSD. The same rate (13.3%), on the basis
of a self-report questionnaire (PTSD Inventory; (Solomon et al., 1993), was repor-
ted by Ginzburg and Ein-Dor (Ginzburg & Ein-Dor, 2011) in a sample of myocar-
dial infarction patients eight years post-MI. In order to pinpoint the differences in
CDI-PTSD prevalence according to the instrument used, Einsle, Kraft, and Kollner
(Einsle, Kraft & Köllner, 2012) focused specifically on comparing different dia-
gnostic tools for PTSD among CAD, heart transplantation and cardiac arrhythmia
patients, but again found limited agreement between self-report measures (e.g., Im-
pact of Events Scale-IES-R; (Horowitz, Wilner & Alvarez, 1979); The Post-Traumatic
Stress Syndrome 10-Questions Inventory-PTSS-10; (Stoll et al., 2000)) and the SCID
(Structured Clinical Interview for DSM-IV-TR; (First, Spitzer, Gibbon, Williams
& others, 2002)APA, 2002). As in the aforementioned studies, the prevalence of
CDI-PTSD ranged from 15%− 48% when the PTSS-10 was applied, from 5%− 12%
when the IES-R was applied, and only from 1.7%− 9.8% when the SCID was used.
The vast variance in interval times − between index event and follow-up − should
be taken into consideration, however, as they differed greatly among each of the
diagnostic groups (ranging from two months to seven years). In a recent review
paper, Edmondson, Richardson, et al. (Edmondson, Shaffer, Denton, Shimbo &
Clemow, 2012) and Edmondson, Shaffer, et al. (Edmondson, Richardson et al.,
2012) suggested an aggregated prevalence estimate of 12% (95% CI, 9%− 16%)
for clinically significant symptoms of ACS-induced PTSD. Overall, the prevalence
estimate was 16% when self-report instruments were used, while the clinical dia-
gnostic interview yielded a prevalence estimate of 4%.
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3.2.2 Risk factors for Cardiac-disease-induced post-traumatic stress
disorder
In some studies, a younger age (i.e., early illness onset) was shown to be a risk
factor for PTSD (e.g., (Bennett & Brooke, 1999; Dinenberg, McCaslin, Bates & Co-
hen, 2014)). Other studies, however, did not find any age effect (e.g. (Roberge
et al., 2008)), or showed an opposite effect (Gao et al., 2015). This inconsistency
in findings was also detected with regard to gender. Some studies found that fe-
male myocardial infarction patients were more prone to develop PTSD than male
myocardial infarction patients (Hari et al., 2010; Brancu et al., 2016). Other studies
did not find any gender differences (e.g. (Marke & Bennett, 2013; Wikman et al.,
2012)), or found that male patients were at higher risk for PTSD than female pa-
tients (Gao et al., 2015). Ethnicity was also shown to be a risk factor in some studies
(e.g. (Kutz et al., 1994), (Wikman et al., 2008)), but not in others (e.g. (Ayers, Co-
pland & Dunmore, 2009; Wikman, Molloy, Randall & Steptoe, 2011)). Finally, all
but one study (Wikman et al., 2008) found no effect for socio-economic status (SES)
(e.g. (Ginzburg et al., 2003; Kutz et al., 1994; Whitehead, Perkins-Porras, Strike &
Steptoe, 2006; Wikman et al., 2011, 2012)). Other demographic variables including
marital status, cohabitation, number of children, income, education, employment,
and religion were found to be unrelated to CDI-PTSD (e.g. (Ayers et al., 2009;
Dinenberg et al., 2014; Edmondson et al., 2011; Ginzburg et al., 2003; Kutz et al.,
1994; Roberge et al., 2008)). Thus, no demographic variable was consistently found
to be a reliable risk factor for CDI-PTSD(Vilchinsky et al., 2017). In other areas of
post-trauma, however, the following variables were found to be reliable risk factors
for PTSD: female gender, younger age, racial/ethnic minority status, and lower
intelligence (e.g. (Brewin, Andrews & Valentine, 2000)). This discrepancy may be
attributed to some of the specific characteristics of cardiac disease (i.e., a higher
prevalence of male patients than female patients, who have their first cardiac epis-
ode at a younger age than women do (Bjarnason-Wehrens, Grande, Loewel, Völler
& Mittag, 2007)). The most consistent risk factor found for CDI-PTSD − as has
also been found for PTSD resulting from other (‘traditional’) events ((King et al.,
2012)) − was psychological functioning, whether it was conceptualised as premor-
bid distress, distress during the event, or premorbid personality difficulties. Fo-
cusing on medical- and illness-related putative risk factors, it was the perceived
severity rather than the objective severity which was associated with the develop-
ment of CDI-PTSD. This finding corresponds with numerous findings in the health
psychology field attesting to the more important role played by perceived illness
severity than by objective illness severity in terms of determining both patient dis-
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tress and adherence ((DiMatteo, Haskard & Williams, 2007; Grigioni et al., 2003;
Naidoo & Wills, 2000)). CDI-PTSD was found to be associated with a wide range
of negative physical and emotional consequences, from overall psychopathology to
mortality. Since most studies reviewed were either cross-sectional or retrospective,
however, it was often difficult to differentiate the consequences of CDI-PTSD from
its risk factors. Yet the findings regarding elevated levels of mortality and cardiac
events associated with CDI-PTSD are worthy of continued study, considering the
world-wide prevalence of cardiac disease.
3.2.3 Physiological factors
Additional biological mechanisms may be responsible, including increased activ-
ity in the hypothalamic pituitary adrenal axis, autonomic nervous system reactiv-
ity, inflammation, oxidative stress, and endothelial dysfunction. There is strong
evidence that these changes occur in response to chronic, daily stressors as well as
traumatic events and PTSD, but it remains to be seen whether they are responsible
for the associations of stress/trauma and CVD (Gill, Saligan, Woods & Page, 2009).
3.2.4 Treatment
Though more psychologically oriented CVD prevention trials have first and
foremost focused on reducing depressive symptoms, some evidence for the protect-
ive effects of stress reduction on CVD risk is available. Previous small trials found
that a variety of psychosocial interventions reduced the risk of recurrent CVD
events when added to traditional cardiovascular rehabilitation programs (Linden,
Stossel & Maurice, 1996). More recent large trials with carefully selected control
groups have provided further support. Gulliksson et al. (Gulliksson et al., 2011)
randomised 362 men and women with a CHD event in the last year to standard
care that included control of traditional cardiovascular risk factors or to standard
care plus a 20-session cognitive behavioural therapy intervention focused on stress
management. Over a mean follow-up period of 7.8 years, the stress management
group had significantly fewer recurrent CVD events (HR : 0.59, 95% CI : 0.42-
0.83) and myocardial infarctions (HR : 0.55, 95% CI : 0.36-0.85). Another recent
trial comparing transcendental meditation to health education in 201 black men
and women with CHD found the meditation group had a significant reduction in
a combined endpoint of all-cause mortality, myocardial infarction, or stroke over a
mean of 5.4 years (HR : 0.52, 95% CI : 0.29− 0.92) (Schneider et al., 2012). Ad-
ditional studies are needed to examine the effects of stress reduction for primary
prevention of CVD as well as to explore treatments in patients with PTSD. How-
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ever, these prior studies suggest that psychological stress is a reasonable target for
CVD prevention.
However, while traumatic conditions within the spectrum of acute coronary
syndrome and potentially traumatic cardiological treatment procedures (e.g., de-
fibrillator implantation) have been at the centre of research efforts, the relationship
of PTSD and CTR has not received any attention so far.
3.3 Depression and cardiovascular disease
Depression and anxiety are the most frequent disorders accompanying somatic
diseases. Depressive disorders are predominantly characterised by persistent de-
pressive mood combined with loss of interest, pleasure, and energy . With a life-
time prevalence of up to 24% for major depressive episodes ((Ferrari et al., 2013;
Kessler, Chiu, Demler & Walters, 2005)), depressive disorders represent one of the
most frequent types of psychiatric disorders. More common in females, depressive
disorders are associated with a significant impairment of quality of life ((Saarni et
al., 2007)) and high psychological strain, including suicidal ideation and behaviour
((Hardy, 2009; Scott et al., 2007).
3.3.1 Prevalence of depression and cardiac mortality
Major depression is a highly prevalent condition, affecting approximately 10%
of the population (Kessler, Chiu et al., 2005). It is also a growing global problem
(Whiteford et al., 2013), and has been consistently associated with increased risk
of CHD (Carney & Freedland, 2017). It is therefore not surprising that depression
is highly comorbid with CHD: Major depression is two to three times more com-
mon among patients with CHD than in the general population. The prevalence
of depression is 15− 30% in patients with CHD (Lichtman et al., 2014), and is ap-
proximately twice as high in women than men, especially affecting young women
in the aftermath of acute myocardial infarction (Vaccarino & Bremner, 2017).
3.3.2 Risk factors
Depression as a risk factor for CHD has been characterised from mild depress-
ive symptoms to a clinical diagnosis of major depression. As defined by the Dia-
gnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V), clinical
depression, or major depression, is characterised by depressed mood or anhedo-
nia (loss of interest or pleasure) for at least 2 weeks accompanied by significant
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functional impairment and additional somatic or cognitive symptoms (Association,
2013). Most epidemiological studies of depression and incidence of CHD have used
depressive symptom scales, and have frequently demonstrated a dose−response
pattern, with higher levels of depressive symptoms being associated with higher
risk (Carney & Freedland, 2017).
The exact mechanisms linking depression to increased CHD risk are complex
and multi-factorial, and still incompletely understood (Carney & Freedland, 2017).
Although adverse lifestyle behaviours and traditional CHD risk factors, such as
smoking and sedentary lifestyle, largely contribute to the risk, they do not explain
it entirely. In CHD patients, depression is also associated with severity of func-
tional impairment, lower adherence to therapy and lower participation in cardiac
rehabilitation. Whether and to what extent these factors explain the relationship
between depression and CHD deserves future study. The present paper summar-
ises key aspects in our current knowledge, linking depression and CHD within
the intersecting fields of neuroscience, cardiovascular physiology, and behavioural
medicine. It is our objective of bringing attention to this area and stimulating in-
terdisciplinary research, clinical awareness, and improved care (Vaccarino et al.,
2019).
3.3.3 Depression and coronary heart disease
As stated above, many studies have shown a relationship between major de-
pression, or depressive symptoms, and CHD (Carney & Freedland, 2017; Meijer et
al., 2011; Gan et al., 2014). This literature has been summarised by a number of
meta-analyses (Meijer et al., 2011; Gan et al., 2014; Nicholson, Kuper & Heming-
way, 2006), all providing evidence for an association between clinical depression
(or depressive symptoms) and CHD. This link is seen in individuals initially free
of CHD and in a variety of CHD patient populations, including patients with ACS,
heart failure, stable CHD, and post-coronary bypass surgery. However, individual
studies have produced heterogeneous risk estimates and have varied in their ability
to adjust for other factors such as smoking, physical inactivity, other risk factors,
and severity of CHD (Vaccarino et al., 2019). Indeed, depression is associated with
several CHD risk factors and health behaviours as described above. In statistical
models that adjust for these risk factors, depression usually remains an independ-
ent risk factor for CHD, suggesting a biological relationship between these two
disease states that remains in part unexplained by an increase in traditional risk
factors or lifestyle behaviours. In one of the relatively recent meta-analyses, which
included 30 prospective cohort studies of individuals initially free of CHD, depres-
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sion was associated with a 30% increased risk of future coronary events (Gan et
al., 2014). The association remained significant in the group of studies that ad-
justed for socio-demographic factors and lifestyle behaviours (Meijer et al., 2011).
In community samples and in general practice clinics, the rate of depression is
about, 10−%11 but it goes up to about 15− 30% in patients with CHD (Cassano
& Fava, 2002; Ziegelstein, 2001). Studies have also suggested that specific subtypes
of depression may be more strongly associated with CHD risk than others. For in-
stance, patients with a new onset of depression after ACS, with treatment-resistant
depression, or with somatic depressive symptoms as opposed to cognitive symp-
toms, are all at increased risk of developing adverse CHD outcomes. However,
there is no clear consensus on whether these different phenotypes carry variations
in risk (Freedland & Carney, 2013).
Gender differences
Among women, depression is approximately twice as prevalent as in men and
has shown some of the most robust associations with CHD (Vaccarino, 2015). De-
pression in women is also on average more severe than in men and has an earlier
age of onset. Women with CHD similarly have twice the rates of depression as men
with CHD (Mallik et al., 2006; Vaccarino et al., 2014; Smolderen et al., 2015). The
condition is especially common in young women who have survived a myocardial
infarction (Mallik et al., 2006; Vaccarino et al., 2014, 2018) about half of women
younger than 60 years with a previous myocardial infarction have a history of ma-
jor depression (Vaccarino et al., 2014; Smolderen et al., 2015; Vaccarino et al., 2018).
Of note, young women are more likely to die of myocardial infarction than men
(Cenko et al., 2018). Depression is linked to early life adversities and psycholo-
gical trauma, which tend to be more common in girls than boys and may result in
chronic dysregulation of neurohormonal stress systems. This may begin at an early
age, setting the stage for an increase in cardiovascular risk in women many years
before CHD becomes manifest (Vaccarino & Bremner, 2017).
Among women, depression increases their risk for CHD between 30% and two-
fold depending on depression measures and CHD endpoints (Wassertheil-Smoller
et al., 2004; Whang et al., 2009). Two follow-up studies of young community
samples (< 40 years old) found that the impact of depression on CHD risk was
higher among women than men (A. J. Shah, Veledar, Hong, Bremner & Vaccarino,
2011; Wyman, Crum & Celentano, 2012). In the Third National Health and Nutri-
tion Examination Survey (NHANES III), a history of major depression or suicide at-
tempt was associated with almost 15-fold increased risk of ischaemic heart disease
among women, and 3.5 in men (A. J. Shah et al., 2011). In the prospective Com-
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munity Mental Health Epidemiology Study of Washington County, mean (MD),
women younger than 40 years with depression had a six-fold increased risk of
CHD compared with women of the same age without depression, while depres-
sion was not associated with CHD in men or older individuals (Wyman et al., 2012).
Even among patients referred for coronary angiography, depression is more pre-
dictive of adverse cardiovascular outcomes in young women than in other groups
(A. J. Shah et al., 2014). After an acute myocardial infarction, however, depression
seems to affect prognosis to a similar extent in women and men (Parashar et al.,
2009). Overall, the evidence suggests that depression is more closely associated
with CHD for women than for men, with the strongest effects for younger women.
Depression as a prognostic factor in acute coronary syndromes
Despite some heterogeneity of findings, the bulk of the evidence supports the
notion that depression after ACS is a risk factor for all-cause and cardiac mortality,
as well as for composite outcomes including mortality or non-fatal cardiac events
(Lichtman et al., 2014). Among patients hospitalised for ACS, the increased risk oc-
curs regardless of whether depression pre-dated the ACS event or developed sub-
sequently (Lichtman et al., 2014; Parashar et al., 2006; LEUNG et al., 2012). How-
ever, some evidence suggests that depressive episodes that develop soon after an
ACS may carry a higher risk than episodes that begin before the event (Spijkerman
et al., 2005; Carney et al., 2009; Peter de Jonge, van den Brink, Spijkerman & Ormel,
2006). Depression is also a major determinant of unplanned hospitalisations within
30 days after a hospital discharge for myocardial infarction (Hess et al., 2016).
Some studies have found that the somatic symptoms of depression may carry
a higher risk than cognitive symptoms (Martens, Hoen, Mittelhaeuser, de Jonge &
Denollet, 2010; Smolderen et al., 2009; de Jonge et al., 2006). Depressive episodes
that do not respond to standard treatments have also been identified as high-risk
subtypes (Carney & Freedland, 2009). However, evidence suggests that recognition
and treatment of depression improves prognosis. In a previous study, patients with
depression that was recognised or treated during an myocardial infarction hospit-
alisation or at discharge had similar 1-year mortality than those without depres-
sion, while a higher mortality was confined to patients with untreated depression
(Smolderen et al., 2017). These data are important since depression in ACS patients
is frequently under-recognised and untreated (Smolderen et al., 2009; Huffman et
al., 2006; Cepoiu et al., 2008).
Patients with comorbid depression and CHD have lower adherence to treat-
ments and lifestyle changes; for example, they are significantly less likely to adhere
to medication regimens (Gehi, Haas, Pipkin & Whooley, 2005; Benner et al., 2002)
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to follow lifestyle recommendations (e.g. smoking cessation, exercise), and practice
self-management (e.g. weight monitoring in heart failure) (Rumsfeld & Ho, 2005).
They are also less likely to participate in cardiac rehabilitation programmes and
more likely to drop out of these programmes (Gehi et al., 2005; Swardfager et al.,
2011; Blumenthal, Williams, Wallace, Williams Jr & Needles, 1982). Improvement
in depression is associated with better self-reported adherence to medications and
secondary prevention lifestyle (Hare, Toukhsati, Johansson & Jaarsma, 2014; Bauer
et al., 2012).
During the first year post-MI, the presence of depression is associated with
about 40% higher health-care costs, including outpatient care and hospital re-
admissions (Frasure-Smith et al., 2000). In addition, the presence of major depres-
sion in the past 12 months can affect societal costs indirectly through work absence
(Stein, Cox, Afifi, Belik & Sareen, 2006). For all the above reasons, major depres-
sion has been proposed as a risk factor for adverse medical outcomes in patients
with ACS (Lichtman et al., 2014). The application of collaborative care interven-
tions for depression in CHD populations has emerged as a promising health-care
model to reduce the societal impact of this common comorbidity (Katon et al., 2010;
P. J. Tully & Baumeister, 2014).
3.3.4 Physiological factors
The well-documented association between depression and CHD has prompted
a search for underlying mechanisms. One possibility is that changes in neuro-
biology in depressed patients alter cardiovascular function and structure (Burg
& Soufer, 2014; Soufer Robert, 2004; Vaccarino & Bremner, 2013). Additionally,
because of the known link between stressful exposures and depression, (Kendler,
Thornton & Gardner, 2000) dysregulation of stress-response pathways may contrib-
ute to CHD in vulnerable individuals. Thus, neuro-biological mechanisms associ-
ated with stress and depression may be relevant for CHD risk. These mechanisms
include changes in sympathetic nervous system and neurohormonal function as
well as alterations in central brain function (Veith et al., 1994; Carney et al., 1999).
3.3.5 Behavioural factors
Although positive behaviour changes for primary and secondary prevention of
CHD are recommended (Piepoli et al., 2016), a sizeable proportion of patients do
not make any changes (McBride et al., 2008). One factor that may shape indi-
viduals’ responses to a health behaviour change is their emotional state, such as
the presence of depression. Prior studies have extensively documented the associ-
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ation of depression with adverse health behaviours, including smoking (Mykletun,
Overland, Aarø, Liabø & Stewart, 2008), excessive drinking, (Levola, Holopainen
& Aalto, 2011) physical inactivity, and overeating (Ferrer-Garcia et al., 2017; Bruch,
1964; van Strien, Peter Herman & Verheijden, 2012). For example, depression is
associated with an increased risk of becoming a smoker, with an increased rate of
daily smoking, and with a lower probability of quitting smoking (Breslau, Peterson,
Schultz, Chilcoat & Andreski, 1998; Fergusson, Goodwin & Horwood, 2003; Anda
et al., 1990; Hall, Muñoz, Reus & Sees, 1993). Depression is also associated with
overweight and obesity, and with approximately 40% higher risk of developing
Type 2 diabetes (Petri et al., 2017; Mason & Lewis, 2014; Lee et al., 2017; Pine, Gold-
stein, Wolk, Weissman & others, 2001; Goodman & Whitaker, 2002; Kawakami,
Takatsuka, Shimizu & Ishibashi, 1999; Golden et al., 2004; Arroyo et al., 2004). Some
of these associations appear bidirectional (Pan et al., 2010, 2012). Obesity and other
cardiometabolic risk factors have been linked to increased oxidative stress, inflam-
mation, and microvascular dysfunction (Badimon et al., 2017; Sorop et al., 2017;
Ngo et al., 2014), which lend further support for a central role of inflammation
and microvascular disease as possible links between cardiometabolic disturbances,
depression and CHD (Vaccarino et al., 2009, 2008; Capuron et al., 2008; Agtmaal,
Houben, Pouwer, Stehouwer & Schram, 2017).
3.3.6 Treatment of depression in patients with cardiovascular dis-
ease
There are several treatments options for the CHD patient with depression, from
medications to various forms of psychotherapy, to exercise and stress management
approaches. Although treatment of depression has not been shown to improve
cardiovascular outcomes in CHD patients, depression should still be addressed
if severe enough, in order to promote patient wellness and Quality of life (QoL).
Tricyclics should be avoided in this patient population.
3.3.7 Psychotherapeutic treatment
A number of interventions can be useful for CHD patients with depression.
Psychotherapy helps people with depression understand the behaviours, emotions,
and ideas that contribute to depression, regain a sense of control and pleasure in
life, and learn to apply coping skills (Hirschfeld, 2012). Psychodynamic therapy
is based on the assumption that a person is depressed because of unresolved,
generally unconscious conflicts, often stemming from childhood. Interpersonal
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therapy focuses on patients’ behaviour and interactions with family and friends.
The primary goal of this therapy is to improve communication skills and increase
self-esteem during a short period of time. Cognitive Behavioural Therapy (CBT)
involves examining thought patterns that can be negative and self-defeating, and
going over the basis of such thoughts and how they contribute to negative emo-
tions. Other therapies useful for depression include stress management and stress
reduction techniques, such as deep breathing, progressive muscle relaxation, yoga,
meditation, and mindfulness-based stress reduction. These interventions can be
provided in group format or individually by trained personnel. Psychotherapy has
been shown to be equally effective for depression as medications, and some people,
especially with early life stress issues, may not respond to medication without psy-
chotherapy.
The Enhanced Recovery in Coronary Heart Disease Patients (ENRICHD) trial
could not demonstrate a benefit for CBT, with medication intervention for severe
depression, for the improvement of cardiac outcomes in depressed or socially isol-
ated patients with CHD (Berkman et al., 2003). The effects of the intervention on
depression, however, were modest, and patients who responded to treatment did
have a better outcome than those who did not respond (Freedland & Carney, 2013).
Unanswered questions, therefore, remain on whether treatment of depression may
improve CHD outcomes.
3.3.8 Pharmacological treatment
Antidepressant medications are a useful tool for the treatment of depression
in patients with CHD, especially those with moderate-to-severe depression (Davis,
Hamner & Bremner, 2016; Fournier et al., 2010). Antidepressants act on the sero-
tonin, dopamine, and norepinephrine systems and other neurotransmitter circuits
in the brain.
However, while depressive conditions and CHD have been at the centre of many
important research efforts, the relationship of depressive disorders and CTR has not
received any attention so far.
3.4 Anxiety disorders and cardiovascular disease
Anxiety is characterised by transient fear, uncertainty, and apprehension about
the future (Cervellin et al., 2016). Individuals vary on the frequency and intensity
with which they experience anxiety (Barlow, 2004). When an individual exper-
iences anxiety frequently, at high intensities, and/or in inappropriate situations,
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they may then be diagnosed with an anxiety disorder, including generalised anxi-
ety disorder, panic disorder, phobias, and others(Barlow, 2004). Resulting avoid-
ance behaviour and social withdrawal are very resistant to spontaneous recovery
without specialised treatment (Celano, Daunis, Lokko, Campbell & Huffman, 2016;
Nikendei, Kindermann, Junne & Greinacher, 2019). Of note, DSM-V, reclassified
PTSD as a ‘trauma and stressor-related disorder’ rather than an anxiety disorder.
In the United States, the lifetime prevalence of any anxiety disorder is greater than
25% (Kessler, Berglund et al., 2005).
Generalised Anxiety Disorder
General anxiety disorder is highly prevalent in patients with cardiac disease
(Celano et al., 2016). A recent meta-analysis found an 11% point prevalence and
26% lifetime prevalence of General anxiety disorder in CAD patients (P. J. Tully &
Cosh, 2013). A similar meta-analysis in HF patients found General anxiety disorder
prevalence to be 14% (Easton, Coventry, Lovell, Carter & Deaton, 2016). These
rates are significantly higher than the 3− 7% lifetime prevalence of General anxiety
disorder in the general US population (Hoge, Ivkovic & Fricchione, 2012; Kessler,
Chiu et al., 2005).
GAD is independently associated with poor outcomes in patients with estab-
lished cardiac disease, especially CAD. Though one study found that General anxi-
ety disorder was protective in the post-ACS period (Parker, Hyett, Hadzi-Pavlovic,
Brotchie & Walsh, 2011), most studies suggest that General anxiety disorder is asso-
ciated with poor cardiac health in all stages of CAD (Frasure-Smith & Lespérance,
2008; Roest, Zuidersma & de Jonge, 2012; P. J. Tully, Winefield et al., 2015). Fol-
lowing myocardial infarction, General anxiety disorder has been linked to a nearly
twofold increased risk of mortality over the subsequent 10 years (Roest et al., 2012),
and in patients with stable CAD, General anxiety disorder is associated with a two-
fold increased risk of major adverse cardiac events over the next 2 years (Frasure-
Smith & Lespérance, 2008). In a prospective study of 158 patients undergoing
CABG surgery, General anxiety disorder was associated with incident major ad-
verse cardiac events over the subsequent 5 years (P. J. Tully, Winefield et al., 2015).
The associations between General anxiety disorder and outcomes in HF have not
yet been studied (Bankier, Barajas, Martinez-Rumayor & Januzzi, 2008).
Panic Disorder
panic Disorder (PD) also is common in patients with heart diseases. Among
patients with CAD, studies have varied results for prevalence: one review provides
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PD prevalence estimates of 10− 50% (Fleet, Lavoie & Beitman, 2000), another ana-
lysis and a recent cross-sectional study estimate PD prevalence of 5− 8% in patients
with established CAD (Todaro, Shen, Raffa, Tilkemeier & Niaura, 2007). These lat-
ter studies are likely closer to the true estimate, as a study of post-ACS patients
found PD to be significantly less prevalent than General anxiety disorder or de-
pression (Celano, Suarez, Mastromauro, Januzzi & Huffman, 2013).
While less common than General anxiety disorder, PD significantly increases
the risk of the development and progression of cardiac disease. In a cohort study of
nearly 80, 000 individuals without pre-established CAD (and half with PD), PD was
associated with a nearly twofold increased risk of incident CAD (Gomez-Caminero,
Blumentals, Russo, Brown & Castilla-Puentes, 2005). In another cohort study of
57, 615 patients with PD and nearly 350, 000 age- and sex-matched controls, pa-
tients with PD had a significantly higher risk of the development of CAD, but a
lower risk of CAD-related mortality (Walters, Rait, Petersen, Williams & Nazareth,
2008). Finally, a systematic review and meta-regression analysis of over 1 million
patients found that PD was significantly associated with incident CAD, major ad-
verse cardiac events, and myocardial infarction (P. Tully et al., 2015).
3.4.1 Prevalence of anxiety disorders and cardiac mortality
Relative to psychological stress and trauma (Richardson et al., 2012) and de-
pression, (Nicholson et al., 2006) less is known about the association of anxiety and
anxiety disorders with cardiovascular risk. In a 2010 meta-analysis of 20 studies
(N = 249, 846) assessing the association of anxiety (i.e., anxiety, panic, phobia, post-
traumatic stress, and worry) with incident CHD, Roest et al. (Roest, Martens, de
Jonge & Denollet, 2010) found that initially healthy individuals with high anxiety
were at increased risk for incident CHD (HR : 1.26; 95% CI : 1.15− 1.38; P <
0.0001) and cardiac death (HR : 1.48; 95% CI : 1.14 − 1.92; P = 0.003), inde-
pendent of demographic variables, biological risk factors, and health behaviours.
Although studies of post-traumatic stress were included, no significant differences
in effect size estimates were found by anxiety type, suggesting that PTSD did not
account for the significant meta-analytic estimate. However, the meta-analytic es-
timate for the association of anxiety with CHD was not adjusted for depression,
which is highly comorbid with anxiety. More recently, 2 large prospective na-
tional registry studies have reported on the association of anxiety with incident
CHD. In a study of (Crum-Cianflone et al., 2014), 321 men who were assessed for
anxiety prior to military service, any anxiety disorder diagnosis was strongly asso-
ciated with incident CHD and acute myocardial infarction over 37 years of follow-
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up (multivariate adjusted HR : 2.17 (95% CI : 1.28− 3.67) and 2.51 (95% CI :
1.38− 4.55), respectively) (Janszky, Ahnve, Lundberg & Hemmingsson, 2010). An-
other prospective cohort study of (Berkman et al., 2003), 895 Finnish men and
women reported a significant association of anxiety with elevated risk of incident
CHD over 7 years of follow-up(Nabi et al., 2010). However, after adjustment for
confounders and concurrent depression, the only remaining signal of an association
of anxiety with fatal and nonfatal CHD was in women, with HR : 1.24; 95% CI :
0.91− 1.70 per unit increase in anxiety symptoms. Further, the anxiety scale as-
sessed somatic symptoms such as palpitation without exercise, irregular heartbeat,
chest pain upon anger or emotion, sweating without exercise, and flushing which
may themselves be symptoms of cardiovascular abnormalities that predisposed pa-
tients to cardiovascular events rather than due to anxiety, alone(Cohen, Edmondson
& Kronish, 2015). The association of anxiety with adverse outcome in patients with
existing CHD is similarly mixed. For example, in some studies generalised anxi-
ety disorder is associated with increased risk for recurrent events and mortality
(HRs = 1.7− 1.9) (Martens, de Jonge et al., 2010; Roest et al., 2012), but others
have found no association, (Versteeg et al., 2013) or even a protective effect for this
anxiety disorder (Parker et al., 2011).
3.4.2 Behavioural factors
Although the true association between anxiety/anxiety disorders and CVD is
unclear, a number of pathways by which anxiety may influence CVD onset or pro-
gression have been proposed. For example, anxiety is associated with poorer health
behaviours, such as cigarette smoking, excess alcohol consumption, lower physical
activity (Strine, Chapman, Kobau & Balluz, 2005), and poor diet (Antonogeorgos
et al., 2012), which increase the risk of CVD. Interestingly, anxiety has not been
clearly associated with medication non-adherence (DiMatteo, Lepper & Croghan,
2000).
3.4.3 Treatment of anxiety disorders in patients with cardiovascu-
lar disease
Anxiety disorders are common, and should be treated with pharmacotherapy
and cognitive behavioural therapy, based on the substantial quality of life burden
they represent. Although anxiety disorders may contribute to cardiovascular risk,
and may set the stage for emotionally triggered acute events in particular, currently
no study has demonstrated whether treating anxiety disorders offsets cardiovascu-
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lar risk. Thus, based on current evidence, clinicians should focus on assessing and
treating anxiety disorders in cardiovascular patients as an approach to improving
the quality of life of their patients (Celano et al., 2016).
3.4.4 Risk factors
Health behaviours may explain part of the link between anxiety disorders and
cardiac health. Adherence to a number of healthy behaviours, such as maintain-
ing a healthy diet, healthy level of physical activity, and medication adherence,
is clearly linked to improved outcomes in patients with cardiac disease (Duncan
& Pozehl, 2003; Kronish & Ye, 2013; McDermott, Schmitt & Wallner, 1997). Fur-
ther, for patients with stable HF or following myocardial infarction, attendance at
cardiac rehabilitation programs is an important step to improving health-related-
quality of life (HRQoL) and reducing the risk of future hospitalisation (Anderson
& Taylor, 2014). In contrast, unhealthy behaviour can lead to the development
or worsening of risk factors including diabetes, hypertension, elevated cholesterol,
obesity, and smoking, all which increase mortality in patients with cardiac disease
(Stamler et al., 1993).
Though the evidence is mixed, individuals who experience anxiety appear less
likely to engage in health behaviours. Anxious individuals tend to have an in-
creased dietary cholesterol intake and total energy intake, a sedentary lifestyle,
and decreased physical activity (Bonnet et al., 2005). This is consistent with the
finding that patients with PD and General anxiety disorder have increased odds
of dyslipidemia, obesity, diabetes, and substance use (Kinley et al., 2015; Simon et
al., 2006). Patients with PTSD have poor diet quality (with most energy obtained
from fatty acids), decreased physical activity, increased obesity, and increased rates
of smoking (Gavrieli, Farr, Davis, Crowell & Mantzoros, 2015). Among cardiac
patients, anxiety is associated with a lower likelihood of adhering to a number
of risk-reducing recommendations after myocardial infarction, including smoking
cessation, social support utilisation, and stress reduction (Kuhl, Fauerbach, Bush
& Ziegelstein, 2009). Patients with anxiety disorders also are less likely to both
attend and complete cardiac rehabilitation programs (Zolnierek & DiMatteo, 2009;
Lane, Carroll, Ring, Beevers & Lip, 2001). These behavioural factors in patients
with anxiety disorders could increase the likelihood of cardiovascular morbidity
and mortality.
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3.4.5 Diagnosis and treatment of anxiety disorders in patients with
cardiovascular disease
Diagnosing anxiety disorders in patients with cardiovascular disease is difficult
given the substantial overlap between the symptoms of anxiety disorders and those
of cardiovascular disease. Many symptoms of General anxiety disorder, such as
restlessness, fatigue, poor concentration, and sleep disturbance, are very common
in patients with cardiac disease, especially HF. Similarly, nearly all the symptoms
of a panic attack (e.g., palpitations, diaphoresis, dyspnea, nausea, chest pain) could
potentially be experienced in the setting of an arrhythmia, ACS, or paroxysmal
nocturnal dyspnea. If one relies too heavily on these overlapping symptoms, there
is a significant risk of attributing cardiac symptoms to anxiety (Celano et al., 2016).
Psychotherapy
Psychotherapy, especially CBT, is a reasonable alternative to pharmacotherapy
in cardiac patients and in some cases may be preferable to pharmacologic treat-
ment. In contrast to antidepressant and anxiolytic medications, psychotherapy has
no side effects or medication interactions. Thus, it can be utilised in patients re-
gardless of illness severity, comorbidities, or medication use(Celano et al., 2016).
CBT has been the most-studied psychotherapy in patients with heart disease.
To date, nearly all studies examining the use of CBT in cardiac patients have fo-
cused on the management of depression, not anxiety disorders (Cully et al., 2010;
Gary, Dunbar, Higgins, Musselman & Smith, 2010; Dekker et al., 2011; P. J. Tully,
Selkow, Bengel & Rafanelli, 2015; Freedland et al., 2009; Berkman et al., 2003).
In patients with CAD (post-MI or post-CABG surgery) or HF, CBT leads to sig-
nificantly greater improvements in psychological symptoms (typically depression
and anxiety) compared to usual care or enhanced usual care (Berkman et al., 2003;
Freedland et al., 2009; Freedland, Carney, Rich, Steinmeyer & Rubin, 2015). While
these studies targeted patients with depression, they are important because they
demonstrate that CBT is feasible in patients with cardiac disease and can lead to
improvement in psychological health.
Only one study has examined the impact of CBT for anxiety in patients with
cardiovascular disease. This study enrolled 29 patients with comorbid major de-
pression and General anxiety disorder who were participating in a HF self-care
program (P. J. Tully, Selkow et al., 2015). Patients chose whether to receive CBT
focused on General anxiety disorder or depression, then received CBT focused
on that disorder for 12 weeks. Both interventions led to non-significant improve-
ments in depression and anxiety scores, with minimal differences between groups,
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though the GAD-focused CBT group had fewer unplanned admissions during the
follow-up period than the MDD-focused group (P. J. Tully, Selkow et al., 2015).
Limitations of this study include the small sample size, lack of randomisation, and
the presence of pharmacologic intervention concurrent with CBT. However, it does
suggest that CBT focused on anxiety disorders may be effective.
Pharmacotherapy
Antidepressant medications are the most commonly used pharmacological treat-
ments for a variety of anxiety disorders, including General anxiety disorder, PTSD,
and PD. While there is evidence that selective serotonin reuptake inhibitorss
(SSRIs), some serotonin-norepinephrine reuptake inhibtors (SNRIs), and tricyclic
antidepressantss (TCAs) are effective for the management of General anxiety dis-
order, PTSD, and PD (Zitrin, Klein & Woerner, 1980; Linehan, Goodstein, Nielsen
& Chiles, 1983; Stein & Sareen, 2015). No studies have been conducted to examine
their efficacy for treating these disorders in patients with cardiovascular disease.
However, these agents have been studied in depressed cardiac patients, providing
data on their safety and tolerability in this population.
Again, although anxiety disorders at large and CHD have been at the centre of
many important research efforts, the relationship of anxiety disorders and CTR has
not received any attention so far.
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Chapter 4
Aim of Thesis
Chapter four discusses the aim of this thesis and delineates the research ques-
tions which will be addressed in the analysis of the study data.
4.1 Problem statement
As detailed in Chapter three, the psychological (accompanying) reactions to
acute and chronic heart diseases are the subject of current research. In a nut-
shell, there is robust evidence supporting the relevance of psychosocial factors for
coronary heart disease, chronic heart failure, arterial hypertension, and some ar-
rhythmias (Albus et al., 2019). Large-scale epidemiological studies have shown
that mental illness (Albus et al., 2019; Vaccarino et al., 2019; Cohen et al., 2015),
such as PTSD, depression, and anxiety disorders increase the risk of coronary
heart disease and worsen the prognosis of affected patients. Furthermore, it has
been shown that mental illness almost doubles the risk of (further) heart attacks
and, ultimately, mortality (Rutledge, Redwine, Linke & Mills, 2013). To the best
of my knowledge, only three studies by Bayer-Topilsky et al. (Bayer-Topilsky et
al., 2016, 2015, 2013) have specifically focused on the psychological burden of valv-
ular heart disease in the context of chronic mitral regurgitation to date. In their
2013 study, Bayer-Topilsky et al. endeavoured to define the prevalence and con-
sequences of PTSD as an emotional response to cardiac diseases in patients with
chronic mitral regurgitation. For this, they prospectively enrolled 186 patients
with moderate or severe organic mitral regurgitation, presenting NYHA class I
(absent) or II (minimal) dyspnea and compared them with 80 controls of similar
age (38 with completely normal cardiac function; 42 with mild mitral-valve pro-
lapse). They assessed mitral-regurgitation severity as well as PTSD, anxiety, and
depression symptoms. However, only patients with no, or at most mild, mitral
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regurgitation were included in their study. Bayer-Topilsky et al. were able to
show that PTSD prevalence was higher in chronic mitral regurgitation patients
than in controls (23% vs. 9%, p < .01). Although mitral regurgitation object-
ive severity (regurgitant volume : 77.8± 28.9 vs. 79.0± 27.5mL, p = .8) and ob-
jective consequences (le f t atrial volume : 59.1 ± 20.9 vs. 54.02 ± 15.6mL, p =
.1 right ventricular systolic pressure : 34.1 ± 11.4 vs. 32.9 ± 7.2mm Hg, p = .6)
were similar with and without PTSD (all p ≥ .1), patients with PTSD displayed
more symptoms (class II 74% vs. 38%; fatigue 71% vs. 38%, both p < .0001) and had
higher anxiety and depression scores (p < .0001). However, Bayer-Topilsky et al.
specifically excluded cardiac patients with an ejection fraction < 50%; NYHA class
≥III in their effort to clarify the possible association between psychological burden
and NYHA class II, a controversial indicator for surgery (Enriquez-Sarano, Nkomo
& Michelena, 2009).
In their 2015 study, Bayer-Topilsky et al. were able to show that patients with
severe chronic MR showed significant psychological stress (measured by anxiety
and post-traumatic stress [PTS]; both p < 0.01) and reported decreased physical
health-related-QoL (p < 0.01) compared to patients who had not undergone a
mitral valve operation or normal controls directly after operations but improved
over time (Bayer-Topilsky et al., 2015). In 2016, Bayer-Topilsky et al. assessed
whether mitral valve prolapse is associated with patients’ reported psychological
stress (Bayer-Topilsky et al., 2016). For this, they compared 216 patients with mitral
valve prolapse to 65 controls without mitral valve prolapse of similar age and sex
(age 61± 13 years; 63% men) and assessed the patients’ psychological burden (anxi-
ety, depression, post-traumatic stress symptoms), health-related quality of life, and
perceived severity of illness. Their results indicated that differentiating patients
into no/mild vs. moderate/severe chronic mitral regurgitation revealed no dif-
ferences in psychological burden or mental health-related quality of life between
patients with mitral valve prolapse and those without mitral valve prolapse within
each subgroup; no/mild mitral regurgitation and moderate/severe mitral regur-
gitation (all p ≥ .5). Via multivariate analysis, they revealed that in their sample
mitral valve prolapse was not independently associated with psychological burden
or health-related quality of life (all p ≥ .4). In addition, while objective severity of
the illness was not related to psychological burden or health-related quality of life
(all p ≥ .2), the patient’s perceived severity of illness predicted all psychological
burden (all p < .03) and quality-of-life outcomes (all p < .003).
These are important findings with regard to chronic mitral regurgitation and
associated mitral prolapse. However, to date, the psychological burden of cardiac
CTR patients in the wake of AMR has been starkly neglected. Despite its poten-
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tially devastating effects on affected patients’ physical health, the potential psy-
chological effects have yet to be described. Moreover, while traumatic conditions
within the spectrum of acute coronary syndrome and potentially traumatic car-
diological treatment procedures (e.g., defibrillator implantation) have been at the
centre of research efforts, neither the relationship of PTSD, depression, nor anxiety
and CTR has received any attention so far.
The objective of the study presented in this thesis was to use well-established
quantitative methods to map psychological stress and the prevalence of PTSD after
CTR in a predefined population. However, as these questionnaires, although val-
idated, only provide a limited opportunity for patients to express their views and
experiences (Haydon, van der Riet & Inder, 2017), a mixed-method approach was
chosen to enable this pilot study to capture a more differentiated picture of the
CTR patients’ situation.
4.2 Research questions and hypotheses
The presented cross-sectional study aimed to address the following research
questions: to assess the prevalence of post-traumatic stress disorder, depression,
anxiety disorder as well as medication adherence in CTR patients; to compare the
Chordae tendineae rupture sample’s assessed symptom burden to an age and sex
matched myocardial infarction sample; and to examine resilience and risk factors
influencing psychological burden. It was hypothesised that (i) the symptom bur-
den of Post-traumatic stress disorder, depression, and anxiety disorders would be
elevated. The psychological burden would be comparable to the symptom burden
found in myocardial infarction patients. (ii) Good medication adherence would be
associated with lower psychological burden. Furthermore, it was estimated that
(iii) males, patients with poorer NYHA status, lower educational level, and a more
severe degree of mitral regurgitation would present more psychological burden
symptoms. The qualitative part of this work examined how CTR patients perceived
the CTR event, ensuing coping mechanisms, and changes in health behaviour and
world view following the CTR event at an individual level.
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Chapter 5
Materials and methods
The following section details the methodological approaches used to assess the
CTR case sample and the myocardial infarction control sample. German versions of
implemented instruments, the developed interview guideline as well as the study’s
patient information and consent forms can be found in the appendix.
5.1 Ethical considerations
Prior to implementation, the presented study was approved by the Ethics Com-
mittee of the University Hospital Heidelberg (Ethics application no. S-041/2017)
and all participants provided their informed written consent. All participants were
able to withdraw their consent at any time without fear of any disadvantage to
them. The study was conducted in accordance with the Declaration of Helsinki
(most recent version: Fortaleza, Brazil, 2013; (Assembly, n.d.).
5.2 Study design and procedure
For this monocentric, non-interventional, cross-sectional study, clinical and psy-
chometric data was systematically collected in two cardiological samples (CTR case
study patients and myocardial infarction control study patients) after hospitalisa-
tion for a CTR event or myocardial infarction. Only patients who had been treated
for CTR or myocardial infarction in the Department of Cardiology, Heidelberg
University Hospital, Germany, were asked to participate in this study. The study
design for each of the two study sample groups is detailed in Flowchart 5.1 and 5.2
and the samples will be detailed in the following sections.
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5.2.1 Study sample
CTR participants
All patients treated for CTR in the Department of Cardiology of the Heidelberg
University Hospital, Germany, in the period between January 2013 and July 2017
were prospectively included in the study (n = 65). Predefined exclusion criteria
where: manifest psychotic disorder, bipolar disorder, and drug addiction, as well
as cognitive impairment as well as current severe comorbid physical conditions, for
example, cancer, human immunodeficiency virus. Following initial screening, pa-
tients who had either died or who were marked as no longer able to give informed
consent (cognitive impairment) were excluded from the sample (n = 11, 16.9%).
Thereafter, all potentially eligible patients (n = 54, 83.1%) were contacted via tele-
phone by an experienced researcher (Anna Cranz (AC)). Two patients could not be
contacted as the available contact details were no longer correct (n = 2, 3.1%).
Figure 5.1: Study design flowchart to illustrate the CTR case sample recruitment process
Hence, n = 52 CTR patients (80%) were approached and invited to particip-
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ate in the study. Of these, eight people (n = 8, 12, 3%) declined participation. In
total, n = 44 CTR patients agreed to participate in the study on a voluntary basis
and provided their informed written consent (see A.3). All 44 patients who had
agreed to participate, completed the quantitative psychometric measures detailed
in Section 5.3.3. These psychometric measures could be filled in either during a
routine check-up appointment in the Department of Cardiology, Heidelberg Uni-
versity Hospital, Germany, or in the comfort of the patients’ homes as restrictions in
autonomous mobility must be considered when evaluating patients of this age and
frailty. Patients assessed during a routine check-up appointment in the Department
of Cardiology, Heidelberg University Hospital, Germany, were met by AC and com-
pleted the questionnaires during unavoidable but irksome waiting times in a quiet
section of the respective department. Patients choosing to participate in the com-
fort of their homes scheduled an individual appointment with AC. All patients
were able to ask any arising questions during assessment and were able to stop the
assessment at any time. After CTR patients had given their written consent, their
medical history was screened to differentiate the overall CTR case group into two
subgroups according to whether they had been diagnosed with ‘CTR only’ or had
also been diagnosed with ‘CTR and subsequent AMR’. Following this screening,
the overall sample of CTR patients was divided into two subgroups: the ‘CTR only’
group comprised 23 patients (35.4%), and the group ‘CTR with AMR’ comprised 21
participants (32.3%). In addition, a subgroup of 21 (32.3%) patients was invited to
participate in a semi-structured interview, the guideline of which is detailed in the
section Qualitative measures and can be found in full in the appendix. In total, 20
(30.7%) of these participants agreed to participate in the interview that either took
place after the participants had completed the quantitative measures, or during a
scheduled appointment with the researcher AC at their home.
Myocardial infarction participants
As the control sample, all patients over the age of 60 who were hospitalised
for myocardial infarction and treated on the cardiological ward ‘Siebeck’ of the
Department of Cardiology of the Heidelberg University Hospital, Germany, in the
period between January 2016 and July 2018 and were prospectively included in the
study (n = 196). Predefined exclusion criteria whereas before: manifest psychotic
disorder, bipolar disorder, and drug addiction, as well as cognitive impairment as
well as current severe comorbid physical conditions, for example, cancer, human
immunodeficiency virus. Subsequently, case subjects (CTR patients) were matched
with control subjects (myocardial infarction sample) according to age and sex. Fol-
lowing this matching procedure, several control subjects matched each case subject
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in terms of sex and age (n = 96). In a next step, control cases who had either died
or who were not reachable via telephone were excluded (n = 25, 26%). In total, 71
patients (74%) were contacted via telephone and invited to participate in the study
as controls. For each matched case subject, the researcher contacted potentially eli-
gible control subjects. For example, for an 83-year-old male, the myocardial infarc-
tion sample held four control subjects matching his age and gender. In an iterative
process, the researcher then contacted the four potential matches to invite them to
participate in the study. Once a potential control provided informed consent to par-
ticipate in the study, the researcher did not contact further matching controls. Fol-
lowing this initial screening process, 27 patients were excluded (28.2%) as they were
either no longer able to give informed consent (cognitive impairment : n = 7, 7.3%)
or declined participation (n = 20, 28.2%). In total, n = 44 myocardial infarction
patients agreed to participate in the study on a voluntary basis and either chose to
receive the qualitative measures detailed below by post, including a postage paid
return envelope and full contact and consent information, or scheduled an appoint-
ment with AC. Nine participants were excluded (9.4%), as three failed to include
their written consent in the return envelope, while a further two did not return
the questionnaires and four questionnaires were excluded due to extensive miss-
ing data. Hence, finally, a total of n = 35 myocardial infarction controls provided
their informed written consent and completed all the quantitative psychometric
measures detailed in Section 5.3.3.
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Figure 5.2: Study design flowchart to illustrate the myocardial infarction sample recruitment process
5.3 Study instruments, medical information, and qual-
itative data
Socio-demographic, medical, psychometric, and qualitative data were collected.
Where applicable, established and carefully validated questionnaires were applied
to evaluate psychometric parameters.
5.3.1 Patients’ socio-demographic characteristics
A demographic questionnaire was used to obtain participant characteristics,
such as age, sex, level of education, employment, marital status, previous psychi-
atric history, namely the history of diagnosed past PTSD, depression, and anxiety
disorder, as well as prior and current medication use.
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Table 5.1: Normal ranges and severity partition cutoff values for 2DE-derived LVEF
Normal range Mildly abnormal Moderately abnormal Severely abnormal
LV EF (%) LV EF (%) LV EF (%) LV EF (%)
Female 52–72 41–51 30–40 <30
Male 54–74 41–53 30–40 <30
5.3.2 Patients’ medical characteristics
Patients’ medical characteristics were retrieved from their electronic hospital
medical files and included their cardiac history (documented previous myocar-
dial infarction or angiographically documented coronary artery stenosis or insuffi-
ciency), the presence and type of significant present co-morbid risk factor illnesses,
namely diabetes mellitus, obesity, nicotine abuse, and the indexed cardiac event
diagnosis (i.e.myocardial infarction, CTR, AMR). Additionally, the following clin-
ical data were collected, where available: left ventricular ejection fraction (LVEF),
left ventricular end-diastolic diameter (LVEDD), 6-Minute walking distance as-
sessed via the Six-Minute Walk Test (6MWT), degree of mitral regurgitation, and
NYHA class.
The left ventricular ejection fraction and the left ventricular end-diastolic dia-
meter
To quantify how well the left ventricle is able to pump blood through the
body with each heartbeat, left ventricular function measurements are used (Dupuis
Marlène et al., 2017). The LVEF is an key parameter in echocardiography as it
can alter in several diseases. The LVEF correlates with numerous clinical symp-
toms, such as the severity of dyspnea, and is an important prognostic factor in
acute myocardial infarction. LV systolic dysfunction is defined as an LVEF fraction
< 60% and/or an LVEDD ≥ 45 mm. Severe LV dysfunction is set at a LVEF of
< 30% (Members et al., 2012). The normal range cut-off values of dysfunction are
shown in Table 5.1 for males and females (Lang et al., 2015):
The LVEDD indicates LV end diastolic dimension and normal ranges diastolic
dimension (mm) are defined as between for males 42.0− 58.4 and between 37.8−
52.2 for females. It can be used to calculate Fractional Shortening (FS) is a 2D
M-Mode method.
The Six-Minute Walk Test
6MWT is used to measure the maximum distance that a person can walk in 6
minutes and is commonly used to assess function in patients with cardiovascular
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or pulmonary disease (Steffen, Hacker & Mollinger, 2002). In studies in patients
with CHD, lung disease and elderly patients, the 6MWT has be shown to be a valid
functional performance test and is accordingly recommended by the European So-
ciety of Cardiology (Remme, Swedberg, Task Force for the & Treatment of Chronic
Heart Failure, 2001). A distance of less than 300 min 6 minutes predicted an in-
creased likelihood of death among 833 subjects with left ventricular dysfunction
(Steffen et al., 2002).
5.3.3 Quantitative measures
The following established psychometric measures were used to evaluate the
participants’ psychological burden:
The Post-traumatic Diagnostic Scale
Primary traumatisation was assessed by the well-established German version
(Griesel, Wessa & Flor, 2006) of the Post-traumatic Stress Diagnostic Scale (Post-
traumatic Diagnostic Scale (PDS); (Foa, Cashman, Jaycox & Perry, 1997). The
PDS was developed in 1997 by Foa et al. as the first psychometric instrument
to map all criteria A - F of PTSD from DSM-IV (A = traumatic experience, B = in-
trusions, C = avoidance, D = hypervigilance, E = time criterion, F = functional impair-
ment; (Foa et al., 1997). It consists of 4 parts: part 1 and 2 evaluate the presence
of a traumatic experience, part 3 assesses the intensity of the three main symp-
toms intrusions, avoidance, hypervigilance as well as the time criterion and part
4 assesses functional impairment in everyday life. The PDS allows for both the
dichotomous (PTSD yes/no) and continuous evaluation of data (symptom severity
of intrusions, prevention and hypervigilance). Every item is answered on a four
point Likert scale ranging from 0 to 3; the severity score ranges from 0 to 51. The
German translation of the PDS was validated by Griesel et al. in 2006 (Griesel
et al., 2006). The cut-offs for the symptoms severity rating categories are as fol-
lows: < 10 : mild, > 11 and < 20 : moderate, > 21 and < 35 : moderate to severe
> 36 : severe. In relation to PTSD diagnoses through structured clinical interviews
Clinician-Administered PTSD Scale for DSM-5 (CAPS), a sensitivity of 100 % and
a specificity of 64% have been shown. The PDS result is evaluated as positive (high
probability of PTSD) if at least one positive value is achieved for all symptom cri-
teria A - F (Griesel et al., 2006). In the present work, the PDS was applied in an
adapted form: the CTR or myocardial infarction event was defined as the A cri-
terion and all DSM-IV criteria A - F were reviewed with the focus on the event.
Accordingly, the evaluation resulted in a dichotomous parameter (PDS-adap, see
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appendix). The procedure is based on Kiphuth et al. approach in their well-known
preliminary study on PTSD and transient ischemic attacks (Kiphuth, Utz, Noble,
Kohrmann & Schenk, 2014).
The German Dissociative Experience (Fragebogen zu Dissoziativen Symptomen)
20-Item Scale
The questionnaire on dissociative symptoms (German: Fragebogen zu Dis-
soziativen Symptomen, Questionnaire for Dissociative Symptoms (FDS)) is the
authorised German translation and editing of the Dissociative Experiences Scale
(Dissociative Experiences Scale (DES); (E. M. Bernstein & Putnam, 1986) by Frey-
berger (Freyberger et al., 1998; Rodewald, Gast & Emrich, 2006). The DES is the
internationally most frequently used and best-validated screening instrument for
dissociative disorders (E. M. Bernstein & Putnam, 1986). The DES records everyday
dissociative experiences and pathological dissociative symptoms and provides an
overall measure of the severity of the dissociative symptoms. Further differential
diagnosis is recommended above a certain total value (cut-off). However, there is
no generally accepted rule. In the literature rather different cut-off values of 15 - 30
points are mentioned for the DES (cf. e.g.(E. Bernstein et al., 1993; Boon & Draijer,
1993; Steinberg, Rounsaville & Cicchetti, 1991)). The FDS (Freyberger et al., 1998)
is a German version of the DES, which was extended by a subscale to conversion
symptoms in order to adapt the questionnaire to the ICD-10 classification. In ad-
dition, Spitzer et al. (C. Spitzer, Mestel, Klingelhöfer, Gänsicke & Freyberger, 2004)
published a 20 item short version of the FDS, the FDS-20, which was extracted from
the FDS’s 44 item version based on item analysis results. The 20 items with the
highest selectivity were extracted from the FDS’s original 44 items and combined
into the short version FDS-20. On a rating scale (0 = never, 100 = always) divided
into 10% steps, the participants estimate how often they have encountered the re-
spective dissociative experience. The mean value is calculated from the frequency
estimates as the total score. In addition, subscale values for amnesia, depersonal-
isation/derealisation, absorption experience and conversion can be calculated. For
the evaluation, which requires that no more than two items remain unanswered,
the item values are aggregated and then divided by the number of answered items;
the calculated mean value can thus fluctuate between 0 and 100. The cut-off values
of 13 FDS and 15 points DES, FDS, DES and FDS-20 enable reliable screening for
complex dissociative disorders. The FDS, as well as its short form FDS-20, shows
similarly good quality criteria as the original version (Freyberger et al., 1998). The
internal consistency (Cronbach’s α) lies between 0.91 and 0.93, the test-retest reli-
ability between 0.80 and 0.82. Furthermore, there are percentile rank standards for
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samples of healthy individuals and various clinical groups.
The Patient Health Questionnaire
The Patient Health Questionnaire (PHQ) was developed as a self-rating instru-
ment by the American psychiatrist Robert L. Spitzer and the internist Kurt Kroenke
(C. Spitzer et al., 2004). A German version (PHQ-D) was developed at the Heidel-
berg University Hospital and its validity has since been proven in numerous stud-
ies involving multiple patient groups (Gräfe, Zipfel, Herzog & Löwe, 2004). The
PHQ-D covers eight mental disorders that can be divided into two groups: A)
Disorders for which the PHQ-D assesses all diagnostic criteria for the specific dia-
gnosis according to DSM-IV (‘threshold’ disorders) including major depression,
panic disorder, and bulimia nervosa. B) disorders for which fewer criteria are
requested than are necessary for a specific DSM-IV diagnosis (‘subthreshold dis-
orders’). These include the other depressive disorders, other anxiety disorders,
somatoform disorders, alcohol abuse, and the binge eating disorder. As the DSM-
IV criteria are not completely assessed, these sections have a screening rather than
a diagnostic function. Since the PHQ-D directly queries the diagnostic DSM-IV
criteria, the instrument has a high content validity. In addition to the diagnostic
modules, psychosocial functioning as well as eight frequent psychosocial stressors
are also investigated. For this work, established short form of the PHQ-D was used
comprising the depression module (9 items), the panic disorder (5 items), and gen-
eral anxiety disorder module (7 items) as well as one item assessing psychosocial
functioning ((Gräfe et al., 2004); (Löwe et al., 2008)). In the following subsections
each used module will be presented in more detail.
The Brief PHQ-D’s Depression Module
Depressive symptoms were assessed with the German version of the PHQ-9 De-
pression Module (Gräfe et al., 2004) from the Patient Health Questionnaire [PHQ;
(Gräfe et al., 2004)]. The module assesses depressive symptoms, the severity of the
disorder, and the development of symptoms according to DSM-IV criteria (Gräfe et
al., 2004) and shows very good validity (Kroenke, Spitzer & Williams, 2001). Nine
items evaluate whether a patient has experienced depressive symptoms in the past
two weeks. The items are scored on a scale from 0 (not at all) to 3 (nearly every day).
The severity of depressive symptoms is determined by calculating the sum score
ranging between 0 (no depressive symptoms) and 27 (all symptoms occur daily).
Scores between 1 and 4 suggest minimal depressive symptoms, scores between 5
and 9 suggest a mild depression, scores between 10 and 14 suggest a moderate
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depression, and scores of 15 or above suggest a severe depression (Kroenke et al.,
2001). In a representative German norm sample, the mean sum score for depression
was M = 3.60 (SD = 4.08; (Rief, Nanke, Klaiberg & Braehler, 2004).
The Brief PHQ-D’s Panic Disorder Module
The PHQ Panic Module consists of 15 questions, each question assessing a DSM-
IV criterion of the panic disorder. The Brief PHQ-D’s panic disorder scale only
comprises five items and has been proven to be suitable for the screening of panic
disorders according to the DSM-IV criteria. The scale is evaluated categorically, i.e.
(based on the procedure for diagnosing a panic disorder according to DSM-IV) a
given number of questions in the module must be answered with "Yes" in order to
be able to diagnose a panic syndrome (Gräfe et al., 2004).
The Brief PHQ-D’s Generalised Anxiety Disorder Module
The German version (Löwe et al., 2008) from the Patient Health Questionnaire
Anxiety Module, the Generalised Anxiety Disorder Scale (GAD-7; (R. L. Spitzer,
Kroenke, Williams & Löwe, 2006)), was used to assess symptoms of a generalised
anxiety disorder. This questionnaire was designed to assess anxiety symptoms
according to DSM-IV criteria over the past two weeks and shows good validity.
All seven items are scored on a scale from 0 (not at all) to 3 (nearly every day).
The severity of anxiety symptoms is determined by calculating the sum score ran-
ging between 0 (no anxiety symptoms) and 21 (all symptoms occur daily): scores
between 1 and 4 suggest minimal anxiety disorder symptoms, scores between 5
and 9 suggest a mild anxiety disorder, scores between 10 and 14 suggest a moder-
ate anxiety disorder, and scores of 15 or above suggest a severe anxiety disorder. In
a study with a representative population sample, the mean sum score of the GAD-7
was M = 2.9; (SD = 3.4; (Löwe et al., 2008)).
The Morisky Medication Adherence Scale
The MMAS is an eight-item questionnaire developed by Morisky et al. to meas-
ure drug compliance (Morisky, Ang, Krousel-Wood & Ward, 2008). This scale was
initially developed to evaluate medication adherence in patients with hypertension
but it is now widely used in various other patient populations. The scale consists
of eight questions: the first seven items have a dichotomous answer (yes/no) that
indicates adherent or non-adherent behaviour; item 8 assesses how often a patient
fails to take their medication via a 5-point Likert scale. A total score of all items is
calculated with a sum score ranging from 0 to 8 for adherence. MMAS-8 score can
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be calculated if the respondent answered at least 6 of the 8 items. The MMAS scores
were trichotomized previously into the following 3 levels of adherence: high ad-
herence (score, 8), medium adherence (score, 6 to < 8), and low adherence (score,
< 6). These cut-off values were established based on the association between ad-
herence to medication and blood pressure control in patients with hypertension.
The validity was demonstrated with a sample of patients taking antihypertensive
drugs by measuring the actual improvement in values. The German version was
validated in 2015 by Arnet et al. (Arnet, Metaxas, Walter, Morisky & Hersberger,
2015).
5.3.4 Qualitative measures
All qualitative data was gained during individual, semi-structured interviews
conceptualised to last between 10 to 30 minutes on average. The interviewing
researcher, AC, is an experienced clinical psychotherapist. A specially developed
interview guideline was followed in individual face-to-face settings either in the
hospital or at the participants’ homes. All interviews were audio-recorded and
subsequently verbatim transcribed.
Interview guideline
The interview guideline was developed based on an in-depth literature review,
the criteria of the COREQ checklist (Tong, Sainsbury & Craig, 2007), as well as dis-
cussions in a team of experts (N = 3, all of whom were experienced in qualitative
research). The interview manual was constructed in a semi-standardised manner
(Helfferich, 2019); (Knox & Burkard, 2009). Key leading questions concentrating
on the patient’s experiences of the CTR event were developed (see appendix). If
necessary, these questions were followed by encouraging and clarifying questions.
In line with the ‘consolidated criteria for reporting qualitative research’-checklist
[COREQ] (Tong et al., 2007), all participants were again informed about the study’s
background, objectives, and procedure.
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Chapter 6
Data analysis
6.1 Quantitative analysis and statistical measures
The data were evaluated using individually generated codes to ensure anonym-
ity. All data were coded and analysed using the software package IBM® SPSS®
Statistics (version 24). Descriptive statistics were used to describe the major study
variables and sample demographics, raw data are displayed by showing the MD
and standard deviation (SD). Stepwise and robust multiple regression models were
computed in R (RDevelopment, 2018) to estimate the influence of group (myocar-
dial infarction, CTR only, and CTR with AMR) and socio-demographic variables
(sex, age, marital status and educational level) on psychological burden (PTSD,
Depression, General anxiety disorder) and medication adherence. For all models,
the same blocks of predictive variables were sequentially entered in the following
order: (1) socio-demographic information, (2) group variables ‘CTR only’ and ‘CTR
with AMR’ and always compared with the myocardial infarction group. Intercor-
relations among study variables and variance inflation factors (VIF) were assessed
to determine multicollinearity.
6.2 Qualitative content analysis
For qualitative analysis, a constructivist thematic analysis approach was imple-
mented. The constructivist approach implies that existing relevant literature, e.g.
comparative studies on psychopathology, such as PTSD, depression, anxiety and
CHD (Haydon et al., 2017), influences research question development and that the
resulting sensitisation primes ensuing data analysis. thematic analysis (TA) is a
pragmatic approach to qualitative analysis focusing on the search for identifiable
themes across a data set (Braun & Clarke, 2006). Although it draws on some tech-
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niques of grounded theory (Kennedy & Lingard, 2006; Strauss & Corbin, 2000), TA
follows a six-phase analysis process allowing more flexibility and alleviating adap-
tion to specific study ramifications (Mayring, 2015). After verbatim transcription,
open line by line coding of all 20 interviews was conducted to identify recurring
topics. Specific sentences (or combinations of sentences) were identified as a code
representing the most elemental unit of meaning (Mayring, 2015). The assignment
of codes to specific themes was conducted by two independent analysts (Christoph
Nikendei (CN) and AC) using the software MaxQDA (2010 version, VERBI GmbH,
Berlin), discussed to reach consensus, and adjusted if necessary. Themes were com-
pared and adapted, until overarching relevant themes could be defined. In a final
step, themes were summarised into three relevant categories. All codes were ana-
lysed for each theme comparing meaning and frequency, and consolidated through
a profound expert team discussion. Figure 6.1 illustrates the analysis procedure.
Participants’ characteristics were managed with the software package IBM® SPSS®
Statistics (version 24) and displayed by showing the mean (MD) and standard de-
viations (SD).
Figure 6.1: The subsequent content analysis followed the principles of Mayring’s qualitative content
analysis methodology (Mayring, 2015). First, an open coding for all interviews was carried out in
order to search for recurring motifs. Single or few contiguous propositions were identified as
code representing the most elementary unit of meaning. In the next step, the codes were grouped
into relevant categories individually for each interview using the MaxQDA software (2010 version,
VERBI GmbH, Berlin).
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Chapter 7
Results
7.1 Results of the quantitative evaluation
7.1.1 Sample description
A summary of socio-demographic characteristics and study variables is shown
in Table 7.1. The sample’s age ranged from 63 to 91, with an average of 81.9 years
(SD = 5.1) for the overall CTR sample and slightly younger for the myocardial
infarction sample with an average of 78.9 years (SD = 5.1, range 63 to 89), as
reported drop out was largely attributable to old age and female sex. More than
half of the overall CTR sample (58.8%) were male (60% for the myocardial infarction
sample). 22.7% were widowed without new partner in the overall CTR group
and 31% were widowed without new partner in the myocardial infarction sample.
Hence, almost 78% of participants reported that they were either in a relationship
or married. About 73% of the whole sample had completed at least between 9
to 12 years of school education and were qualified in a trade or craft. 15.2% had
completed higher education (university degree) and only 6,3% reported no school
qualifications. Overall, 88,8% of the CTR group and 97% of myocardial infarction
group reported to have had either PTSD, depression or anxiety disorder in their
lifetime prior to this study.
7.1.2 Psychological burden and medication adherence
With regard to the study response variables (PTSD, General anxiety disorder,
depression and medication adherence), means and SD are presented in Table 7.1.
Analysis of means for PTSD, assessed with the PDS, revealed moderate symptom
burden for the overall CTR group (M = 21.40, SD = 12.5), mild PTSD symptom
burden for the group ’CTR without AMR’ (M = 13.74, SD = 10.78) and moderate
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to severe symptom burden for the group ’CTR with AMR’ (M = 29.81, SD = 6.91),
while the myocardial infarction group also showed moderate PTSD symptom bur-
den (M = 22.94, SD = 4.99). Across all groups the symptom burden for General
anxiety disorder, assessed with the GAD-7, was mild to moderate (overall CTR
group: M = 9.91, SD = 4.24; myocardial infarction group (M = 8.60, SD = 4.91).
Means for depression scores revealed moderate symptom burden across all groups
(overall CTR group: M = 7.84, SD = 4.05; myocardial infarction group (M =
7.60, SD = 4.70). Overall, medication adherence was good across groups, with the
group ’CTR without AMR’ yielding the highest means (M = 6.09, SD = 1.44) and
the group myocardial infarction yielding the lowest mean (M = 4.77, SD = 1.82).
With regard to dissociative symptoms, assessed with the FDS-20, means indicated
minimal burden for all groups (overall CTR group: M = 2.95, SD = 5.9; myocar-
dial infarction group (M = 2.28, SD = 5.46).
Table 7.1: CTR and myocardial infarction patients’ socio-demographic characteristics and study
variables for PTSD, General anxiety disorder, depression, and medication adherence. CTR patients
data are as a whole and as two subgroups: "CTR without AMR" and "CTR with AMR"
overall CTR1n = 44 CTR1without AMR2n = 23 CTR1with AMR2n = 21 MI3n = 35
n (%) M11(SD12) n (%) M11(SD12) n (%) M11(SD12) n (%) M11(SD12)
Gender
Male 25 (58.8) 11 (47.8) 14 (66.7) 21 (60.0)
Female 19 (43.2) 12 (52.2) 7 (33.3) 14 (40)
Age 81.9 (5.1) 81.6 (5.9) 82.3 (4.2) 78.9 (5.1)
Marital status
Married 7 (15.9) 3 (13.0) 4 (19) 10 (28.6)
In a relationship 27 (61.4) 16 (69.6) 11 (52.4) 14 (40.0)
Widowed 10 (22.7) 4 (17.4) 6 (28.6) 11 (31.4)
Educational level (scale 1 to 5) 2.7 (1.1) 2.8 (1.2) 2.7 (0.9) 3 (1.2)
Clinical parameters
LV EF4% 28 (63.6) 30.0 (11.9) 10 (43.5) 34.4 (15.1) 18 (85.7) 27.5 (9.2)
LV EDD5 36 (81.8) 59.9 (10.8) 5 (56.5) 57.9 (12.7) 18 (85.7) 61.9 (8.4)
6 min walking distance [s] 37 (84.1) 346.8 (97.3) 16 (69.6) 342.4 (116.9) 21 (100) 350.2 (82.2) 8 (22.9) 438.5 (131)
Degree of mitral regurgitation 31 (40.5) 3.1 (0.5) 15 (65.2) 3.1 (0.5) 16 (76.2) 3.1 (0.5) 2 (5.7) 2 (1.4)
NYHA6(scale 1 to 5) 38 (86.4) 2.9 (0.5) 17 (73.9) 2.9 (0.5) 21 (100) 2.8 (0.6)
Additional diagnoses
Nicotine 27 (61.4) 13 (56.5) 14 (66.7) 26 (74.3)
Diabetes 24 (54.5) 14 (60.9) 10 (47.6) 24 (68.6)
Adipositas 25 (56.8) 14 (60.9) 11 (52.4) 20 (57.1)
History of treatment for
Anxiety disorder 15 (34.1) 7 (30.4) 8 (38.1) 13 (37.1)
Depressive disorder 17 (38.6) 9 (39.1) 8 (38.1) 16 (45.7)
PTSD7 7 (15.9) 4 (17.4) 3 (14.3) 5 (14.3)
Study response variables
PTSD7 21.40 (12.5) 13.74 (10.78) 29.81 (6.91) 22.94 (4.99)
GAD8 9.91 (4.24) 9.91 (4.48) 9.90 (4.08) 8.60 (4.91)
DEP9 7.84 (4.05) 8.82 (4.07) 6.76 (3.83) 7.60 (4.70)
MED AD10 5.89 (1.51) 6.09 (1.44) 5.67 (1.59) 4.77 (1.82)
1 Chordae tendineae rupture; 2 acute mitral regurgitation; 3 myocardial infarction; 4 left ventricular ejection fraction;
5 left ventricular end-diastolic diameter; 6 New York Heart Association classifications; 7 Post-traumatic stress disorder;
8 General anxiety disorder; 9 depression; 10 medication adherence; 11 Mean; 12 Standard deviation;
7.1.3 Resilience and risk factors
Stepwise and robust multiple regression models were computed to estimate
the influence of group (myocardial infarction, CTR only, and CTR with AMR)
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and socio-demographic variables (sex, age, marital status and educational level)
on psychological burden (PTSD, Depression, General anxiety disorder) and med-
ication adherence. All regression assumptions were tested for violation with the
R-package olsrr (Hebbali, 2018). Inspection revealed no assumption violations for
the models with the response variables PTSD, General anxiety disorder and med-
ication adherence. However, for the model with the response variable depression,
the assumption of normal distribution was violated (Shapiro −Wilk = 0.96, p =
0.015; Anderson− Darling = 0.89, p = 0.022). Hence, results were computed us-
ing robust regression analyses by the lm_robust function of the R-package estimate
(Graeme Blair & Sonnet, 2019). Colinearity among covariates was assessed using
pairwise scatterplots, correlation coefficients and VIF. According to (Kleinbaum,
Kupper, Nizam & Rosenberg, 2013), a VIF value greater than 10, and tolerance val-
ues less than 0.10 may indicate the presence of multicollinearity. The two measures
indicated no sign of multicollinearity between the predictor variables in the present
data. The VIF for all predictors was less than 1.28.
The results of the stepwise and robust multiple regression analyses are shown
in Table 7.2. In the Model for PTSD, stepwise multiple regression analysis was used
to test if groups (myocardial infarction, CTR only, and CTR with AMR) and socio-
demographic variables (sex, age, marital status and educational level) significantly
predicted participants’ PTSD score as compered to myocardial infarction patients.
The model explained 44% of the variance (R2 = .44, F(9, 44) = 6, 72, p < .001).
However, only two predictors namely group membership in either ‘CTR with AMR’
or ‘CTR only’ were significant. Hence, data suggests that CTR patients who had
experienced AMR (β = 7.87, p < .001) were more likely to have PTSD as compared
to the myocardial infarction group, while patients who had only experienced CTR
(β = −8.06, p < .001) were less likely to report PTSD as compared to the myocar-
dial infarction group.
In the Model for General anxiety disorder, stepwise multiple regression analysis
was used to test if groups (myocardial infarction, CTR only, and CTR with AMR)
and socio-demographic variables (sex, age, marital status and educational level)
significantly predicted participants’ General anxiety disorder score as compared to
myocardial infarction patients. The results of the regression showed no significant
findings (R2 = 0.07, F(0, 97) = 6, 72). Hence, no group differences were found and
the General anxiety disorder score could not be predicted by the risk and resilience
factors.
In the Model for depression, robust multiple regression analysis was used to
test if groups (myocardial infarction, CTR only, and CTR with AMR) and socio-
demographic variables (sex, age, marital status and educational level) significantly
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predicted participants’ depression score as compared to myocardial infarction pa-
tients. The model explained 17% of the variance (R2 = .17, F(2, 80) = 6.72, p < .05).
However, only gender turned out to be a significant risk factor (β = 2.75, p < .01).
Hence, data indicates that female gender significantly predicted depression across
all groups.
In the Model for medication adherence, multiple regression analysis was used
to test if groups (myocardial infarction, CTR only, and CTR with AMR) and socio-
demographic variables (sex, age, marital status and educational level) significantly
predicted participants’ medication adherence score as compered to myocardial in-
farction patients. The model explained 23% of the variance (R2 = .23, F(3.62) =
6, 72, p < .01). However, only educational level (β = −.41, p < .05), and ‘CTR only’
(β = 1.26, p < .01) were significant predictors of medical adherence. Participants
with a lower educational level and with CTR only, had a better medical adherence.
Table 7.2: Results of the regression analyses with models for Post-traumatic stress disorder, Gen-
eral anxiety disorder, depression and medication adherence assessing the influence of the groups
myocardial infarction, CTRCTR, AMR and socio-demographic variables (sex, age, marital status,
and educational level) on psychopathology (PTSD, depression, General anxiety disorder) and med-
ication adherence
Model for PTSD1 Model for GAD2 Model for DEP3 Model for MEDAD4
β5 se6 t7 p8 β5 se6 t7 p8 β5 se6 t7 p8 β5 se6 t7 p8
Age -0.32 0.17 -1.86 0.067† 0.09 0.10 0.9 0.368 0.06 0.08 0.91 0.365 -0.03 0.04 -1.01 0.314
Sex -2.16 1.80 -1.20 0.235 0.90 1.10 0.82 0.411 2.75 1.03 2.67 0.009** 0.63 0.38 1.65 0.103
Marital status -0.07 1.26 -0.06 0.953 -0.16 0.77 -0.21 0.830 -0.25 0.67 -0.36 0.715 0.37 0.36 -1.01 0.313
Educational
level 0.11 0.80 0.14 0.889 0.95 0.48 1.95 0.055† -0.29 0.40 -0.71 0.477 -0.41 0.17 -2.42 0.018*
CTR only9 -8.06 2.07 -3.88 0.000*** 1.11 1.26 0.88 0.380 0.64 1.20 0.53 0.594 1.26 0.43 2.88 0.005**
CTR with AMR10 7.87 2.16 3.64 0.000*** 1.36 1.32 1.04 0.303 -0.99 1.15 -0.85 0.393 0.90 0.45 1.98 0.051†
Model summary
Model F11 F = 9.44*** F = 0.97 F = 2.80* F = 3.62**
df12 6.72 6.72 6.72 6.72
(R2)13 0.44 0.07 0.17 0.23
(∆ R2)14 0.39 -0.00 0.10 0.17
1 Post-traumatic Stress Disorder; 2 Generalised Anxiety Disorder; 3 Depression;
4 medication adherence 5 Regression coefficient; 6 Standard error; 7 t-error; 8 ∗ ∗ ∗ = p < .001, ∗∗ = p < .01, ∗ = p < .05,
† = p < 0.1; 9 Chordae Tendineae Rupture subgroup without acute mitral regurgitation; 10 Chordae Tendineae Rupture subgroup
with acute mitral regurgitation (myocardial infarction subgroup = reference group for both subgroups);
11 Indicator if there is a relationship between the predictors and the response variables (∗ ∗ ∗ = p < .001, ∗∗ = p < .01, ∗ = p < .05,
† = p < 0.1); 12 degrees of freedom; 13 explained variance of the response variables by the predictors; 14 adjusted R2;
Figure 7.1 visualises the model for PTSD that was computed via stepwise mul-
tiple regression analysis to test if groups (myocardial infarction, CTR only, and
CTR with AMR) and socio-demographic variables (sex, age, marital status and
educational level) significantly predicted participants’ PTSD score as compered to
myocardial infarction patients.
Figure 7.2 shows the box chart comparison of group differences with regard
to PTSD scores. The visualised data indicates that the CTR subgroup ‘CTR with
AMR’ reported the highest means 7.1, followed by the myocardial infarction group,
while patients in the ‘CTR only group’ reported the lowest means.
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Figure 7.1: Post-traumatic Stress Disorder - Visualised model for variables Chordae Tendineae Rup-
ture subgroup without acute mitral regurgitation (CTR), Chordae Tendineae Rupture subgroup
with AMI (myocardial infarction subgroup = reference group for both subgroups), Educational
level, Sex, Age and Marital status
Figure 7.2: Box Chart: comparison of post-traumatic stress disorder means across study groups CTR
= Chordae Tendineae Rupture subgroup without acute mitral regurgitation, AMR = Chordae Tendineae Rupture subgroup with acute mitral regurgitation, MI =
myocardial infarction group
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Figure 7.3: Generalised anxiety disorder - Visualised model of variables Chordae Tendineae Rup-
ture subgroup without acute mitral regurgitation (CTR), Chordae Tendineae Rupture subgroup
with acute mitral regurgitation (AMI) (myocardial infarction subgroup = reference group for both
subgroups), educational level, sex, age and marital status
Figure 7.3 visualises the model for General anxiety disorder that was computed
via stepwise multiple regression analysis to test if groups (myocardial infarction,
CTR only, and CTR with AMR) and socio-demographic variables (sex, age, marital
status and educational level) significantly predicted participants’ General anxiety
disorder score as compered to myocardial infarction patients.
Figure 7.4: Box Chart: comparison of generalised anxiety disorder means across study groups CTR
= Chordae Tendineae Rupture subgroup without acute mitral regurgitation, AMR = Chordae Tendineae Rupture subgroup with acute mitral regurgitation, MI =
myocardial infarction group
Figure 7.4 shows the box chart comparison of group differences with regard
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to General anxiety disorder scores. The visualised data indicates no differences
between the groups 7.1.
Figure 7.5: Depression - Visualised model of variables Chordae Tendineae Rupture subgroup
without acute mitral regurgitation (CTR), Chordae Tendineae Rupture subgroup with acute mitral
regurgitation (AMI) (myocardial infarction subgroup = reference group for both subgroups), Edu-
cational level, Sex, Age and Marital status
Figure 7.5 visualises the model for depression that was computed via robust
multiple regression analysis to test if groups (myocardial infarction, CTR only, and
CTR with AMR) and socio-demographic variables (sex, age, marital status and edu-
cational level) significantly predicted participants’ depression score as compered to
myocardial infarction patients.
Figure 7.6 shows the box chart comparison of group differences with regard
to depression scores. The visualised data indicates that the CTR subgroup ‘CTR
only’ reported slightly higher means 7.1, while patients in the ‘CTR with AMR’
and patients in the myocardial infarction group reported similar lower depression
means.
Figure 7.7 visualises the model for medication adherence that was computed via
stepwise multiple regression analysis to test if groups (myocardial infarction, CTR
only, and CTR with AMR) and socio-demographic variables (sex, age, marital status
and educational level) significantly predicted participants’ medication adherence
score as compered to myocardial infarction patients.
Figure 7.8 shows the box chart comparison of group differences with regard to
medication adherence scores. The visualised data indicates high means across all
study groups, suggesting high perceived medication adherence in all groups. How-
ever, patients in the myocardial infarction group reported lower means compared
to overall CTR patients 7.1.
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Figure 7.6: Box Chart: comparison of depression means across study groups CTR = Chordae Tendineae Rupture
subgroup without acute mitral regurgitation, AMI = Chordae Tendineae Rupture subgroup with acute mitral regurgitation, MI = myocardial infarction group
Figure 7.7: Medication Adherence - Visualised model of variables AMR, CTR, Educational level,
Sex, Age and Marital status
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Figure 7.8: Box Chart: comparison of medication adherence means across study groups CTR = Chordae
Tendineae Rupture subgroup without acute mitral regurgitation, AMR = Chordae Tendineae Rupture subgroup with acute mitral regurgitation, myocardial infarction
=myocardial infarction group
7.2 Results of the qualitative evaluation
In the following section, the results of the qualitative analysis of the 20 semi-
structured interviews with CTR patients shall be presented, including an overview
of the main categories and themes as well as exemplary quotes to illustrate the
description of the themes.
Interviewed participant’s characteristics
Twenty participants gave their consent on a voluntary basis to take part in the
qualitative section of the study (60% : male; aged : 81±; SD : 5.9 years; range :
63− 89). On average, an interview lasted 20.3 minutes (± SD : 8.9; range : 10−
35 min). The length of the interview was adapted to meet individual needs of the
interviewees.
Main categories and themes
The qualitative analysis of the interviews identified 1290 single codes, from
which three main categories and twelve themes were derived. Figure 7.9 provides
an overview of the main categories and themes as defined below for interviewed
patient group. The number of codes per category and corresponding theme is
shown in parentheses. Illustrative quotations for main categories and themes are
listed in Figures 7.10, 7.11 and 7.12.
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Figure 7.9: Summary of the main categories and themes after qualitative analysis of the CTR pa-
tient’s experiences as reported during the semi-structured interview
Main category 1: Experience of fear and threat (324 codes)
The experience of fear and the confrontation with death was a prominent point
in the participants’ narratives. Feeling that they had experienced their own mor-
tality and the finiteness of life, many participants felt fortunate to have survived.
Four themes could be differentiated for this main category; exemplary statements
are shown in figure 7.10
Theme: 1.1. Feelings of stark insecurity and vulnerability (129 codes)
The CTR patients who had experienced AMR all reported feelings of intense
fear of dying and threat during the event. They highlighted their feeling helpless-
ness as well as stressing their perception of being overwhelmed by the situation.
Most participants explained that they felt that something was seriously wrong and
that they needed immediate medical attention. Several patients thought that they
were going to die. Many patients found stark metaphors and similes for their ex-
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perience of progressing oedema and breathlessness, describing that they felt like
they were drowning outside of water. Others described an intense feeling of loss
of control mixed with anxiety. They also reported feeling vulnerable and unstable
in the wake of the event to the extent of not feeling secure in their environment or
body. Several of them mentioned that they sometimes had reoccurring nightmares
of the event or re-experienced the event if they revisited the place where it had
happened.
Theme: 1.2. Thinking about and fear of death afterwards (89 codes)
The interviewees reported increased reminiscing about death and fear of dying
in the wake of the CTR event. Many reported the need to take appropriate legal
measures, such as writing their will and defining their patient disposal statement.
Some began sorting their papers and belongings in fear of burdening their relatives
in case of their deaths. Others began looking back on their life and evaluating it.
All reported feeling that the experience of the CTR event had a major impact on
their feeling of longevity. Although they had been conscious of their age, many had
not thought a lot about their death. Several patients felt that the event impressed
upon them that they were nearing the end of their life and that their time left was
limited.
Theme: 1.3. Searching for meaning and support (61 codes)
Several patients sought comfort and support in their families after hospital dis-
charge which often left them a little insecure as they had largely felt well cared for
and harboured in a safe environment. Many were preoccupied with finding mean-
ing in the CTR event. Some felt grateful to have been given ‘a wake-up call’, while
others found it hard to understand why they had been so unlucky to have exper-
ienced such an ordeal. Most participants said that they felt an increased wish for
talking about the event and seeking security in their existing familial relationships.
Theme: 1.4 A changed view on life (45 codes)
Most participants described that the event had changed their view or perception
of life and they felt different after the incident. Although experiencing a large
amount of mixed emotions including fear and sometimes a feeling of defeat, most
felt that they were able to appreciate life more intensely after having feared to
lose it. Many reported to be working hard at living a healthier and balanced life,
such as exercising, modifying their diets and quitting smoking. However, some
participants felt that though they were more mindful in their everyday life, they
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had no wish of changing long-standing habits or routines as they felt they had
reached such a high age that it was ‘enough’.
Figure 7.10: Qualitative analysis of CTR patient’s statements: exemplary quotations related to the
main category 1 and respective themes. The number of codes per category and corresponding
theme is shown in parentheses.
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7.2.1 Main category: 2. Experience of loss of autonomy (280 codes)
The experience of new limitations of their body and new challenges in their
everyday functionality was also a key issue across all participants’ narratives. Four
themes emerged following qualitative analysis; exemplary statements are shown in
figure 7.11
Theme: 2.1. Difficulties adjusting in everyday life (119 codes)
Many participants found reemerging in everyday life after hospitalisation dif-
ficult and frightening. Several participants required additional help and felt an
extreme loss of prior independence and autonomy. They described feeling forced
to ask their friends and family for more help and support. While they were grateful
for assistance, they found it difficult to ask and to be dependent on others. Many
reported to feel that their perception of themselves and their body had altered
and that they were struggling to adjust to their new limitations, often behaving
more cautiously and conservatively than before. Adjusting their lifestyles made
many feel anxiety and insecurity on the one hand but also set them new challenges
which increased their sense of control. Many reported to have been advised to
change their lifestyle with regards to diet, nicotine abuse and exercise regimes.
Two interviewees said that they had moved home, while a further two had moved
in with their children for additional support.
Theme: 2.2. Feeling the need for support (78 codes)
Several participants reported that they felt an increased need for support and
social interaction in the wake of the CTR event. Many sought to reconnect or
reaffirm existing relationships and to intensify their contact with friends and family.
Many also expressed their need to talk about the event. Though most felt well
cared for during hospitalisation, many felt that they would have benefited from
further emotional care or even counselling. One participant reported to have felt
so burdened by anxiety and recurring scenes of the event that she had sought
professional help. Many of the male participants on the other hand felt reluctant
to seek professional help for fear of stigmatisation.
Theme: 2.3. Avoidance behaviour and social withdrawal (59 codes)
Beyond adjusting to their new bodily limits, many participants reported to have
developed specific avoidance behaviours. Some felt too insecure to even leave the
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house without company. Others had bought cell phones or had enrolled in emer-
gency plans that kept them connected to emergency services by the touch of a but-
ton. Many reported having given up more active and strenuous activities, such as
bike riding or football. Some of the participants described avoiding certain places
for fear of being forcibly reminded of the incident. Some showed further signs
of social withdrawal and actively avoided larger groups of people outside. They
also mentioned withdrawing from social activities and friends for fear of feeling
overwhelmed or exhausted on the one hand, or being confronted with their own
limitations and frailty on the other hand.
Theme: 2.4. Feelings of marginalisation and worthlessness (24 codes)
Many participants reported feeling treated differently since they were more
overtly limited in their physical fitness. Most participants described being belittled
during doctor’s appointments in busy practises. Others felt ostracised by society,
feeling they no longer had a productive role to play which left them with feelings of
self-doubt and worthlessness. Many expressed worry that they were burdensome
to their families and too ineffective in their everyday lives. Some participants re-
ported having experienced vexation and lesser treatment from younger, more agile
people who wanted to show them that they had been hindered in their routines by
their slower pace. One participant said that only now had he noticed how young
he felt inside because of the discrepancy between his self-perception and his newly
limited physical capacities.
7.2.2 Main category: 3. Experience of gratitude for having sur-
vived (125 codes)
Participants experienced a multitude of contrasting feelings during the inter-
views. Though many reported anxiety and fear of dying, they were largely very
grateful to have survived. Again, four themes emerged following qualitative ana-
lysis; exemplary statements are shown in figure 7.12.
Theme: 3.1. Finding motivation for lifestyle changes (53 codes)
Most participants, who had reported to have good social networks, felt mo-
tivated to embrace necessary lifestyle changes in order to be able to enjoy many
further years with their family and friends. Though they often stated to have
hoped for more improvement of their health with time and, as described previ-
ously, found it difficult to adjust to their new limitations in physical capacity, most
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Figure 7.11: Qualitative analysis of CTR patient’s statements: exemplary quotations related to the
main category 2 and respective themes. The number of codes per category and corresponding
theme is shown in parentheses.
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interviewees were very grateful to have survived the event. Many especially em-
phasised the importance of taking their medication regularly and as the doctor
had prescribed. However, some interviewees felt that they were not willing to
undertake great change in their everyday habits as well as amending health risk
behaviours as they felt that their time was already too limited to live a lifestyle
they did not perceive as joyful or fitting. However, all participants reported to be
more mindful of their lifestyle choices since the event.
Theme: 3.2. Feeling well and active (18 codes)
Some participants reported feeling very well and staying quite active since phys-
ical recovery from the CTR event. Many had adopted healthier life choices and
said to regularly attend specialist exercise groups (e.g. silver gymnast classes and
walking groups) or mindfulness meetings. Though most felt that they were not as
bodily able and emotionally stable as prior to the CTR event, they felt that they
were taking control over the situation and trying to make the best of life.
Theme: 3.3 Mindfulness of existing relationships (31 codes)
Several participants described changes in their social behaviours and habits
after the CTR event. Especially two interviewees who had still been working at
the time of the event reported to have previously taken their social relationships
for granted and to have invested little energy in maintaining friendships or even
their marriages. They highlighted to feel a paradigm shift in their priorities after
the event. Most participants reported on being more heedful and mindful of their
existing relationships, also feeling that their own vulnerability had enabled them
to engage in more open and intimate conversations and self-disclosures.
Theme: 3.4 Coping with anxiety and avoidance (23 codes)
After having initially felt profoundly destabilised and discomforted by the event,
reporting increased anxiety, social withdrawal, or clinginess, several participants
described the feeling of needing to face their fears and ’get on with the rest of
their life’. Some of the participants revealed to have fallen in a rather regress-
ive, depressive state. They portrayed how they had been motivated by others or
by themselves to take a more progressive stance with regard to their judgement
of their physical and emotional abilities. Some reported an experimental, playful
approach, especially when engaging with grandchildren. Other reported a more
systematic approach of trial and error to extend their subjective boundaries of their
functioning in everyday life. Overall, these interviewees expressed that actively
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addressing fears and subsequent avoidance behaviour had helped them to regain
some confidence in themselves and the world.
Figure 7.12: Qualitative analysis of CTR patient’s statements: exemplary quotations related to the
main category 3 and respective themes. The number of codes per category and corresponding
theme is shown in parentheses.
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Chapter 8
Discussion
The cross-sectional study presented in this thesis aimed to use well-established
quantitative methods to map psychological stress and the prevalence of Post-traumatic
stress disorder after Chordae tendineae rupture in a predefined population in a
mixed-method approach. In this chapter, both the quantitative as well as the qual-
itative results of the data analysis shall be discussed and the limitations of this
study will be addressed. At the end of the chapter, a conclusion is drawn and an
outlook on possible future research questions is given.
8.1 Quantitative data
The results of the data analysis revealed important findings: as hypothesised,
chordae tendineae rupture patients are significantly burdened by post-traumatic
stress disorder. Moreover, post-traumatic stress disorder is significantly more pre-
valent in chordae tendineae rupture patients who had suffered acute mitral regur-
gitation than in chordae tendineae rupture patients with moderate/severe mitral
regurgitation. Most interestingly, chordae tendineae rupture patients who had
suffered acute mitral regurgitation showed higher post-traumatic stress disorder
scores, nearly reaching the Post-traumatic Diagnostic Scale’s cut-off score for severe
post-traumatic stress disorder symptoms (> 30), than myocardial infarction con-
trols. Accordingly, higher post-traumatic stress disorder scores were primarily
predicted by the group factor ’chordae tendineae rupture with acute mitral re-
gurgitation’, (R2 = .44, F(9, 44) = 6, 72, p < .001; β = 7.87, p < .001), and ac-
counted for approximately 44% of the variance of post-traumatic stress disorder
in the stepwise multiple regression model. The mean scores for depression and
anxiety were mild to moderate across all groups. In the robust multiple regression
model, depression was predicted by female gender (R2 = .17, F(2, 80) = 6.72, p <
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.05; β = 2.75, p < .01) which is in line with current global prevalence distribu-
tions but was not predicted by age, educational level, or study groups (myocardial
infraction, chordae tendineae rupture only, and chordae tendineae rupture with
acute mitral regurgitation). Anxiety score could not be predict based on the mul-
tiple regression model variables. There has been ample discussion with regard to
the prevalence and symptoms of anxiety disorders in cardiological patients due to
the fact that many symptoms of anxiety are difficult to differentiate from typically
cardiac symptoms, such as dyspnea. In extent literature and results remain con-
troversial. Future research should address the predictors of anxiety disorders in
chordae tendineae rupture patients in a longitudinal design with a larger sample
size. Medical adherence was predicted by lower educational level and the group
variable ’chordae tendineae rupture only’. These results suggest that lower symp-
tom severity improves medical adherence, while higher educational level decreases
it. Clear associations have been established between elderly patients’ medication
adherence and race, drug and dosage form, number of medications, cost of med-
ications, insurance coverage, and physician-patient communication. However, the
findings are inconsistent with regard to the effects of patients’ age, sex, socioeco-
nomic status, living arrangement, comorbidities, number of physician visits, and
knowledge, attitudes, and beliefs about health and need to be addressed in future
study designs. The qualitative analysis of the conducted interviews identified 1290
single codes from which three main categories, namely the experience of fear and
threat (324 codes) during the chordae tendineae rupture, the experience of loss of
autonomy (280 codes) and the experience of gratitude for having survived (125
codes) in the wake of chordae tendineae rupture with four themes each emerged.
Qualitative analysis results elucidated the stark physical and psychological impact
on patients who had experienced the chordae tendineae rupture and corroborated
the quantitative findings of high post-traumatic stress disorder scores on an indi-
vidual level but also painted a picture of functional as well as dysfunctional coping
strategies. In the following subsections, the results summarised above will be
discussed in more detail:
8.1.1 PTSD
The presented study is the first to assess psychological burden in terms of PTSD,
depression, and anxiety in Chordae tendineae rupture patients. The results of the
data analysis revealed important findings: First, as hypothesised, CTR patients are
significantly burdened by Post-traumatic stress disorder. Moreover, PTSD is sig-
nificantly more prevalent in CTR patients who had suffered AMR than in CTR
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patients with moderate/severe mitral regurgitation. Compared to myocardial in-
farction controls, CTR patients who had suffered AMR also showed higher PTSD
scores, nearly reaching the PDS cut-off score for severe PTSD symptoms (> 30).
Accordingly, the stepwise multiple regression model for PTSD predicted that 44%
of variance could be resolved through CTR patients who had experienced AMR
in its wake. However, PTSD could neither be predicted by age or gender, nor
by medical adherence. The fact that the severity of somatic symptoms in the as-
sessed patients predicted PTSD-pathology is seemingly in contrast to the findings
of Bayer-Topilsky et al. (2013). Although their study was able to show that PTSD
is also prevalent in chronic moderate or severe mitral-regurgitation patients, their
data suggested that PTSD was not determined by objective mitral-regurgitation
severity or consequences (Bayer-Topilsky et al., 2013). Bayer-Topilsky et al. (2013)
hypothesised that PTSD is linked to anxiety and depression and to somatic cardiac
symptoms, such as dyspnea. However, the difference between PTSD as a comor-
bitiy with negative prognostic impact and PTSD as cardiac induced disease needs
to find strong consideration here. In his comprehensive review, detailed in Chapter
3, Vilchinsky et al. argues that in the case on Cardiac-disease-induced PTSD, thus,
when criteria A is the cardiac event itself the severity of cardiac disease is a risk
factor (Vilchinsky et al., 2017), This studies data on PTSD corroborates these find-
ings and our results are in line with his suggestion that CDI-PTSD is both conceptu-
ally and empirically a valid diagnostic entity. Moreover, apart from the quantitative
data, the qualitative interviews with the affected patients impressed upon the in-
terviewer and author of this thesis that the experience of an CTR with ensuing
AMR is no walk in the park. The interviewees reported anxiety and fear of death
during the CTR and ensuing AMR which clinically matched the emotional turmoil
and upheaval experienced by victims of violence. That is, as a clinical psychologist
the clinical picture did not differ and some interviewees required stabilisation and
help in self regulation during the qualitative interview.
The study aimed to determine the prevalence of PTSD and other emotional
comorbidities in patients with CTR and acute mitral regurgitation. Our findings
reveal a higher prevalence of PTSD among the patients than in the controls. Not-
ably, while the link between anxiety and CTR has been disputed (Margraf, Ehlers
& Roth, 1988), PTSD prevalence in CTR with AMR patients did not differ from
the MI control group, indicating that PTSD manifestation is associated with the
potentially serious cardiac condition and not with the mere presence of a degen-
erative mitral lesion. The patients also had slightly higher scores and prevalence
of anxiety (not significant), but low depression prevalence similar to the MI con-
trols, indicating that psychological manifestations in mitral-regurgitation patients
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differ from other coronary patients who manifest high depression rates. How-
ever, CTR patients with PTSD had higher scores and prevalence of depression (not
significant), which indicates that psycho-emotional manifestations associated with
organic-mitral regurgitation may often occur in combination.
Associations between Somatic Symptoms and PTSD
The severity of mitral regurgitation is characterised by a number of object-
ive measurements directly reflecting the valvular lesion (effective-regurgitant ori-
fice, regurgitant volume) or cardiac and haemodynamic consequences of mitral
regurgitation. Symptoms are often considered as equivalent in indicating surgery,
whether mild (class II) or severe (class III-IV) (Grigioni et al., 2003). Symptoms
are less frequent in mild mitral-regurgitation patients but are inconsistently noted
among severe organic mitral-regurgitation patients(Avierinos et al., 2008). While
purely cross-sectional, data suggests that the response to severe acute mitral re-
gurgitation is highly psycho-emotional, with strong links among development of
PTSD, anxiety, potential cardiac symptoms (such as mild dyspnea or fatigue), and
the perception that the cardiac disease is more severe in the assessed qualitative
data. This association of psycho-emotional response with the symptomatic re-
sponse has been observed in patients with cardiac or other conditions such as
pulmonary disease(Jenkins, Stanton, Savageau, Denlinger & Klein, 1983), asthma
(Smith, Redd, DuHamel, Vickberg & Ricketts, 1999), and cancer (Costa-Requena &
Gil, 2010). This study is the first to observe it in CTR patients. One possible ex-
planation is that somatic symptoms may lead to high distress, emotional response,
and the perception of being more severely affected by somatic symptoms (Nkomo
et al., 2006).
8.1.2 Depression and Anxiety
The mean scores for depression and anxiety reached mild to moderate PHQ-9
cutoff scores across all groups. Depression was significantly predicted by female
gender but was not predicted by age, educational level, or study groups which is
in line with previous findings. In the robust multiple regression model, depression
was predicted by female gender (R2 = .17, F(2, 80) = 6.72, p < .05; β = 2.75, p <
.01) which is in line with current global prevalence distributions but was not pre-
dicted by age, educational level, or study groups (myocardial infraction, chordae
tendineae rupture only, and chordae tendineae rupture with acute mitral regurgit-
ation). Although CHD mortality rates have declined over the past four decades
in western countries, this condition remains responsible for one-third of all deaths
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in individuals over age 35. Nearly one-half of all middle-aged men and one-third
of middle-aged women in the USA will develop some manifestation of CHD. The
2016 Heart Disease and Stroke Statistics update of the AHA reported that 15.5 mil-
lion people in the USA have CHD. The reported prevalence increases with age
for both women and men. For those US people, the lifetime risk of developing
CHD with ≥ 2 major risk factors is 37.5% for men and 18.3% for women. CVD
disease mortality has been declining in the USA and in regions where economies
and health care systems are relatively advanced, but the experience is often quite
different around the globe. The studies outlined in the sections above illustrate
the increasing evidence base for establishing mental health problems as risk factors
for the development and progression of CVD. Though evidence is more consistent
for depression and traumatic stress, many studies demonstrate that chronic anxi-
ety and exposure to daily stressors also have a negative impact on cardiovascular
health. Guidelines from major societies also reflect the growing recognition of the
connection between mental and cardiovascular health. The American Heart Asso-
ciation now officially recognises depression as risk factor for poor prognosis among
patients following acute coronary syndromes (Zigmond & Snaith, 1983). In addi-
tion, European guidelines identify depression, anxiety, and psychosocial stressors,
such as work-related stress or poor social support, as risk factors for incident CVD
and adverse outcomes in patients with existing CVD (Davidson, 2010). Anxiety
score could not be predict based on the multiple regression model variables. There
has been ample discussion with regard to the prevalence and symptoms of anxiety
disorders in cardiological patients due to the fact that many symptoms of anxi-
ety are difficult to differentiate from typically cardiac symptoms, such as dyspnea.
In extent literature and results remain controversial. Future research should ad-
dress the predictors of anxiety disorders in chordae tendineae rupture patients in
a longitudinal design with a larger sample size. The current prevalence rates of
anxiety disorder subtypes in CHD samples were generally 2–3% above popula-
tion estimates obtained in a North American epidemiological survey utilising the
DSM-IV (Hohensinner, Niessner, Huber, Weyand & Wojta, 2011). However, the
prevalence rate in this study (with any criteria) was markedly lower than the es-
timates for specific phobias and social phobias (Hohensinner et al., 2011). The pre-
valence of any anxiety disorder was 15.52%, though this pooled estimate excluded
post-traumatic stress disorder which occurs in approximately 1–4% of myocardial
infarction patients (Boscarino, 2008). There are few cardiac studies to compare the
anxiety disorder prevalence rate other than that reported in populations receiv-
ing implantable-cardioverter defibrillators which is between 11 and 28%(Lindahl,
Toss, Siegbahn, Venge & Wallentin, 2000). By contrast to anxiety disorders, a 20%
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prevalence of major depression was reported in survivors of myocardial infarction
(Magyar-Russell et al., 2011) and 15% prevalence reported in coronary artery by-
pass graft patients (Roest et al., 2010). Together, the findings suggest that anxiety
disorders are equally common as depressive disorders in CHD. Importantly, there
was considerable comorbidity between depression and anxiety in up to 50% of
CHD patients. Though high comorbidity between depression and anxiety is not
surprising, the findings might support several learned societies’ recommendations
(Pelle et al., 2010; P. J. Tully & Cosh, 2013) to assess mood and anxiety disorders
contemporaneously. Celano et al. argue that the methodological characteristics of
the studies they reviewed was that DSM-IV diagnoses were associated with sig-
nificantly lower prevalence of panic disorder, agoraphobia, and GAD(Celano et
al., 2016). The apparent reduction in anxiety disorder prevalence among CHD
samples was likely associated with the methodological trend to report ‘any anxiety
disorder’ rather than specific anxiety disorder subtypes (Bankier et al., 2008) dur-
ing the post-DSM-IV period. Likewise, Celano highlights the apparent decrease in
anxiety disorder prevalence occurred during a period of increased recognition of
depression morbidity and large depression trials (von Känel et al., 2007). Consid-
ering the uncertainty surrounding the apparent change in anxiety disorder preval-
ence in CHD, there is a requisite need for larger epidemiological studies of specific
anxiety disorders in CHD patients with the most recent taxonomic nosology delin-
eated in the DSM-V (Drexler, 1997). Such studies will enrich our understanding
of anxiety disorder diagnosis in CHD, and in turn, enable additional prognostic
MACE studies.
8.1.3 Medication adherence
Medication adherence is a crucial part in the management of chronic diseases.
As older adults form a greater proportion of the population with chronic diseases
and multiple (co-)morbidities, understanding medication adherence in older adults
is important. As detailed at the beginning of this chapter, medical adherence was
predicted by lower educational level and the group variable ’chordae tendineae
rupture only’. These results suggest that lower symptom severity improves medical
adherence, while higher educational level decreases it. Clear associations have been
established between elderly patients’ medication adherence and ethnicity, drug and
dosage form, number of medications, cost of medications, insurance coverage, and
physician-patient communication. However, the findings are inconsistent with re-
gard to the effects of patients’ age, sex, socioeconomic status, living arrangement,
comorbidities, number of physician visits, and knowledge, attitudes, and beliefs
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about health and need to be addressed in future study designs(Balkrishnan, 1998).
While some factors, such as mental state factors, physical function, age, sex, edu-
cation level, marital status, lack of medication knowledge, polypharmacy, complex
dosing regimen, pillbox usage and poor labelling instructions, had contradictory
results on investigation. The reason could be that adherence to medication in this
population might be context driven. Therefore, when addressing these factors,
clinicians should exercise clinical judgement and propose appropriate solutions to
them (Yap, Thirumoorthy & Kwan, 2016). Furthermore, multiple studies regarding
patient-doctor relationship have stressed the importance of patients understanding
why and what kind of medication they are supposed to take. These findings are
corroborated by the patients that were interview as part of the qualitative part of
this study narratives. Feelings of dependency and worthlessness as well as being
treated in a derogatory manner by care givers was a key theme for CTR patients.
Interviewed CTR Patients particularly stressed that feeling respected and purpose-
fully was a key factor in their recovery and coping with the traumatic event as
well as their perceived doctor-patient relationship. One patient stated that he mis-
trusted his new care-giver team, as he found contact with them impersonally and
generic, hence he also felt wary of taking the prescribed medicines. Moreover,
findings suggest that patients inner illness narratives or bio-psychological models
should match or be at least partially consistent with the clinicians explanation of
their illness. Beyond the well established factor of relationship and the timing of
these explanations are also important (Yap et al., 2016). Recently, studies assess-
ing cognitive functioning in patients with mitral insufficiency were able to show
executive impairment in patients prior to MitraClip intervention (Terhoeven et al.,
2019). Hence, depressed executive functioning may be a further factor contributing
to the studies findings that the patients with objectively higher symptom sever-
ity (assessed defined by NYHA class and LVEF) and more sever diagnosis (MI)
showed poorer medication as compared to CTR Patients who had not experienced
AMR. In line with this studies data, Terhoeven et al. state that age and psycho-
logical functioning seem less important for cognitive performance improvements
n(Terhoeven et al., 2019).
8.2 Qualitative data
The qualitative part of this work examined how CTR patients perceived the CTR
event, ensuing coping mechanisms, and changes in health behaviour and world
view following the CTR event at an individual level. The qualitative analysis of
the conducted interviews identified 1290 single codes from which three main cat-
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egories, namely the experience of fear and threat (324 codes) during the chordae
tendineae rupture, the experience of loss of autonomy (280 codes) and the experi-
ence of gratitude for having survived (125 codes) in the wake of chordae tendineae
rupture with four themes each emerged. Surviving a CTR with resulting AMR
creates a whirlpool of emotions, ranging from fear, vulnerability and loneliness
to gratitude and joy which is in line with other qualitative findings assessing the
trauma of cardiac events (Bremer, Dahlberg & Sandman, 2009; Ketilsdottir, Alberts-
dottir, Akadottir, Gunnarsdottir & Jonsdottir, 2014) Commonly reported were feel-
ings of loss, a search for meaning and a need to find answers as to why it happened
to them and why they survived. Impatience and irritability were common in the
beginning when survivors had to adjust to their new situation; they wanted life to
be as normal, find a reason and determine their possible contribution to the CA,
regardless of the real causes. Thoughts of being a terrible person who deserved
this were occasionally verbalised, creating feelings of separation and loneliness
(Bremer et al., 2009; Ketilsdottir et al., 2014). Bayer-Tolispy et al. were able to
show that PTSD in their study sample was also associated with a more severe per-
ceived illness, despite chronic mitral-regurgitation objective measures being very
similar between patients with and without PTSD. This observation is consistent
with previous findings showing that subjective perception of the traumatic event
is a stronger determinant of PTSD than the actual severity of the trauma(Costa-
Requena & Gil, 2010). This pessimistic view of the cardiac condition emphasises
the importance of examining the association between PTSD and somatic symp-
toms. And gives rise for future research endeavour to consider perceived severity
of illness in a systematic manner. In sum, the qualitative analysis results elucid-
ated the stark physical and psychological impact on patients who had experienced
the chordae tendineae rupture and corroborated the quantitative findings of high
post-traumatic stress disorder scores on an individual level but also painted a pic-
ture of functional as well as dysfunctional coping strategies. Haydon et al. critically
appraise and synthesise the qualitative literature on survivors’ experiences of a car-
diac arrest in order to identify common themes that can inform clinical pathways
and thereby improve survivors’ psychological burden, assessed via QoL, in their
systematic review and meta-synthesis of over 204 qualitative studies assessing sur-
vivors’ experiences of a cardiac arrest and CPR (Haydon et al., 2017). Their results
revealed five emerging themes: multitude of contrasting feelings; disruption in the
continuum of time; new reality and psychological challenges; changed body with
new limitations; and confrontation with death. These themes are in line with the
findings f this study. Another important factor is the individual ability to adjust to
mental and health-related demands. This comprises the ability to cope emotionally
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with diseases including adapting and/or maintaining favourable health-related be-
haviour. Despite high demands, several individuals are able to adequately adjust
(high resilience), while others develop maladaptive, disease-promoting behavioural
patterns. For example, people with traumatic childhood experiences, chronic stress
or mental comorbidities (e.g., depression, anxiety) exhibit more disease-promoting
behaviour (Michal, Subic-Wrana & Beutel, 2014). The same holds for people with
certain personality characteristics like the “Type D personality” (Denollet & Peder-
sen, 2008) or chronic hostility (Chida & Steptoe, 2009).
8.2.1 Limitations and future research directions
This study has several limitations that need to be noted. Although all patients
treated for Chordae tendineae rupture in the Department of Cardiology of the
Heidelberg University Hospital, Germany, in the period between January 2013 and
July 2017 were prospectively included in the study (n = 65), only 44 out of 65
eligible patient participants consented to participate in the study. This limits find-
ings by potentially biasing the analyses, as the current sample represents a selected
group of participants. Furthermore, the study is limited by the small number of
participants due to the rare nature of the condition CTR. A further concern lies in
the fact that the presented study does not represent a randomised controlled trial,
leaving the possibility that effects will not be replicable (Ioannidis, 2005). As the
presented study is limited by its small pilot sample size, also the number of pre-
dictor variables which could be included in the multiple regression models were
limited. In addition, the predictors of the study variables were evaluated within a
cross-sectional design. In order to confirm the results, longitudinal research would
be necessary. However, the presented data are still important as they over a baseline
assessment of psychological burden in CTR using more complex statistical meth-
ods. Furthermore, limiting the study’s generalisability, it must be assumed that the
specific pathology profile of this elderly patient sample is different to the patho-
logy profile of younger chordae tendineae rupture patients, especially with regard
to number of diagnosis and resulting variable interference as well as with regard to
cognitive functioning and perspective on their personal future outlook. Although
specific risk factors, such as nicotine abuse and obesity were assessed, and the pa-
tients history was screened for severe comorbid conditions, for example, cancer,
human-immunodeficiency virus, overt renal failure, lung disease, previous stroke
or any other major neurological disease; history of valve repair or replacement as
well as a history of psychological illness and substance abuse, they were not com-
prehensively assessed in this elderly sample. Further potential influencing factors
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need to be addressed in a more comprehensive assessment of socio-demographic,
medical and psychological aspects, such as attachment style and personality traits,
data in a longitudinal design in a younger larger sample. Lastly, although the
qualitative content analysis was performed according to principles of inductive
category development and was verified by a second researcher, the examination
can be considered to be less generalisable than quantitative approaches due to the
subjective nature of qualitative studies. However, with the aim of drawing a more
complete picture of this multivariate topic and identifying new research aspects,
this methodological approach was specifically chosen to elucidate CTRs patients’
perceptions and experiences of the CTRs event. However, the qualitative analysis
results elucidated the stark physical and psychological impact on patients who had
experienced the chordae tendineae rupture and corroborated the quantitative find-
ings of high post-traumatic stress disorder scores on an individual level but also
painted a picture of functional as well as dysfunctional coping strategies. Hence,
this potential shortfall, can also be considered as a important strength of the study
design in light that this is a pilot study. Protective factors found in extent literat-
ure, such as social support and progressive coping strategies, were also relevant in
the interviewed patients’ narratives. Future research should address these protect-
ive factors more comprehensively by including quantitative measures in the study
design. Despite its limitations, the study presented at the heart of this thesis was
able to shed light on the so far neglected psychological burden of cardiac patients
with chordae tendineae rupture and presented results point to the fact that there is
indeed a need for considering psychosocial factors in the care of chordae tendineae
rupture patients. Especially, with regard to the high prevalence of post-traumatic
stress disorder in chordae tendineae rupture patients with acute mitral regurgit-
ation, the presented data suggests the necessity for meaningful interventions to
prevent post-traumatic stress disorder after chordae tendineae rupture.
8.2.2 Clinical implications and outlook
The research presented in Chapter three has firmly established that psychoso-
cial factors, such as low socioeconomic status, acute and chronic stress, depression,
anxiety, and low social support are associated with an unfavourable prognosis in
CHD. The findings presented in this thesis with regard to the psychological burden
of cardiac patients with CTR corroborate the need for routine assessment of psycho-
social problems and mental comorbidities should be routinely assessed in cardiac
patients to initiate targeted diagnostics and treatment. With regard to medication
adherence, for all patients, treatment should consider age and gender differences
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as well as individual patient preferences to ensure better adherence to the some-
time challenging and irksome medication regime. Taking a synoptic view on the
research reviewed for this thesis, multimodal treatment concepts should comprise
education, physical exercise, motivational counselling, and relaxation training or
stress management, as suggested. In cases of mental comorbidities, brief psychoso-
cial interventions by primary care providers or cardiologists, regular psychother-
apy and/or medications should be offered. While these interventions have positive
effects on psychological symptoms, robust evidence for possible effects on cardiac
outcomes is still lacking. For coronary heart disease, chronic heart failure, arter-
ial hypertension, and some arrhythmias, there is robust evidence supporting the
relevance of psychosocial factors, pointing to a need for considering them in cardi-
ological care. However, there are still shortcomings in implementing psychosocial
treatment, and prognostic effects of psychotherapy and psychotropic drugs remain
uncertain. There is a need for enhanced provider education and more treatment tri-
als. As the number of studies finding associations between psychological stressors,
Post-traumatic stress disorder, and cardiovascular disease grows, the focus of re-
search has appropriately turned to prevention. In order to identify causal mechan-
isms that could serve as targets for interventions, further prospective studies with
repeated measures of psychological stress, biological factors, and cardiovascular
outcomes or surrogate markers of CVD are needed. Ongoing data collection in
some of the prospective cohort studies described above should help to establish
the pathways linking stress and CVD. With regard to CTR patients, the results of
the presented pilot study point to a need for considering psychosocial factors in
the care of CTR patients. Especially, in light of the found high prevalence of PTSD
in CTR Patients with AMR, the data suggests the need for meaningful preventive
interventions to deal with PTSD after CTR. As average life expectancy increases, so
do the incidence of chronic diseases and the number of persons receiving longterm
drug therapy. Hence, elderly patients’ psychological burden in general and elderly
CTR patients in particular, as assessed in this study sample, as well as their treat-
ment and noncompliance with medication regiments has the potential for sweeping
medical and economic consequences and is likely to become increasingly important
in the design of disease-management programs for this population (Balkrishnan,
1998). However, a better understanding of the prevalence of psychological stress
after CTR needs to be more comprehensively assessed in larger sample sized and
across wider age groups in future research. In a nutshell, the presented find-
ings are in line with Shakespeare’s imagery: broken heart strings matter and future
research needs to determine what pulls the heart strings in further detail.
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Chapter 9
Summary
Chordae tendineae rupture is a potentially life-threatening cardiac event often
resulting in acute mitral regurgitation with significant haemodynamic dysfunc-
tions that require immediate medical intervention. However, to date, the psycholo-
gical burden of cardiac patients with chordae tendineae rupture have been starkly
neglected. Despite its potentially devastating effects on affected patients’ physical
health, the potential psychological effects have yet to be described. Moreover, while
traumatic conditions within the spectrum of acute coronary syndrome and poten-
tially traumatic cardiological treatment procedures (e.g., defibrillator implantation)
have been at the centre of research efforts, neither the relationship of post-traumatic
stress disorder, depression, nor anxiety and chordae tendineae rupture has re-
ceived any attention so far. Hence, although psycho-emotional comorbidities of
heart disease have received much attention, little is known about patients’ psy-
chological burden after acute severe mitral regurgitation due to chordae tendineae
rupture. This pilot study aimed to assess affected cardiological patients’ psycho-
logical burden after acute severe mitral regurgitation due to chordae tendineae
rupture in a mixed-method approach. For the monocentric, cross-sectional, non-
interventional study presented in this thesis clinical and psychometric data was
systematically collected in two cardiological samples (chordae tendineae rupture
case study patients and myocardial infraction control study patients) after hos-
pitalisation for a chordae tendineae rupture event or myocardial infraction. Only
patients who had been treated for chordae tendineae rupture or myocardial in-
fraction in the Department of Cardiology, Heidelberg University Hospital, Ger-
many, were asked to participate in this study on a voluntary basis. The psy-
chological burden (post-traumatic stress symptoms, depression, and anxiety) in
cardiac patients with chordae tendineae rupture n = 44 chordae tendineae rup-
ture patients (age 81.9± 5 years; 59% men, range 63− 91) and in n = 35 myocar-
dial infraction patients (age 78.9 ± 5 years; 60% men, range 63 − 89) was assessed
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using validated questionnaires. In addition, semi-structured interviews were con-
ducted with a subgroup of 20 chordae tendineae rupture patients from the case
sample and subsequently evaluated by means of qualitative content analysis to
provide a more precise picture of psychological stress, individual coping mech-
anisms, and changes in health behaviour after chordae tendineae rupture. De-
scriptive statistics were used to describe the major study variables and sample
demographics. Stepwise and robust multiple regression models were computed
in R to estimate the influence of group (myocardial infraction, chordae tendineae
rupture only, and chordae tendineae rupture with acute mitral regurgitation) and
socio-demographic variables (sex, age, marital status and educational level) on psy-
chological burden (post-traumatic stress disorder, depression, generalised anxiety
disorder) and medication adherence. Intercorrelations among study variables and
the variance inflation factor were assessed to determine multicollinearity. The res-
ults of the data analysis revealed important findings: as hypothesised, chordae
tendineae rupture patients are significantly burdened by post-traumatic stress dis-
order. Moreover, post-traumatic stress disorder is significantly more prevalent in
chordae tendineae rupture patients who had suffered acute mitral regurgitation
than in chordae tendineae rupture patients with moderate/severe mitral regurgit-
ation. Most interestingly, chordae tendineae rupture patients who had suffered
acute mitral regurgitation showed higher post-traumatic stress disorder scores,
nearly reaching the Post-traumatic Diagnostic Scale’s cut-off score for severe post-
traumatic stress disorder symptoms (> 30), than myocardial infraction controls.
Accordingly, higher post-traumatic stress disorder scores were primarily predicted
by the group factor ’chordae tendineae rupture with acute mitral regurgitation’,
(R2 = .44, F(9, 44) = 6, 72, p < .001; β = 7.87, p < .001), and accounted for ap-
proximately 44% of the variance of post-traumatic stress disorder in the stepwise
multiple regression model. The mean scores for depression and anxiety were mild
to moderate across all groups. In the robust multiple regression model, depression
was predicted by female gender (R2 = .17, F(2, 80) = 6.72, p < .05; β = 2.75, p <
.01) which is in line with current global prevalence distributions but was not pre-
dicted by age, educational level, or study groups (myocardial infraction, chordae
tendineae rupture only, and chordae tendineae rupture with acute mitral regurgit-
ation). Anxiety score could not be predict based on the multiple regression model
variables. There has been ample discussion with regard to the prevalence and
symptoms of anxiety disorders in cardiological patients due to the fact that many
symptoms of anxiety are difficult to differentiate from typically cardiac symptoms,
such as dyspnoea. In extent literature and results remain controversial. Future
research should address the predictors of anxiety disorders in chordae tendineae
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rupture patients in a longitudinal design with a larger sample size. Medical ad-
herence was predicted by lower educational level and the group variable ’chordae
tendineae rupture only’. These results suggest that lower symptom severity im-
proves medical adherence, while higher educational level decreases it. Clear asso-
ciations have been established between elderly patients’ medication adherence and
race, drug and dosage form, number of medications, cost of medications, insur-
ance coverage, and physician-patient communication. However, the findings are
inconsistent with regard to the effects of patients’ age, sex, socioeconomic status,
living arrangement, comorbidities, number of physician visits, and knowledge, at-
titudes, and beliefs about health and need to be addressed in future study designs.
The qualitative analysis of the conducted interviews identified 1290 single codes
from which three main categories, namely the experience of fear and threat (324
codes) during the chordae tendineae rupture, the experience of loss of autonomy
(280 codes) and the experience of gratitude for having survived (125 codes) in the
wake of chordae tendineae rupture with four themes each emerged. Qualitative
analysis results elucidated the stark physical and psychological impact on patients
who had experienced the chordae tendineae rupture and corroborated the quant-
itative findings of high post-traumatic stress disorder scores on an individual level
but also painted a picture of functional as well as dysfunctional coping strategies.
Protective factors found in extent literature, such as social support and progressive
coping strategies, were also relevant in the interviewed patients’ narratives. Future
research should address these protective factors more comprehensively by includ-
ing quantitative measures in the study design. The presented study is limited by
its small pilot sample size which also limited the number of predictor variable
which could be included in the multiple regression models. Furthermore, limit-
ing generalisability, it must be assumed that the specific pathology profile of this
elderly sample is different to the pathology profile of younger chordae tendineae
rupture patients, especially with regard to number of diagnosis and resulting vari-
able interference. Further potential influencing factors need to be addressed in a
more comprehensive assessment of socio-demographic, medical and psychological
data, such as attachment style and personality traits in a longitudinal design in a
younger larger sample. Nevertheless, the study presented at the heart of this thesis
was able to shed light on the so far neglected psychological burden of cardiac pa-
tients with chordae tendineae rupture and presented results point to the fact that
there is indeed a need for considering psychosocial factors in the care of chordae
tendineae rupture patients. Especially, with regard to the high prevalence of post-
traumatic stress disorder in chordae tendineae rupture patients with acute mitral
regurgitation, the presented data suggests the necessity for meaningful interven-
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tions to prevent post-traumatic stress disorder after chordae tendineae rupture. In
a nutshell, presented data are in line with Shakespeare’s imagery: broken heart
strings matter and future research needs to determine what pulls the heart strings
in further detail.
9.1 Zusammenfassung
Die Chordae Tendineae Ruptur ist ein potenziell lebensbedrohliches Herzereignis,
das oft zu einer akuten Mitralinsuffizienz mit erheblichen hämodynamischen Dys-
funktionen führt, die eine sofortige medizinische Intervention erfordern. Bislang
wurde jedoch der psychischen Belastung von kardialen Patienten mit Ruptur der
Chordae tendineae und akuter Mitralinsuffizienz nur wenig Beachtung geschenkt.
Trotz der potenziell verheerenden Auswirkungen auf die körperliche Gesundheit
der betroffenen Patienten, gibt es noch keine Untersuchungen zu den psychologis-
chen Auswirkungen. Während traumatische Zustände im Spektrum des akuten
Koronarsyndroms und potenziell als traumatisch erlebte kardiologische Behand-
lungsverfahren (z.B. Defibrillatorimplantation) im Mittelpunkt der Forschungsan-
strengungen standen, wurde die Beziehung zwischen Ruptur der Chordae tendineae
sowie Posttraumatischen Belastungsstörungen, Depression oder Angst bisher nicht
erforscht. Untersuchungen, welche spezifisch die psychischen Belastungen in Folge
einer Ruptur der Chordae tendineae fokussieren, stehen somit noch aus. Die Erken-
ntnis, ob die Posttraumatische Belastungsstörung eine relevante Komplikation der
Ruptur der Chordae tendineae darstellt, ist besonders im Hinblick auf sekundär-
präventive Maßnahmen bedeutend. Ziel dieser Pilotstudie war es, die psychische
Belastung von betroffenen Patienten nach einer akuten schweren Mitralinsuffizienz
durch Chordae Tendineae Ruptur, Resilienzfaktoren und Änderungen des Gesund-
heitsverhaltens in einem Mixed-Method-Ansatz zu untersuchen. Neben quantitat-
iven psychometrischen Fragebögen wurden semistrukturierte Interviews durchge-
führt und mittels qualitativer Inhaltsanalyse ausgewertet. Ein besseres Verständnis
der Prävalenz von psychischen Belastungen nach einem Sehnenfadenabriss, mit
besonderem Fokus auf die Prävalenz von Posttraumatische Belastungsstörungen,
ist bedeutend für die Entwicklung präventiver Interventionen zur Verhinderung
einer PTBS nach Ruptur der Chordae tendineae. In der vorgestellten Untersuchung
wurden die psychische Belastung bei Herzpatienten mit Sehnenruptur (Posttrau-
matische Stresssymptome, Depressionen, Angststörungen und Medikamentenein-
nahme) unter Verwendung validierter psychometrischer Fragebögen bei n = 44 Pa-
tienten mit Sehnenfadenabriss (Alter 81, 9± 5 Jahre; 59% Ma¨nner, Bereich 63 bis 91)
und bei n = 35 Patienten mit Myokard Infarkt (Alter 78, 9± 5 Jahre; 60% Ma¨nner,
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Bereich 63 bis 89) erhoben. Darüber hinaus wurden mit einer Untergruppe von
20 Patienten mit Sehnenfadenabriss Patienten teilstrukturierte Interviews durchge-
führt und anschließend mittels qualitativer Inhaltsanalyse ausgewertet, um ein
genaueres Bild von psychischem Stress, individuellen Bewältigungsmechanismen
und Veränderungen im Gesundheitsverhalten nach dem Sehnenfadenabriss zu er-
halten. Deskriptive Statistiken wurden verwendet, um die Belastungsfaktoren und
die demographische Stichprobe zu beschreiben. Die Rohdaten werden durch die
Darstellung des Mittelwerts (MD) und der Standardabweichungen (SD) angezeigt.
Schrittweise und robuste multiple Regressionsmodelle wurden in R berechnet, um
den Einfluss der Gruppe (‚Myokardinfraktion‘, ‚nur Chordae Tendineae Ruptur‘
und ‚Chordae Tendineae Ruptur mit akuter Mitralinsuffizienz‘) und soziodemo-
graphischer Variablen (Geschlecht, Alter, Familienstand und Bildungsniveau) auf
die psychische Belastung (Posttraumatische Belastungsstörung, Depression, Gen-
eralisierte Angststörung) und Medikamente Adhärenz abzuschätzen. Interkorrela-
tionen zwischen den Untersuchungsvariablen wurden mittels Varianz-Inflationsfaktor
untersucht, um auf Multikollinearität zu prüfen. Die Datenanalyse zeigte, dass
Chordae Tendineae Ruptur Patienten signifikant durch posttraumatische Belast-
ungssymptome beeinträchtigt sind. Darüber hinaus ist die Posttraumatische Be-
lastungsstörung bei Chordae Tendineae Ruptur-Patienten, die eine akute Mitralin-
suffizienz erlitten haben, signifikant häufiger als bei Chordae Tendineae Ruptur-
Patienten mit mittlerer/schwerer Mitralinsuffizienz. Interessanterweise zeigten
Chordae Tendineae Ruptur-Patienten, die an akuter Mitralinsuffizienz gelitten hat-
ten, höhere Werte für posttraumatische Belastungsstörungen und erreichten fast
den Cut-off-Score der Posttraumatischen Diagnoseskala für schwere posttraumat-
ische Belastungsstörungssymptome (> 30) als Myokardinfraktionskontrollen. De-
mentsprechend wurden höhere posttraumatische Belastungsstörungswerte in er-
ster Linie durch den Gruppenfaktor "Chordae tendineae ruptur with acute mitral
regurgitation" vorhergesagt (R2 = .44, F(9, 44) = 6, 72, p < .001; β = 7, 87, p <
.001) und machten etwa 44% der Varianz der posttraumatischen Belastungsstörung
im schrittweisen multiplen Regressionsmodell aus. Die Durchschnittswerte für De-
pressionen und Angstzustände waren in allen Gruppen leicht bis moderat. Im ro-
busten multiplen Regressionsmodell wurde Depression nach weiblichem Geschlecht
vorhergesagt (R2 = .17, F(2, 80) = 6, 72, p < .05; β = 2, 75, p < .01), aber nicht von
Alter, Bildungsniveau oder Studiengruppen (‚Myokardinfraktion‘, ‚nur Chordae
Tendineae Ruptur‘ und ‚Chordae Tendineae Ruptur mit akuter Mitralinsuffizienz‘)
vorhergesagt wurde. Der Angstwert konnte auf der Grundlage der Variablen des
Mehrfach-Regressionsmodells nicht vorhergesagt werden. Über die Prävalenz und
Symptome von Angststörungen bei kardiologischen Patienten wird viel disku-
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tiert, da viele Angstsymptome schwer von typischen kardialen Symptomen, wie
z.B. Dyspnoe, zu unterscheiden sind. Zukünftige Forschungen sollten sich mit
den Prädiktoren von Angststörungen bei Chordae Tendineae Ruptur Patienten in
einem longitudinalen Design mit einer größeren Stichprobengröße befassen. Die
Adhärenz wurde durch ein niedrigeres Bildungsniveau und die Gruppenvariable
"nur Chordae tendineae ruptur" vorhergesagt. Diese Ergebnisse deuten darauf
hin, dass ein geringerer Schweregrad der Symptome die Adhärenz verbessert,
während ein höheres Bildungsniveau sie verringert. Es wurden klare Zusammen-
hänge zwischen der Einhaltung der Medikamente bei älteren Patienten und ihrer
ethnischen Herkunft, der Medikamenten- und Dosierungsform, der Anzahl der
Medikamente, den Medikamentenkosten, dem Versicherungsschutz und der Kom-
munikation zwischen Arzt und Patient festgestellt. Die Ergebnisse sind jedoch
inkonsistent in Bezug auf die Auswirkungen von Alter, Geschlecht, sozioökonomis-
chem Status, Lebensweise, Komorbiditäten, Anzahl der Arztbesuche sowie Wissen,
Einstellungen und Überzeugungen über Gesundheit und müssen in zukünftigen
Studiendesigns berücksichtigt werden. Die qualitative Analyse der durchgeführten
Interviews identifizierte 1290 Einzelcodes, aus denen drei Hauptkategorien, näm-
lich die Erfahrung von Angst und Bedrohung (324 Codes) während des Sehen-
fadenabrisses, die Erfahrung des Verlustes der Autonomie (280 Codes) und die
Erfahrung der Dankbarkeit für das Überleben (125 Codes) nach dem Chordae
Tendineae Bruchsprung mit jeweils vier Unterthemen entstanden sind. Qualit-
ative Analyseergebnisse verdeutlichten die starken physischen und psychischen
Auswirkungen auf Patienten, die die Chordae-Sehnenruptur erlebt hatten, und
bestätigten die quantitativen Ergebnisse hoher posttraumatischer Belastungswerte
auf individueller Ebene, zeichneten aber auch ein Bild von funktionellen und dys-
funktionalen Bewältigungsstrategien. Schutz-faktoren, wie soziale Unterstützung
und progressive Bewältigungsstrategien, waren auch in den Erzählungen der be-
fragten Patienten relevant. Zukünftige Forschung sollte diese Schutzfaktoren durch
die Einbeziehung quantitativer Maßnahmen in das Studiendesign umfassender
behandeln. Die vorgestellte Studie ist durch ihren geringen Stichprobenumfang
begrenzt, der auch die Anzahl der Prädiktorvariablen begrenzt, die in die mul-
tiplen Regressionsmodelle einbezogen werden konnten. Darüber hinaus ist von
einer Einschränkung der Verallgemeinerbarkeit auszugehen, da sich das spezifis-
che Pathologieprofil dieser älteren Probe vom Pathologieprofil jüngerer Chordae
Tendineae Ruptur-Patienten wahrscheinlich unterscheidet, insbesondere in Bezug
auf die Anzahl der Diagnosen und die daraus resultierenden möglichen Interfer-
enzen. Weitere potenzielle Einflussfaktoren müssen in einer umfassenderen Be-
wertung soziodemographischer, medizinischer und psychologischer Daten, wie
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z.B. Bindungsstil und Persönlichkeitsmerkmale, in einer Längsschnittstudie mit
einer jüngeren größeren Stichprobe berücksichtigt werden. Dennoch konnte die in
dieser Arbeit vorgestellte Studie Aufschluss über die bisher vernachlässigte psych-
ische Belastung von Herzpatienten mit Chordae Tendineae Ruptur geben und die
präsentierten Ergebnisse deuten darauf hin, dass es notwendig ist, psychosoziale
Faktoren bei der Versorgung von Chordae Tendineae Ruptur Patienten zu berück-
sichtigen. Insbesondere im Hinblick auf die hohe Prävalenz posttraumatischer Be-
lastungsstörungen bei Chordae Tendineae Ruptur Patienten mit akuter Mitralin-
suffizienz deuten die vorliegenden Daten auf die Notwendigkeit sinnvoller Inter-
ventionen hin, um posttraumatische Belastungsstörungen nach Chordae Tendineae
Ruptur zu verhindern.
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 PDS-ADAP  
 
Bitte kreuzen Sie für die folgenden Fragen JA oder NEIN an:  
 
Während des Sehnenfadenabrisses ... 
 
JA NEIN ... fühlten Sie sich hilflos? 
JA NEIN ... hatten Sie starke Angst oder waren Sie voller Entsetzen? 
JA NEIN ... dachten Sie, dass Ihr Leben in Gefahr war? 
JA NEIN ... wurden Sie körperlich verletzt? 
 
Im Folgenden finden Sie eine Reihe von Problemen, die Menschen manchmal nach 
belastenden Erlebnissen haben. Bitte lesen Sie sich jedes der Probleme sorgfältig durch. 
Wählen Sie diejenige Antwortmöglichkeit (0 - 3) aus, die am besten beschreibt, wie häufig 
Sie IM LETZTEN MONAT von diesem Problem betroffen waren. Die Fragen sollten Sie dabei 
auf das Erlebnis des Sehnenfadenabrisses beziehen.  
 
Dabei bedeutet 
0 = überhaupt nicht oder nur einmal im letzten Monat 
1 = einmal pro Woche oder seltener / manchmal 
2 = 2 bis 4 Mal pro Woche / die Hälfte der Zeit 
3 = 5 Mal oder öfter pro Woche / fast immer 
 
Hatten Sie belastende Gedanken oder Erinnerungen an das 
Erlebnis, die ungewollt auftraten und Ihnen durch den Kopf 
gingen, obwohl Sie nicht daran denken wollten? 
 
 
0 
 
1 
 
2 
 
3 
 
Hatten Sie schlechte Träume oder Alpträume über das 
Erlebnis? 
 
 
0 
 
1 
 
2 
 
3 
 
War es, als würden Sie das Ereignis plötzlich noch einmal 
durchleben, oder handelten oder fühlten Sie so, als würde es 
wieder passieren? 
 
 
0 
 
1 
 
2 
 
3 
 
Belastete es Sie, wenn Sie an das Erlebnis erinnert wurden 
(fühlten Sie sich z.B. ängstlich, ärgerlich, traurig, schuldig 
usw.)? 
 
 
0 
 
1 
 
2 
 
3 
 
Hatten Sie körperliche Reaktionen (z.B. Schweißausbruch oder 
Herzklopfen), wenn Sie an das Erlebnis erinnert wurden? 
 
0 
 
1 
 
2 
 
3 
 
Haben Sie sich bemüht, nicht an das Erlebnis zu denken, nicht 
 
0 
 
1 
 
2 
 
3 
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darüber zu reden oder damit verbundene Gefühle zu 
unterdrücken? 
 
 
Haben Sie sich bemüht, Aktivitäten, Menschen oder Orte zu 
meiden, die Sie an das Erlebnis erinnern? 
 
 
0 
 
1 
 
2 
 
3 
 
Konnten/ können Sie sich an einen wichtigen Bestandteil des 
Erlebnisses nicht erinnern? 
 
 
0 
 
1 
 
2 
 
3 
 
Hatten Sie deutlich weniger Interesse an Aktivitäten, die vor 
dem Erlebnis für Sie wichtig waren, oder haben Sie sie deutlich 
seltener unternommen? 
 
 
0 
 
1 
 
2 
 
3 
 
Fühlten Sie sich Menschen Ihrer Umgebung gegenüber 
entfremdet oder isoliert? 
 
 
0 
 
1 
 
2 
 
3 
 
Fühlten Sie sich abgestumpft oder taub (z.B. nicht weinen 
können oder sich unfähig fühlen, liebevolle Gefühle zu erleben) 
 
 
0 
 
1 
 
2 
 
3 
 
Hatten Sie das Gefühl, dass sich Ihre Zukunftspläne und 
Hoffnungen nicht erfüllen werden (z.B. dass Sie im Beruf 
keinen Erfolg haben, nie heiraten, keine Kinder haben oder 
kein langes Leben haben werden)? 
 
 
0 
 
1 
 
2 
 
3 
 
Hatten Sie Schwierigkeiten, ein- oder durchzuschlafen? 
 
 
0 
 
1 
 
2 
 
3 
 
Waren Sie reizbar oder hatten Sie Wutausbrüche? 
 
0 
 
1 
 
2 
 
3 
 
 
Hatten Sie Schwierigkeiten, sich zu konzentrieren (z.B. während 
eines Gespräches in Gedanken abschweifen; beim Ansehen 
einer Fernsehsendung den Faden verlieren; vergessen, was Sie 
gerade gelesen haben)? 
 
 
 
0 
 
 
1 
 
 
2 
 
 
3 
 
Waren Sie übermäßig wachsam (z.B. nachprüfen, wer in ihrer 
Nähe ist; sich unwohl fühlen, wenn Sie mit dem Rücken zur Tür 
sitzen; usw.). 
 
0 
 
1 
 
2 
 
3 
 
Waren Sie nervös oder schreckhaft (z.B. wenn jemand hinter 
Ihnen geht). 
 
 
0 
 
1 
 
2 
 
3 
 
 
Wie lange haben Sie schon die Probleme, die Sie in der obigen Tabelle angegeben 
haben? (bitte eine Antwortmöglichkeit ankreuzen): 
 
□ weniger als einen Monat 
□ 1 bis 3 Monate 
□ über 3 Monate 
 
 
Bitte geben Sie an, ob Sie die Probleme, die Sie in der obigen Tabelle angegeben haben, IM 
LETZTEN MONAT in den unten aufgeführten Bereichen Ihres Lebens beeinträchtigt haben. 
Bitte kreuzen Sie JA an, wenn eine Beeinträchtigung vorlag, und NEIN, wenn dies nicht der 
Fall war.  
 
JA NEIN 
 
Arbeit 
 
JA NEIN 
 
Hausarbeit und Haushaltspflichten 
 
JA NEIN 
 
Beziehungen zu Freunden 
 
JA NEIN 
 
Unterhaltung und Freizeitaktivitäten 
 
JA NEIN 
 
(Hoch-)Schule/ Ausbildung 
 
JA NEIN 
 
Beziehungen zur Familienmitgliedern 
 
JA NEIN 
 
Erotik 
 
JA NEIN 
 
Allgemeine Lebenszufriedenheit 
 
JA NEIN 
 
Allgemeine Leistungsfähigkeit in allen Lebensbereichen 
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FDS-20 
 
Dieser Fragebogen besteht aus 20 Fragen über Erfahrungen und Erlebnisse, die Sie  möglicherweise 
aus Ihrem alltäglichen Leben kennen. Wir sind daran interessiert zu erfahren, in welchem Ausmaß 
Sie derartige Erlebnisse in den letzten zwei Wochen gehabt haben. Bitte lassen Sie bei Ihren 
Antworten Episoden unberücksichtigt, in denen Sie unter dem Einfluss von Alkohol, Drogen oder 
Medikamenten gestanden haben.  
Um die Fragen zu beantworten, klicken Sie bitte auf diejenige Prozentzahl, die zeigt, wie oft 
Ihnen so etwas passiert. 0 % bedeutet niemals und 100 % immer. 
 
 
A
.1.2
FD
S-20
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Kurzform PHQ-D 
A) Wie oft fühlten Sie sich im Verlauf der 
letzten 2 Wochen durch die folgenden 
Beschwerden beeinträchtigt? 
 
überhaupt 
nicht 
an 
einzelnen 
Tagen 
an mehr als 
der Hälfte 
der Tage 
beinahe 
jeden Tag 
1. Wenig Interesse oder Freude an Ihren 
Tätigkeiten 
    
2. Niedergeschlagenheit, Schwermut oder 
Hoffnungslosigkeit 
    
3. Schwierigkeiten, ein- oder durchzuschlafen, 
oder vermehrter Schlaf 
    
4. Müdigkeit oder Gefühl, keine Energie zu 
haben 
    
5. Verminderter Appetit oder übermäßiges 
Bedürfnis zu essen 
    
6. Schlechte Meinung von sich selbst; Gefühl, 
ein Versager zu sein oder die Familie 
enttäuscht zu haben 
    
7. Schwierigkeiten, sich auf etwas zu 
konzentrieren, z.B. beim Zeitung lesen oder 
Fernsehen 
    
8. Waren Ihre Bewegungen oder Ihre Sprache 
so verlangsamt, dass es auch anderen 
auffallen würde? Oder waren Sie im Gegenteil 
„zappelig“ oder ruhelos und hatten dadurch 
einen stärkeren Bewegungsdrang als sonst? 
    
9. Gedanken, dass Sie lieber tot wären oder 
sich Leid zufügen möchten 
    
 
B) Fragen zum Thema „Angst“   JA NEIN 
1. Hatten Sie in den letzten 4 Wochen eine Angstattacke (plötzliches 
Gefühl der Furcht oder Panik)? 
    
Wenn „NEIN“, gehen Sie bitte weiter zu Frage C.     
2. Ist dies bereits früher einmal vorgekommen?     
3. Treten manche dieser Anfälle völlig unerwartet auf – d. h. in 
Situationen, in denen Sie nicht damit rechnen, dass Sie angespannt 
oder beunruhigt reagieren? 
    
5. Empfinden Sie diese Anfälle als stark beeinträchtigend und/oder 
haben Sie Angst vor erneuten Anfällen? 
    
6. Litten Sie während Ihres letzten schlimmen Angstanfalls unter 
Kurzatmigkeit, Schwitzen, Herzrasen oder -klopfen, Schwindel oder 
dem Gefühl, der Ohnmacht nahe zu sein, Kribbeln oder 
Taubheitsgefühlen, Übelkeit oder Magenbeschwerden? 
    
 
 
 
A.1.3 Kurzform PHQ-D
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C) Wenn eines oder mehrere der in diesem Fragebogen beschriebenen Probleme bei Ihnen 
vorliegen, geben Sie bitte an, wie sehr diese Probleme es Ihnen erschwert haben, Ihre Arbeit zu 
tun, Ihren Haushalt zu regeln oder mit anderen Menschen zurecht zu kommen: 
 
Überhaupt nicht 
erschwert 
 
Etwas 
 erschwert 
 
Relativ stark erschwert 
 
Sehr stark  
erschwert 
 
 
 
 
GAD-7 
 
 
Wie oft fühlen Sie sich im Verlauf der letzten 2 Wochen durch die folgenden Beschwerden 
beeinträchtigt? 
 
 
Überhaupt 
nicht 
 
An 
einzelnen 
Tagen 
 
An mehr als 
der Hälfte 
der Tage 
 
Beinahe 
jeden Tag 
 
1. Nervosität, Ängstlichkeit oder 
Anspannung 
    
2. Nicht in der Lage sein, Sorgen zu 
stoppen oder zu kontrollieren  
 
    
3. Übermäßige Sorgen bezüglich 
verschiedener Angelegenheiten 
    
4. Schwierigkeiten zu entspannen      
5. Rastlosigkeit, so dass Stillsitzen schwer 
fällt 
    
6. Schnelle Verärgerung oder Gereiztheit     
7. Gefühl der Angst, so als würde etwas 
schlimmes passieren 
    
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 Wie oft haben Sie Mühe, sich an 
die Einnahme aller Ihrer 
Medikamente zu erinnern? 
Immer  
 
Fast 
immer 
Manchmal Kaum Nie 
□ □ □ □ □ 
 
 
 
 
 
 
 
 
 
 
MORISKY 
Vergessen Sie manchmal, Ihre Medikamente einzunehmen? □ Ja □ Nein 
Manchmal wird ein Medikament nicht genommen, und zwar aus einem 
anderen Grund, als Vergesslichkeit. Wenn Sie an die letzten 2 Wochen 
denken, gab es Tage, an denen Sie Ihre Medikamente nicht genommen 
haben? 
□ Ja □ Nein 
Haben Sie jemals die Einnahme Ihrer Medikamente verringert oder 
gestoppt, ohne Ihren Arzt/Ihre Ärztin zu informieren, weil Sie sich nach 
der Einnahme schlechter fühlten? 
□ Ja □ Nein 
Wenn Sie reisen oder Ihr Zuhause verlassen, vergessen Sie manchmal 
Ihre Medikamente mitzunehmen? 
□ Ja □ Nein 
Haben Sie Ihre Medikamente gestern genommen? □ Ja □ Nein 
Wenn Sie das Gefühl haben, dass Ihre Erkrankung unter Kontrolle ist, 
hören Sie manchmal mit der Einnahme Ihrer Medikamente auf? 
□ Ja □ Nein 
Jeden Tag Medikamente zu nehmen, empfinden viele Personen als 
lästig. Fühlen Sie sich manchmal schikaniert, wenn Sie den 
Therapieplan genauestens einhalten müssen? 
□ Ja □ Nein 
A.1.5 MORISKY
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 Wie haben Sie den Sehnenfadenabriss erlebt?  
Was ist Ihre Überzeugung, wie es zu dem 
Sehnenfadenabriss kam? 
 
Welche Auswirkungen hat Sehnenfadenabriss auf Sie 
gehabt? 
 Körperliche Auswirkungen 
 Körperwahrnehmung, Vertrauen in 
den eigenen Körper 
 Stimmung / Ängstlichkeit 
 Reizbarkeit / Wachsamkeit 
 Auswirkungen auf tägliche Aktivitäten 
(Beruf, Freizeit) 
 Auswirkungen auf das soziale Umfeld 
und enge Beziehungen 
Wie sind Sie mit diesen Auswirkungen umgegangen?   Was ist Ihnen dabei schwer gefallen? 
 Was hat Ihnen geholfen? 
Haben Sie seit dem Sehnenfadenabriss etwas an 
Ihrem Gesundheitsverhalten geändert? 
 Was haben Sie geändert?  
 Wie leicht oder schwer war das für 
Sie? 
 Was hat Ihnen dabei geholfen? 
Wie kommen Sie mit der Medikamenteneinnahme 
zurecht? 
 Sehen Sie einen Sinn in der 
Medikamenteneinnahme? 
 Was bereitet Ihnen Schwierigkeiten 
bei der Medikamenteneinnahme, was 
hilft? 
Haben Sie Sorge vor einem weiteren schwierigen 
Krankheitsverlauf? 
 Wie gehen Sie mit diesen Sorgen um? 
Haben sich seit dem Sehnenfadenabriss Ihre 
persönlichen Einstellungen in Bezug auf das eigene 
Leben und die eigene Gesundheit geändert? 
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 „Psychische Belastung   nach Ruptur der Chordae tendineae““ 
 
Einverständniserklärung Studienteilnehmer/in 
 
Ich, ___________________________________, erkläre mich hiermit bereit, an der Studie „Psychische Belastung 
nach Ruptur der Chordae tendineae.“ teilzunehmen. Über die Inhalte der Studie bin ich ausreichend durch die 
Informationsschrift, die ich erhalten habe, informiert und zusätzlich mündlich aufgeklärt worden. 
 
Freiwilligkeit 
Die Teilnahme an der Studie ist freiwillig. Ich kann mein Einverständnis jederzeit, ohne Angabe von Gründen und 
ohne für mich entstehende Nachteile, zurückziehen. Frau Dipl. Psych. Anna Cranz stand mir hierbei für Rückfragen 
zur Verfügung. 
Unbeantwortete Fragen Sollten Sie Fragen haben, wenden Sie sich bitte an den Projektverantwortlichen. 
 
Projektverantwortlicher 
 
Apl. Prof. Dr. med. Christoph Nikendei, MME 
 
Christoph.Nikendei@med.uni-heidelberg.de 
 
Oberarzt 
Universitätsklinikum Heidelberg 
Klinik für Allgemeine Innere Medizin und Psychosomatik 
am Universitätsklinikum Heidelberg 
 
Thibautstr. 4 
69115 Heidelberg 
 
Gemäß § 4 Bundesdatenschutzgesetz (BDSG): "Ich wurde darüber aufgeklärt und stimme zu, dass meine in der 
Studie erhobenen Daten in pseudonymisierter Form aufgezeichnet (und ggf. auch in pseudonymisierter Form 
weitergegeben) werden können. Dritte erhalten jedoch keinen Einblick in personenbezogene Unterlagen. Bei der 
Veröffentlichung von Ergebnissen der Studie wird mein Name ebenfalls nicht genannt." 
Im Falle eines Rücktritts 
 Ja, ich bin damit einverstanden, dass - im Falle eines Rücktritts - die bisher erhobenen Daten meiner 
Person ausgewertet werden. 
 Nein, ich möchte nicht, dass die bisher erhobenen Daten von meiner Person ausgewertet werden/wird. Es 
soll sämtliches Material, das mit meiner Person in Zusammenhang steht vernichtet werden 
 
 ___________________________   ______________________________ 
Ort, Datum     Unterschrift des Studienteilnehmers 
 
      ________________________________ 
  Unterschrift des Aufklärenden 
Ihr persönlicher Code: 
Unter „Pseudonymisierung“ versteht man die Verarbeitung personenbezogener Daten in einer Weise, dass die 
personenbezogenen Daten ohne Hinzuziehung zusätzlicher Informationen („Schlüssel“) nicht mehr einer 
spezifischen betroffenen Person zugeordnet werden können. Diese zusätzlichen Informationen werden dabei 
gesondert aufbewahrt und unterliegen technischen und organisatorischen Maßnahmen, die gewährleisten, dass 
die personenbezogenen Daten nicht einer identifizierten oder identifizierbaren natürlichen Person zugewiesen 
werden. 
 
Um ein Code für Sie zu generieren, mit dem Ihre Daten wie oben beschrieben pseudonymisiert gespeichert werden 
können, bitten wir Sie noch, folgende Angaben zu machen: 
 
Notieren Sie unten nacheinander  
• den zweiten Buchstaben des Vornamens Ihrer Mutter (z.B. „A“ für Sabine)  
• den dritten Buchstaben des Vornamens Ihres Vaters (z.B. „R“ für Herbert)  
• die Summe ihrer Hausnummer als zweistellige Zahl (z.B. „09“ für Hausnr. 18)  
• die ersten beiden Buchstaben des Ortes Ihrer Einschulung (z.B. „Fr“ für Frankfurt).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Zweiter 
Buchstabe d. 
Vornamens 
d. Mutter 
z.B. „A“ 
Die Summe  
Ihrer Hausnr. 
z.B. „09“ 
Dritter Buchstabe 
d. Vornamens d. 
Vaters 
z.B. „R“ 
 
Ersten beiden 
Buchstaben des 
Ortes der 
Einschulung 
z.B. „FR“ 
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 „Psychische Belastung von kardiologischen Patienten nach Ruptur der Chordae tendineae““ 
 
 
Einverständniserklärung Studienteilnehmer/in 
 
Ich habe die Informationsschrift gelesen und wurde zudem mündlich durch Frau Dipl. Psych. Anna Cranz 
über das Ziel und den Ablauf der Studie sowie über die Risiken ausführlich und verständlich aufgeklärt. Im 
Rahmen des Aufklärungsgesprächs hatte ich die Gelegenheit, Fragen zu stellen. Alle meine Fragen wurden 
zu meiner Zufriedenheit beantwortet. Ich stimme der Teilnahme an der Studie freiwillig zu. Für meine 
Entscheidung hatte ich ausreichend Zeit. Ein Exemplar der Informationsschrift und der Einwilligungserklä-
rung habe ich erhalten.  
 
Datenschutz 
Mir ist bekannt, dass bei dieser Studie personenbezogene Daten verarbeitet werden sollen. Die Verarbei-
tung der Daten erfolgt nach gesetzlichen Bestimmungen und setzt gemäß Art. 6 Abs. 1 lit. a der Daten-
schutz-Grundverordnung folgende Einwilligungserklärung voraus: 
 
Ich wurde darüber aufgeklärt und stimme freiwillig zu, dass meine in der Studie erhobenen Daten, insbe-
sondere Angaben über meine Gesundheit1, zu den in der Informationsschrift beschriebenen Zwecken in 
pseudonymisierter Form aufgezeichnet, ausgewertet werden können. Dritte erhalten keinen Einblick in 
personenbezogene Unterlagen. Bei der Veröffentlichung von Ergebnissen der Studie wird mein Name 
ebenfalls nicht genannt. Die personenbezogenen Daten werden anonymisiert, sobald dies nach dem For-
schungszweck möglich ist. Die Daten werden nach Studienabschluss zehn Jahre aufbewahrt und anschlie-
ßend vernichtet. Mir ist bekannt, dass diese Einwilligung jederzeit schriftlich oder mündlich ohne Angabe 
von Gründen widerrufen werden kann, ohne dass mir dadurch Nachteile entstehen. Die Rechtmäßigkeit 
der bis zum Widerruf erfolgten Datenverarbeitung wird davon nicht berührt. In diesem Fall kann ich ent-
scheiden, ob die von mir erhobenen Daten gelöscht werden sollen oder weiterhin für die Zwe-
cke der Studie verwendet werden dürfen. 
 
Gemäß § 4 Bundesdatenschutzgesetz (BDSG): "Ich wurde darüber aufgeklärt und stimme zu, dass meine 
in der Studie erhobenen Daten in pseudonymisierter Form aufgezeichnet (und ggf. auch in pseudonymi-
sierter Form weitergegeben) werden können. Dritte erhalten jedoch keinen Einblick in personenbezo-
gene Unterlagen. Bei der Veröffentlichung von Ergebnissen der Studie wird mein Name ebenfalls nicht 
genannt." 
 
                                                          
1
 Gemäß Art. 9 Abs. 1 DSGVO handelt es sich bei Gesundheitsdaten um personenbezogene Daten besonderer Kategorie in deren 
Verarbeitung der Studienteilnehmer ausdrücklich einwilligen muss. Gleiches gilt für Daten, aus denen die rassische und ethnische 
Herkunft, politische Meinungen, religiöse oder weltanschauliche Überzeugungen oder die Gewerkschaftszugehörigkeit hervorge-
hen, sowie für die Verarbeitung von genetischen Daten, biometrischen Daten zur eindeutigen Identifizierung einer natürlichen 
Person, Daten zum Sexualleben oder zur sexuellen Orientierung. 
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Im Falle eines Rücktritts: 
 Ja, ich bin damit einverstanden, dass - im Falle eines Rücktritts - die bisher erhobenen Daten mei-
ner Person ausgewertet werden. 
 Nein, ich möchte nicht, dass die bisher erhobenen Daten von meiner Person ausgewertet wer-
den/wird. Es soll sämtliches Material, das mit meiner Person in Zusammenhang steht vernichtet werden 
 
Für Ihre Teilnahme an diesem Forschungsprojekt wären wir Ihnen dankbar.  
 
 
______________________                ___________________________________ 
Ort, Datum                                              Name, Vorname des Teilnehmers 
 
 
             ___________________________________      
             Unterschrift des Teilnehmers 
 
 
Aufklärende Person: 
Der Proband wurde von mir im Rahmen eines Gesprächs über das Ziel und den Ablauf der Studie sowie 
über die Risiken aufgeklärt. Ein Exemplar der Informationsschrift und der Einwilligungserklärung habe ich 
dem Probanden ausgehändigt. 
 
 
            ____________________________________ 
       Unterschrift des Aufklärenden 
 
 
Unbeantwortete Fragen: Sollten Sie Fragen haben, wenden Sie sich bitte an den Projektverantwortlichen. 
Sie haben das Recht, vom Verantwortlichen (s.u.) Auskunft über die von Ihnen gespeicherten 
personenbezogenen Daten zu verlangen. Ebenfalls können Sie die Berichtigung unzutreffender 
Daten sowie die Löschung der Daten oder Einschränkung deren Verarbeitung verlangen. 
Der Verantwortliche für die studienbedingte Erhebung personenbezogener Daten ist: 
 
Projektverantwortlicher 
 
Apl. Prof. Dr. med. Christoph Nikendei, MME 
 
Christoph.Nikendei@med.uni-heidelberg.de 
 
Oberarzt 
Universitätsklinikum Heidelberg 
Klinik für Allgemeine Innere Medizin und Psychoso-
matik 
am Universitätsklinikum Heidelberg 
 
Thibautstr. 4 
69115 Heidelberg 
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Bei Anliegen zur Datenverarbeitung und zur Einhaltung der datenschutzrechtlichen Anforderun-
gen können Sie sich an folgenden Datenschutzbeauftragten der Einrichtung wenden: 
 
Datenschutzbeauftragter des Universitätsklinikums Heidelberg 
Im Neuenheimer Feld 672 
69120 Heidelberg 
06221 56 7036 
datenschutz@med.uni-heidelberg.de 
 
 
Im Falle einer rechtswidrigen Datenverarbeitung haben Sie das Recht, sich bei folgender Auf-
sichtsbehörde zu beschweren: 
Der Landesbeauftragte für den Datenschutz und die Informationsfreiheit Baden- Württemberg 
Postfach 10 29 32, 70025 Stuttgart 
Königstraße 10a, 70173 Stuttgart 
Tel.: 0711/61 55 41 – 0 
Fax: 0711/61 55 41 – 15 
E-Mail: poststelle@lfdi.bwl.de 
Internet: http://www.baden-wuerttemberg.datenschutz.de 
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Ihr persönlicher Code: 
Unter „Pseudonymisierung“ versteht man die Verarbeitung personenbezogener Daten in einer Weise, 
dass die personenbezogenen Daten ohne Hinzuziehung zusätzlicher Informationen („Schlüssel“) nicht 
mehr einer spezifischen betroffenen Person zugeordnet werden können. Diese zusätzlichen Informatio-
nen werden dabei gesondert aufbewahrt und unterliegen technischen und organisatorischen Maßnah-
men, die gewährleisten, dass die personenbezogenen Daten nicht einer identifizierten oder identifizierba-
ren natürlichen Person zugewiesen werden. 
 
Um ein Code für Sie zu generieren, mit dem Ihre Daten wie oben beschrieben pseudonymisiert gespei-
chert werden können, bitten wir Sie noch, folgende Angaben zu machen: 
 
Notieren Sie unten nacheinander  
• den zweiten Buchstaben des Vornamens Ihrer Mutter (z.B. „A“ für Sabine)  
• den dritten Buchstaben des Vornamens Ihres Vaters (z.B. „R“ für Herbert)  
• die Summe ihrer Hausnummer als zweistellige Zahl (z.B. „09“ für Hausnr. 18)  
• die ersten beiden Buchstaben des Ortes Ihrer Einschulung (z.B. „Fr“ für Frankfurt).  
 
  
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
Zweiter 
Buchstabe d. 
Vornamens 
d. Mutter 
z.B. „A“ 
Die Summe  
Ihrer Hausnr. 
z.B. „09“ 
Dritter Buchstabe 
d. Vornamens d. 
Vaters 
z.B. „R“ 
 
Ersten beiden Buch-
staben des Ortes 
der Einschulung 
z.B. „FR“ 
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Klinik für Psychosomatische u. Allgemeine Klini-
sche Medizin 
 
Prof. Dr. med. W. Herzog 
  Ärztlicher Direktor 
 
Standort Bergheim 
Prof. Dr. med. H. Schauenburg 
Leiter und geschäftsführender Oberarzt 
apl. Prof Dr. med. C. Nikendei, MME 
Ltd. Oberarzt, Leiter der Ambulanz 
 
 
 
 
 
 
 
 
 
Patienteninformation zur Studie 
 
„Psychische Belastung  nach Ruptur der Chordae tendineae“ 
 
 
Sehr geehrte Patientin, sehr geehrter Patient, 
Sie sind aufgrund einer Herzklappenerkrankungen in unserer kardiologischen Ambulanz in 
Behandlung. Im Rahmen dieser Erkrankung haben Sie einen Sehnenfadenabriss oder eine 
sogenannte Ruptur der Chordae tendineae erlebt. Die Sehnenfäden sind dafür da, dass die 
Herzklappen dicht schließen und das Herz richtig pumpen kann. Wenn die Sehnenfäden 
reißen, schließt die betroffene Herzklappe nicht mehr richtig und wird undicht (Klappeninsuf-
fizienz), typische Symptome sind u.a. Atemnot und Leistungsschwäche. Bei undichten Klap-
pen muss der Herzmuskel mehr oder stärker pumpen, wird dadurch höher beansprucht und 
kann schließlich versagen und muss deshalb kardiologisch behandelt werden. Sie wurden 
aufgrund dieser Undichtigkeit der sogenannten Mitralklappe im linken Teil des Herzens (Mit-
ralklappeninsuffizienz) mit einer kardiologischen Maßnahme (MitraClip®) behandelt. In Ko-
operation mit der kardiologischen Abteilung wird derzeit von der Abteilung für Psychosomatik 
der Universitätsklinik Heidelberg eine wissenschaftliche Studie durchgeführt, die die psychi-
schen Auswirkungen des Sehnenfadenabrisses untersucht.  
 
Wir würden Sie gerne für die Teilnahme an vorliegender Studie gewinnen. Bitte lesen Sie 
sich die folgenden Informationen aufmerksam durch. Eventuelle Fragen beantworten wir 
Ihnen gerne. 
Seite 2 von 4 
 
Patienteninformationsschrift_Sehnenfadenruptur_Version 1 
 
 
Ziel der Studie 
Es ist bisher wenig über die psychischen Belastungsreaktionen nach einem Sehnenfadenab-
riss bekannt. Jedoch weiß man, dass es im Rahmen von Herzerkrankungen zu Belastungs-
reaktionen kommen kann, welche bis hin zur sogenannten posttraumatischen Belastungsstö-
rung führen können. Auf ein traumatisches Erlebnis, wie etwa eine akute Verschlechterung 
des Gesundheitszustands, reagiert jeder Mensch auf seine eigene Art und Weise. Trotzdem 
gibt es Reaktionen, die bei vielen gleich sind. In der Zeit nach einem traumatischen Erlebnis 
können manchmal ungewollt Bilder, Geräusche, andere Empfindungen und Gedanken an 
das Erlebnis auftauchen. 
Wir möchten in dieser Studie die psychischen Belastungen nach einem Sehnenfadenabriss-
erfassen. Dabei möchten wir erfahren, welche Gefühle, Gedanken und körperliche Empfin-
dungen Sie im Zusammenhang mit dem Sehnenfadenabriss erlebt haben und wie ihr aktuel-
les Befinden ist. Psychische Belastungen können auch negative Auswirkungen auf die kör-
perliche Gesundheit haben. Darum soll im Rahmen der Studie auch die Strecke, die Sie ma-
ximal in 6 Minuten gehen können, untersucht werden.  
 
Ein besseres Verständnis der psychischen Belastungsfaktoren nach einem Sehnenabriss 
soll helfen, diesen künftig vorzubeugen, entgegenzuwirken und bessere Unterstützungsmög-
lichkeiten zu entwickeln. 
Beschreibung der Studie 
Die Untersuchung der beschriebenen Inhalte soll mittels Interviews und einer Fragebogener-
hebung erfolgen. Weiterhin soll die Strecke erfasst werden, die Sie maximal innerhalb von 6 
Minuten gehen können. Dies wird insgesamt etwa 50 Minuten dauern. Wir bitten Sie zu be-
richten, wie Sie den Sehnenfadenabriss erlebt haben und einige Fragebögen zu Ihrem Be-
finden auszufüllen. Ergänzend werden medizinische Informationen über den Sehnenfaden-
abriss, sowie eventuelle Vorerkrankungen aus Ihrer Patientenakte erhoben.  
 
Mit einigen Teilnehmerinnen und Teilnehmern wird außerdem ein ausführliches, persönli-
ches Interview durchgeführt, welches etwa 30 Minuten dauern wird. Dabei geht es um Ver-
änderungen, die Sie seit dem Sehnenfadenabriss bemerkt haben und wie Sie damit umge-
hen. Eine Tonaufnahme des Interviews wird gespeichert, verschriftlicht und ohne Verwen-
dung Ihres Namens ausgewertet (Informationen zum Datenschutz weiter unten). Ihren Wün-
schen entsprechend kann das Interview entweder telefonisch, bei Ihnen Zuhause oder in der 
kardiologischen Ambulanz des Uniklinikums Heidelberg durchgeführt werden. Die Teilnahme 
an dem Interview ist freiwillig und Sie können dieses auch ablehnen. 
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Nutzen und Risiken der Teilnahme an der Studie 
Ihre medizinische Behandlung wird durch die Teilnahme an der Studie nicht beeinflusst. Die 
Befragung mittels Fragebögen und Interview birgt kein bekanntes Risiko. Im Rahmen der 
Befragungen kann es zu einer verstärkten persönlichen Auseinandersetzung mit den ange-
sprochenen Inhalten (psychische Belastungen, Beziehungsmuster, Persönlichkeitseigen-
schaften) kommen. Ihr persönlicher Nutzen durch die Teilnahme besteht in der Möglichkeit, 
Ihre Erfahrungen im Zusammenhang mit dem Sehnenfadenabriss zu teilen und zu reflektie-
ren. Durch die Teilnahme tragen Sie dazu bei, Maßnahmen zu entwickeln, welche psychi-
sche Belastung nach einem Sehnenfadenabriss verhindern.  
Freiwilligkeit der Teilnahme  
Die Teilnahme an der Studie ist freiwillig. Sie können Ihr Einverständnis jederzeit, ohne An-
gabe von Gründen und ohne Nachteile für Ihre weitere medizinische Versorgung wieder zu-
rückziehen. Bei Rücktritt von der Studie werden wir, falls Sie dies wünschen, die erhobenen 
Daten vernichten. Wenn Sie zu einem späteren Zeitpunkt von der Studie zurücktreten möch-
ten, setzen Sie sich bitte mit dem Studienleiter Herrn Apl. Prof. Dr. med. Christoph Nikendei 
(Kontakt siehe unten) in Verbindung.  
Was passiert mit meinen Daten? 
Alle Ihre Daten werden mit Ihrem Einverständnis zur wissenschaftlichen Auswertung ge-
sammelt und streng vertraulich behandelt. Sie werden unter keinen Umständen an andere, 
nicht an der Studie beteiligte Personen weitergegeben. Die erhobenen Daten werden aus-
schließlich für die in dieser Studie angegebenen Zwecke verwendet. 
Sie werden an einem für Unbefugte unzugänglichen Ort aufbewahrt und nach 10 Jahren 
vernichtet. 
Datenschutz nach §4 BDSG: 
Im Rahmen der Studie werden die ärztliche Schweigepflicht und die Bestimmungen 
des Bundesdatenschutzgesetzes eingehalten. Ihre Daten und ggf. die Tonaufnahmen 
werden in pseudonymisierter Form aufgezeichnet, ausgewertet und ggf. in pseudo-
nymisierter Form weitergegeben. Pseudonymisiert bedeutet, dass ein Nummern- 
und/oder Buchstabencode verwendet wird, ggf. in Kombination mit dem Geburtsjahr 
(nicht jedoch mit dem vollständigen Geburtsdatum). Eine nachträgliche Zuordnung 
der Daten zu einer bestimmten Person ist nur mit Hilfe einer Art “Schlüssel“ möglich. 
Zugang zu diesem „Schlüssel“ hat ausschließlich der Studienleiter. Dritte erhalten 
keinen Einblick in Ihre Originalunterlagen. Bei der Veröffentlichung von Ergebnissen 
der Studie wird Ihr Name nicht genannt. 
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Wir würden uns freuen, wenn Sie an der Studie teilnehmen!  
 
Leider können wir Ihnen für den Zeitaufwand beim Ausfüllen der Fragebögen sowie das In-
terview keine Aufwandsentschädigung zukommen lassen. 
 
Für Rückfragen stehen wir Ihnen gerne zur Verfügung:  
Studienleiter apl. Prof. Dr. med. Christoph Nikendei, MME 
Klinik für Allgemeine Innere Medizin und Psychosomatik 
Thibautstraße 4 
69115 Heidelberg 
E-Mail: christoph.nikendei@med.uni-heidelberg.de 
Telefon: 06221 56 38663 
Doktorandin Dipl. Psych. Anna Cranz 
E-Mail: anna.cranz@med.uni-heidelberg.de 
Telefon: 06221 56 38553 
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